A PDK1-dependent regulation of PLCγ1 activation is essential for cancer cell migration and invasion

Claudio Raimondi

Supervisor: Marco Falasca
Co-supervisor: Tania Maffucci

Thesis submitted for the degree of PhD

Centre for Diabetes, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London

May 2011
I, Claudio Raimondi, declare that the work presented in this thesis is my own, unless stated otherwise, and is in accordance with the University of London’s regulation for the degree of PhD.

Claudio Raimondi
Abstract

Phospholipase Cγ1 (PLCγ1) is highly expressed in several tumours such as breast carcinomas and has been found overexpressed in metastases compared to primary tumour in breast cancer patients, indicating that PLCγ1 may be important in tumourigenesis and metastasis dissemination. PLCγ1 involvement in cancer cell motility and in cancer cell Matrigel invasion was investigated. Downregulation of PLCγ1 protein expression by siRNA or shRNA inhibited Matrigel cell invasion of highly invasive breast and melanoma cancer cell lines. Furthermore PLCγ1 protein downregulation inhibits intracellular calcium mobilisation upon EGF stimulation demonstrating the essential role of PLCγ1 in EGF-induced calcium release. In the effort to identify specific PLCγ1 inhibitors, Inositol (1,3,4,5,6) pentakisphosphate (InsP5) and 2-O-Bn-InsP5, a synthetic compound based on InsP5 structure, were tested on Matrigel cell invasion and PLCγ1 activity. I found that InsP5 and 2-O-Bn-InsP5 reduce cell migration and Matrigel invasion in breast and melanoma cancer cell lines, with a complete inhibition displayed by 2-O-Bn-InsP5 treated cells. Furthermore InsP5 and 2-O-Bn-InsP5 treatment reduces calcium release upon EGF stimulation, with a complete inhibition showed by 2-O-Bn-InsP5 treated cells, suggesting a potential inhibition on PLCγ1 activity. Analysis of PLCγ1 phosphorylation in tyrosine 783 residue revealed that 2-O-Bn-InsP5 inhibits EGF-induced PLCγ1 tyrosine phosphorylation. Kinase profile assay, performed in vitro to test the inhibitory effect of InsP5 and 2-O-Bn-InsP5 on different kinases, showed a specific inhibition by 2-O-Bn-InsP5 of the 3-phosphoinositide-dependent-protein kinase 1 (PDK1) with an IC50 of 26 nM. Knock down of PDK1 using siRNA and shRNA in MDA-MB-231 showed impairment in cell migration and Matrigel invasion and inhibition of EGF-induced calcium mobilisation. Co-immunoprecipitation and FRET analyses showed that PLCγ1 and PDK1 associate in a protein complex. My finding identified a novel pathway which involves PDK1 in PLCγ1 activation. Furthermore this work highlights PLCγ1 as a potential therapeutic target to prevent metastases spreading and identified 2-O-Bn-InsP5 as a leading compound for development of anti-metastatic drugs.
# Tables of contents

Abstract............................................................................................................................ 3  
Acknowledgements............................................................................................................. 11
List of Figures and Tables.................................................................................................. 12  
Abbreviations..................................................................................................................... 18

## CHAPTER 1: INTRODUCTION .................................................................................. 19

1.1 Phosphoinositides ........................................................................................................ 20
  1.1.1 Phosphatidylinositol-4,5-bisphosphate, PtdIns(4,5P)₂ ........................................ 21
  1.1.1.1 PtdIns(4,5)P₂ and cytoskeleton remodelling .................................................. 22
  1.1.1.2 PtdIns(4,5)P₂ and membrane trafficking ...................................................... 23
  1.1.2 Phosphatidylinositol-3,4,5-trisphosphate, PtdIns(3,4,5)P₃.......................... 24
      1.1.2.1 PtdIns(3,4,5)P₃-dependent AKT and PLCγ₁ activation ............................... 24
1.2 Phospholipase C (PLC) ................................................................................................ 26
  1.2.1 Catalytic domain .................................................................................................. 26
  1.2.2 EF Motifs .......................................................................................................... 28
  1.2.3 C2 domain ......................................................................................................... 28
  1.2.4 PH domain ........................................................................................................ 30
  1.2.5 PLC Isoenzymes ............................................................................................... 32
1.3 PLCγ ............................................................................................................................ 38
  1.3.1 Growth factors induced stimulation of PLCγ₁ .................................................. 39
  1.3.2 PI3K and PLCγ₁ activation .............................................................................. 41
  1.3.3 PLCγ₁ activation and integrins ........................................................................ 43
  1.3.4 Biological functions of PLCγ₁ ........................................................................... 46
  1.3.5 Overview of the cell migration process .............................................................. 49
  1.3.6 PLCγ₁ and Rac1 ............................................................................................... 51
1.4 Role of PLCγ₁ in cancer ............................................................................................. 52
1.5 The metastatic process ............................................................................................... 56
1.6 Breast cancer ............................................................................................................... 59
1.7 3-Phosphoinositide-Dependent-Protein-Kinase-1 (PDK1) in cancer as potential therapeutic target ............................................................. 61
      1.7.1 Biological functions of PDK1 ........................................................................ 61
1.7.2 PDK1 in cancer ................................................................. 62
1.7.3 PDK1-dependent pathways ............................................... 64
1.7.4 PDK1 as therapeutic target ............................................... 68

1.8 Inositol phosphates: promising lead compound for anticancer molecule development .................................................. 69

CHAPTER 2: Materials and Methods........................................... 75

2.1 Cell culture ........................................................................... 76
  2.1.1 Cell lines ....................................................................... 76
  2.1.2 Cell culture and propagation ........................................... 77
  2.1.3 Cell amplification and passage ........................................... 77
  2.1.4 Cryo-conservation and recovery of cell lines ...................... 78

2.2 Molecular Biology .................................................................. 78
  2.2.1 Proteins ......................................................................... 78
    2.2.1.1 Western blotting analysis ......................................... 78
      2.2.1.1.1 Protein sample preparation from cell lysates ............... 78
      2.2.1.1.2 Bradford protein assay .......................................... 79
      2.2.1.1.3 Polyacrylamyde Gel Electrophoresis (PAGE) and Western blot .............................................. 80
      2.2.1.1.4 Immunoblotting and analysis .............................. 81
    2.2.1.2 Co-immunoprecipitation analysis ............................... 82
      2.2.1.2.1 Co-immunoprecipitation analysis by Millipore Catch and release KIT ........................................... 82
      2.2.1.2.2 Endogenous co-immunoprecipitation analysis ............. 83
    2.2.1.3 GST-Pull down assay .............................................. 83

2.2.2 RNA-interference ................................................................ 84
  2.2.2.1 siRNA using Oligofectamine transfecting agent .......... 84
  2.2.2.2 siRNA using Hiperfect reagent ................................. 85
  2.2.2.3 stable knock down using short hairpin RNA ................. 85
    2.2.2.3.1 Stable knock down of PLCg1 using pSUPER™.retro vector-based shRNA ........................................ 85
2.2.3.2 Inducible knock-down of PLCγ1 using pSUPERIOR™ vector-based shRNA

2.2.3.3 Stable downregulation of PDK1 using pSUPER vector-based shRNA

2.2.3 DNA ........................................................................................................................................88

2.2.3.1 Ligation and transformation .............................................88

2.2.3.2 DNA digestion .................................................................88

2.2.3.3 Plasmid preparation .........................................................89

2.2.3.4 Miniprep ...........................................................................89

2.2.3.5 Maxiprep ...........................................................................89

2.2.3.6 Agarose gel .................................................................89

2.2.3.7 Plasmid transfection ......................................................90

2.2.3.8 PCR ..............................................................................91

2.2.4 RNA ..........................................................................................................................92

2.2.4.1 RNA extraction .................................................................92

2.2.4.2 RNA Reverse transcription .............................................92

2.2.4.3 Real Time quantitative Polymerase Chain Reaction (RT-qPCR) ........................................93

2.3 Imaging methods .............................................................................................................94

2.3.1 Ruffling Assay .................................................................................94

2.3.2 Calcium measurement Assay ..................................................94

2.3.3 Incorporation of Fluorescein-conjugated InsP₅ (2-FAM-InsP₅) ...95

2.3.4 Forster Resonance Energy Transfer by acceptor photobleaching ...........................................96

2.3.5 Forster Resonance Energy Transfer by FACS .........................................................98

2.4 Cell Biology .....................................................................................................................100

2.4.1 Cell counting ......................................................................................100

2.4.2 Migration and invasion assay .................................................................................100

2.4.2.1 Cell migration assay ........................................................................100

2.4.2.2 Matrigel cell invasion assay ..................................................101

2.4.3 Inositol phosphate assay ..................................................................................102

2.4.4 [³H]InsP₅ incorporation assay .................................................103

2.5 Statistical analysis .............................................................................................................103
CHAPTER 3: PLCγ1 is essential for cancer cell migration and invasion .............................................. 104

3.1 Introduction .......................................................................................................................... 105

3.2 Results .................................................................................................................................. 106

3.2.1 PLC activity is essential for MDA-MB-231 fibronectin-induced migration ........................................ 107

3.2.2 Effect of a PLCγ1 mutant form constitutively recruited to the plasma membrane on fibronectin-induced cell migration ......... 109

3.2.3 Downregulation of PLCγ1 expression using a pSUPERIOR construct containing specific shRNA targeting PLCγ1 .................. 111

3.2.4 Inducible downregulation of PLCγ1 expression using a pSUPERIOR construct ........................................ 112

3.2.5 Cell invasion assay in breast cancer cells stably downregulated for PLCγ1 expression ............................................................. 114

3.2.6 Cell invasion assay in melanoma cells transiently downregulated for PLCγ1 expression ........................................ 116

3.2.7 Analysis of cytoskeleton remodelling in MDA-MB-435 ........................................ 117

3.2.8 Analysis of cytoskeleton remodelling in TSA murine breast cancer cell line ................................................................. 119

3.3 Discussion ............................................................................................................................ 121

CHAPTER 4: PLCγ1 is the main PLC isoform involved in EGF- and FGF- induced calcium release and InsP₃ production in breast cancer and endothelial cells ..... 124

4.1 Introduction .......................................................................................................................... 125

4.2 Results .................................................................................................................................. 126

4.2.1 Effect of PLCγ1 downregulation on EGF-induced calcium release in MDA-MB-231 ........................................ 126

4.2.2 Effect of PLCγ1 downregulation on EGF-dependent Inositol Phosphates accumulation............................................. 128

4.3 Discussion ............................................................................................................................ 129

4.4 PLCγ1 siRNA interference inhibits FGF-2 induced calcium release in
HUVEC cells .................................................................................................................. 131

4.4.1 Calcium release assay upon FGF-2 addition......................................................... 131

4.4.2 PI3K is required for FGF-2-induced calcium release ........................................ 132

4.4.3 Effect of PLCγ1 and PLCγ2 downregulation on endothelial cell proliferation ............................................................. 133

4.5 Discussion .................................................................................................................. 134

CHAPTER 5: Effect of Ins(1,3,4,5,6)P5 and 2-O-Bn-InsP5 on cell migration, cell invasion and on PLCγ1 activity .......................................................... 136

5.1 Introduction ............................................................................................................... 137

5.2 Results ...................................................................................................................... 138

5.2.1 InsP5 inhibits fibronectin-induced migration in MDA-MB-231. 138

5.2.2 InsP5 inhibits cell invasion on Matrigel of MDA-MB-231 ......................... 139

5.2.3 Effect of InsP5 on cell survival and proliferation in MDA-MB-231 Breast cancer cells .......................................................... 140

5.2.4 InsP5 inhibits Matrigel cell invasion in human and murine breast cancer cell lines ....................................................................... 141

5.2.5 InsP5 does not affect cell proliferation and cell survival of MDA-MB-435, 4T1 and TSA ................................................................. 142

5.2.6 InsP5 inhibits internal calcium release in MDA-MB-231 and MDA-MB-435 cell lines ..................................................................... 144

5.3 Discussion .................................................................................................................. 147

5.4 2-O-Bn-InsP5 – a new synthetic compound based on InsP5 structure ............. 147

5.4.1 2-O-Bn-InsP5 inhibits fibronectin-induced cell migration in MDA-MB-231 .................................................................................. 148

5.4.2 2-O-Bn-InsP5 inhibits cell migration in a dose-dependent manner ..................................................................................... 149

5.4.3 2-O-Bn-InsP5 inhibits cell invasion on Matrigel in different human and murine breast cancer cell lines ................................................. 150

5.4.4 2-O-Bn-InsP5 does not affect cell proliferation and cell survival in MDA-MB-435, 4T1 and TSA cell lines ............................................. 152

5.4.5 2-O-Bn-InsP5 inhibits calcium release response in MDA-MB-
231 and MDA-MB-435 upon EGF stimulation..........................154

5.4.6 2-O-Bn-InsP$_5$ inhibits PLC$_\gamma$1 tyrosine phosphorylation upon EGF stimulation..........................................................156

5.5 Discussion .................................................................................157

Chapter 6: Potential involvement of ABC transporters on inositol polyphosphates transmembrane transport.................................161

6.1 InsP$_5$ internalisation ..................................................................162

6.1.1 Time-course of InsP$_5$ uptake..................................................162

6.1.2 Probenecid and Glibenclamide inhibit 2-FAM-InsP$_5$ uptake...164

6.1.3 ABCC1 transporter is involved in 2-FAM-InsP$_5$ uptake...........166

6.1.4 ABCC1 is potentially involved in $^3$H-InsP$_5$ uptake..............168

6.1.5 Downregulation of ABCC1, but not ABCC5, inhibits InsP$_5$ uptake in MDA-MB-231 .........................................................170

6.1.6 Downregulation of ABCC1 expression inhibits $^3$H-InsP$_5$ uptake ......................................................................................173

6.1.7 Downregulation of ABCC1 and ABCC5 protein levels in

MDA-MB-231.....................................................................................174

6.2 Discussion .....................................................................................175

Chapter 7: PDK1-dependent PLC$_\gamma$1 activation ..........................177

7.1 Transient downregulation of PDK1 in MDA-MB-231, MDA-MB-435
and A375M....................................................................................178

7.1.1 PDK1 protein downregulation in MDA-MB-231, MDA-MB-435
and A375M....................................................................................178

7.1.2 Transient downregulation of PDK1 protein expression
inhibits calcium release upon EGF stimulation .........................180

7.1.3 Matrigel cell invasion is inhibited in breast cancer and
Melanoma cell lines upon PDK1 downregulation.........................182

7.2 Generation of MDA-MB-231 stably downregulated for PDK1
expression......................................................................................183
7.2.1 Design of 22-nucleotide targeting sequence cloned in pSUPERIOR.retro.puro vector .........................................................184
7.2.2 Colony-PCR screening..........................................................187
7.2.3 Clones selection ..................................................................188

7.3 Effect of PDK1 protein downregulation on Inositol phosphates production .................................................................190

7.4 The PDK1-dependent PLCγ1 regulation ......................................192
7.4.1 Analysis of PLCγ1 protein level in MDA-MB-231 downregulated for PDK1 .................................................................192
7.4.2 Effect of downregulation of PDK1 on tyrosine phosphorylation of PLCγ1 in MDA-MB-231 ..........................193

7.5 Investigation of the mechanism of PDK1-mediated PLCγ1 activation .................................................................196
7.5.1 Overexpression of PLCγ1 and PDK1 in HEK293 cells ..........196
7.5.2 Investigation of potential PLCγ1-PDK1 through co-immunoprecipitation analysis .....................................................198
7.5.3 GST pull-down experiments ..................................................200
7.5.4 GST pull down analysis of PDK1-PLCγ1 interaction .............201
7.5.5 Co-immunoprecipitation analysis of endogenous PLCγ1 and PDK1 in MDA-MB-231 ..................................................205
7.5.6 FRET analysis of PLCγ1/PDK1 protein interaction by confocal imaging .................................................................207
7.5.7 FRET analysis of PLCγ1/PDK1 protein interaction by FACS analysis .................................................................214

7.6 Discussion .....................................................................216

Chapter 8: Concluding discussion and future studies ..................219

8.1 Discussion .....................................................................220
8.2 Future works ....................................................................224

Appendices ........................................................................239
Acknowledgement

I am grateful to my supervisor, Professor Marco Falasca and to my co-supervisor Dr. Tania Maffucci for the opportunity to work in their lab, and for their endless support, guidance and enthusiasm and scientific support. It is difficult to express in word my gratitude to these two great scientists that has always been there for me throughout these last 3 years, showing me how to better achieve my goal and how to improve my skills in all the aspects that this job requires.

I want to thank my group, present and prior members, for their guidance in the lab and for the friendly environment; all the collaborators that provided me with reagents, cell lines and advices and the all the people in Centre for Diabetes. A very special thank to my fiancé Anissa, with whom I shared my happiest but also most difficult times, for her support and for the endless scientific discussions that contributed to increase my knowledge and my critical skill. A special thank to Dr. Gianluca Baldanzi for sharing with me some original ideas about the difficult scientific world during my first year of PhD. At that time I did not understand, today I believe he was quite right.

Finally I would like to thank my family, my parents my brother and my grandparents who have always believed in me and supported me in all the ways.
# List of Figures and Tables

## Figures:

| Figure 1.1 | Structure of Phosphatidylinositol .................................. | 20 |
| Figure 1.2 | Schematic representation of phosphoinositides kinases and phosphates enzymes involved in their synthesis .................................. | 21 |
| Figure 1.3 | A) Enzymatic reaction catalyzed by PLCs  
B) Crystal structure of PLCδ1 .................................. | 27 |
<p>| Figure 1.4 | Structure of EF motif of PLCδ1 isoform .................. | 28 |
| Figure 1.5 | Structure of the C2 domain of PLCδ1 .................. | 29 |
| Figure 1.6 | PLCδ1 PH domain structures .................................. | 31 |
| Figure 1.7 | Schematic representation of PLC isoenzymes structures .................................. | 34 |
| Figure 1.8 | Regulation of PLCβ by GPCR .................................. | 35 |
| Figure 1.9 | Schematic mechanism of activation of PLCε .......... | 37 |
| Figure 1.10 | Representation of PLCγ isoenzymes .................. | 38 |
| Figure 1.11 | Relief of the auto-inhibitory interaction ............ | 41 |
| Figure 1.12 | Crosstalk PI3K/PLCγ1 .................................. | 43 |
| Figure 1.13 | Representation of integrins heterodimer ............ | 44 |
| Figure 1.14 | Model of ECM-integrin-induced PLCγ1 activation .................................. | 46 |
| Figure 1.15 | Model of cofilin activation .................................. | 48 |
| Figure 1.16 | Model of cell migration .................................. | 50 |
| Figure 1.17 | Model of EGF-induced Rac1 activation downstream of PLCγ1 .................................. | 52 |
| Figure 1.18 | PLCγ1 is important in metastasis development and progression .................................. | 55 |
| Figure 1.19 | Model of metastasis dissemination and initiation of a novel distant tumour .................................. | 58 |
| Figure 1.20 | Molecular mechanism of AKT activation by PDK1 | 66 |
| Figure 1.21 | Mechanism of activation of S6K and SGK kinases by PDK1 | 68 |
| Figure 1.22 | Representation of the mechanism through which Ins(1,3,4,5,6)P5 may inhibits AKT | 70 |
| Figure 2.1 | Thermal-Cycler protocol for RT-qPCR | 93 |
| Figure 2.2 | Donor and acceptor spectra generated with Fluorescence spectra viewer tool | 97 |
| Figure 3.1 | (A) Pictures of transwell inserts (B) Quantification of migrating cells by cell counting | 106-107 |
| Figure 3.2 | Effect of PLC inhibition on fibronectin-induced cell migration | 108 |
| Figure 3.3 | Cell migration in MDA-MB-231 expressing PALM-PLCγ1 | 110 |
| Figure 3.4 | WB analysis of stable protein downregulation of PLCγ1 | 111 |
| Figure 3.5 | Model of inducible protein downregulation using pSUPERIOR inducible system | 112 |
| Figure 3.6 | Inducible downregulation of PLCγ1 | 113 |
| Figure 3.7 | Analysis of Matrigel invasion in breast cancer cell lines | 115 |
| Figure 3.8 | (A) PLCγ1 transient downregulation in A375M (B) Matrigel cell invasion assay | 116-117 |
| Figure 3.9 | (A) PLCγ1 is important for cytoskeleton remodelling in MDA-MB-435 (B) Quantification of membrane ruffles in MDA-MB-435 | 118-119 |
| Figure 3.10 | (A) Phalloidin staining of actin cytoskeleton in unstimulated and EGF- or Serum-stimulated TSA (B) Quantification of membrane ruffling in TSA | 120 |
| Figure 4.1 | PLCγ1 is essential for EGF-induced calcium mobilisation (A) Calcium increase in EGF-stimulated-MDA-MB-231 when PLCγ1 is expressed (B) Calcium increase in EGF-stimulated-MDA-MB-231 when PLCγ1 expression is downregulated | 127 |
| Figure 4.2 | Inositol phosphate assay | 129 |</p>
<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 4.3</td>
<td>Intracellular calcium increase in serum starved HUVEC</td>
<td>132</td>
</tr>
<tr>
<td>Figure 4.4</td>
<td>PI3K is required for FGF-2-induced calcium release</td>
<td>133</td>
</tr>
<tr>
<td>Figure 4.5</td>
<td>PLCγ2 but not PLCγ1 affects cell proliferation in HUVEC cells</td>
<td>134</td>
</tr>
<tr>
<td>Figure 5.1</td>
<td>InsP₃ inhibits fibronectin-induced migration</td>
<td>138</td>
</tr>
<tr>
<td>Figure 5.2</td>
<td>InsP₃ inhibits Matrigel invasion</td>
<td>139</td>
</tr>
<tr>
<td>Figure 5.3</td>
<td>Cell counting of MDA-MB-231 after 72 hours of treatment with InsP₃</td>
<td>141</td>
</tr>
<tr>
<td>Figure 5.4</td>
<td>InsP₃ inhibits cell invasion on Matrigel of MDA-MB-435, 4T1 and TSA</td>
<td>142</td>
</tr>
<tr>
<td>Figure 5.5</td>
<td>Effect of InsP₃ on cell proliferation/survival</td>
<td>143</td>
</tr>
<tr>
<td>Figure 5.6</td>
<td>Effect of InsP5 on EGF-induced intracellular calcium mobilisation in MDA-MB-231</td>
<td>145</td>
</tr>
<tr>
<td>Figure 5.7</td>
<td>Effect of InsP5 on EGF-induced intracellular calcium mobilisation in MDA-MB-435</td>
<td>146</td>
</tr>
<tr>
<td>Figure 5.8</td>
<td>2-O-Bn-InsP₃ blocks fibronectin-induced migration</td>
<td>148</td>
</tr>
<tr>
<td>Figure 5.9</td>
<td>2-O-Bn-InsP₃ inhibits cell migration in a dose-dependent manner</td>
<td>149</td>
</tr>
<tr>
<td>Figure 5.10</td>
<td>2-O-Bn-InsP₃ inhibits cell invasion on Matrigel</td>
<td>151</td>
</tr>
<tr>
<td>Figure 5.11</td>
<td>Cell proliferation and cell survival upon 2-O-Bn-InsP₃ treatment</td>
<td>153</td>
</tr>
<tr>
<td>Figure 5.12</td>
<td>Effect of 2-O-Bn-InsP₃ on intracellular calcium mobilisation</td>
<td>154-155</td>
</tr>
<tr>
<td>Figure 5.13</td>
<td>PLCγ1 phosphorylation is inhibited by 2-O-Bn-InsP₃ treatment</td>
<td>157</td>
</tr>
<tr>
<td>Figure 6.1</td>
<td>Incorporation of 2-FAM-InsP₃</td>
<td>163</td>
</tr>
<tr>
<td>Figure 6.2</td>
<td>Time course of 2-FAM-InsP₃ uptake in untreated cells and in MDA-MB-231 treated with probenecid and glibenclamide</td>
<td>165</td>
</tr>
<tr>
<td>Figure 6.3</td>
<td>2-FAM-InsP₃ is inhibited by MK-571</td>
<td>167-168</td>
</tr>
<tr>
<td>Figure 6.4</td>
<td>³H-InsP₃ incorporation is inhibited by MK-571</td>
<td>169</td>
</tr>
<tr>
<td>Figure 6.5</td>
<td>Effect of siRNAs targeting ABCC1 or ABCC5 on 2-FAM-InsP₃ uptake</td>
<td>171-172</td>
</tr>
<tr>
<td>Figure 6.6</td>
<td>Figure 6.6: Effect of siRNAs targeting ABCC1 or ABCC5 on ³H-InsP₃ uptake</td>
<td>173</td>
</tr>
</tbody>
</table>
Tables:

<p>| Table 1.1   | PLC family members and respective tissue expression                                      | 33 |
| Table 2.1   | Cell lines                                                                                | 76 |
| Table 2.2   | BSA Standard curve protein concentration                                                 | 80 |
| Table 2.3   | List of Antibodies used for WB                                                           | 81 |
| Table 2.4   | PLCγ1 targeting sequence cloned in pSUPER.retro vector                                   | 86 |
| Table 2.5   | PDK1 targeting sequence                                                                  | 87 |
| Table 2.6   | Transfection protocol                                                                     | 90 |
| Table 2.7   | Typical PCR master mix                                                                   | 91 |
| Table 2.8   | Typical thermal-cycler program for PCR                                                   | 91 |
| Table 2.9   | RNA retrotranscription program                                                           | 92 |
| Table 2.10  | Plasmids, primary and secondary antibodies used for FRET experiments by FACS            | 99 |
| Table 5.1   | Table 5.1: Percentage of MDA-MB-231, MDA-MB-435, 4T1, TSA treated with InsP5 50µM or 2-O-Bn-InsP5 50µM | 150 |
| Table 6.1   | ABC inhibitors (concentration used)                                                      | 165 |
| Table 7.1   | List of colonies chosen for plasmid purification                                         | 188 |
| Table 7.2   | IP buffers                                                                                | 202 |</p>
<table>
<thead>
<tr>
<th>Abbreviations</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABP</td>
<td>actin binding proteins</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphates</td>
</tr>
<tr>
<td>Bp</td>
<td>Bais pair</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine Serum Albumin</td>
</tr>
<tr>
<td>CaCl₂</td>
<td>Calcium Chloride</td>
</tr>
<tr>
<td>CAPS</td>
<td>Ca²⁺-dependent activator protein for secretion</td>
</tr>
<tr>
<td>cDNA</td>
<td>Complementary DNA</td>
</tr>
<tr>
<td>DAG</td>
<td>Diacylglycerol</td>
</tr>
<tr>
<td>DAPI</td>
<td>4',6-diamidino-2-phenylindole</td>
</tr>
<tr>
<td>ddH₂O</td>
<td>Double-distilled water</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s modified Eagle’s medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide (DMSO)</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic Acid</td>
</tr>
<tr>
<td>dNTP</td>
<td>Deoxynucleotide triphosphate</td>
</tr>
<tr>
<td>ECM</td>
<td>Extracellular Matrix Components</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>EGF</td>
<td>Epidermal growth factor</td>
</tr>
<tr>
<td>EGFR</td>
<td>Epidermal growth factor receptor</td>
</tr>
<tr>
<td>EHS</td>
<td>Engelbreth-Holm-Swarm</td>
</tr>
<tr>
<td>ER</td>
<td>oestrogen receptor</td>
</tr>
<tr>
<td>ERK</td>
<td>Extracellular-signal-related-kinase</td>
</tr>
<tr>
<td>ErbB(s)</td>
<td>Epidermal growth factor family</td>
</tr>
<tr>
<td>FAK</td>
<td>focal adhesion kinase</td>
</tr>
<tr>
<td>FBS</td>
<td>Foetal Bovine Serum</td>
</tr>
<tr>
<td>FGF-2</td>
<td>Basic fibroblast growth factor</td>
</tr>
<tr>
<td>FRET</td>
<td>Forster Resonance Energy Transfer</td>
</tr>
<tr>
<td>g</td>
<td>Relative centrifuge force</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Glyceraldehyde-3-phosphates dehydrogenase</td>
</tr>
<tr>
<td>GEF</td>
<td>guanine nucleotide exchange</td>
</tr>
<tr>
<td>GFP</td>
<td>Green fluorescent protein</td>
</tr>
<tr>
<td>GPCR</td>
<td>G-protein-coupled-receptor</td>
</tr>
<tr>
<td>GPI</td>
<td>glycosylphosphatidylinositol</td>
</tr>
<tr>
<td>GTP</td>
<td>Guanosine-5’-triphosphate</td>
</tr>
<tr>
<td>Guanosine diphosphate</td>
<td><strong>Guanosine diphosphate</strong></td>
</tr>
<tr>
<td>HUVEC</td>
<td>humbilical vein endothelial cells</td>
</tr>
<tr>
<td>IgG</td>
<td>Immunoglobulin G</td>
</tr>
<tr>
<td>InsP₁</td>
<td>Inositol-(1,4,5)</td>
</tr>
<tr>
<td>InsP₂</td>
<td>Inositol-(1,3,4,5,6)-pentakisphosphates</td>
</tr>
<tr>
<td>IP₃</td>
<td>Inositol-(1,4,5)-trisphosphates</td>
</tr>
<tr>
<td>MMp</td>
<td>matrix metalloproteinase</td>
</tr>
<tr>
<td>mTOR</td>
<td>mammalian target of rapamycin</td>
</tr>
<tr>
<td>n</td>
<td>Number of value</td>
</tr>
<tr>
<td>NaCl</td>
<td>Sodium chloride</td>
</tr>
<tr>
<td>NP40</td>
<td>Tergitol-type NP-40</td>
</tr>
<tr>
<td>nt</td>
<td>Nucleotide</td>
</tr>
<tr>
<td>Oligo(dt)</td>
<td>Oligodeoxynucleotidylic acid</td>
</tr>
<tr>
<td>PAGE</td>
<td>Polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffer solution</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
</tr>
<tr>
<td>PDGF</td>
<td>platelet-derived growth factor</td>
</tr>
<tr>
<td>PDK1</td>
<td>3-Phosphoinositide-Dependent-Protein-Kinase-1</td>
</tr>
<tr>
<td>PH</td>
<td>Pleckstrin homology</td>
</tr>
<tr>
<td>PI3K</td>
<td>phosphoinositide 3-kinase</td>
</tr>
<tr>
<td>PIP₃</td>
<td>Phosphatidylinositol-3,4,5-trisphosphate</td>
</tr>
<tr>
<td>PIP5K</td>
<td>PtdIns4P 5-kinases</td>
</tr>
<tr>
<td>PKA</td>
<td>cAMP-dependent protein kinase 1</td>
</tr>
<tr>
<td>PKC</td>
<td>protein kinase C</td>
</tr>
<tr>
<td>PKG</td>
<td>cGMP-dependent protein kinase</td>
</tr>
<tr>
<td>PLC</td>
<td>Phospholipase C</td>
</tr>
<tr>
<td>PtdIns(4,5)P₂</td>
<td>Phosphatidylinositol-4,5-bisphosphate</td>
</tr>
<tr>
<td>PTEN</td>
<td>phosphatase tensin</td>
</tr>
<tr>
<td>PTHR1</td>
<td>homology protein</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>RPM</td>
<td>Revolutions per minutes</td>
</tr>
<tr>
<td>RT</td>
<td>Room temperature</td>
</tr>
<tr>
<td>SDS</td>
<td>Sodium-dodecyl-sulphate</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of the mean</td>
</tr>
<tr>
<td>SH</td>
<td>Src homology domain</td>
</tr>
<tr>
<td>shRNA</td>
<td>Short hairpin RNA</td>
</tr>
<tr>
<td>siRNA</td>
<td>Small interfering RNA</td>
</tr>
<tr>
<td>TEA</td>
<td>Tris-acetic acid-EDTA</td>
</tr>
<tr>
<td>Thr</td>
<td>Threonine</td>
</tr>
<tr>
<td>TIM</td>
<td>triose-phosphate-isomerase</td>
</tr>
<tr>
<td>TKR</td>
<td>tyrosine kinase receptor</td>
</tr>
<tr>
<td>TRPC3</td>
<td>transient Receptor Potential C3</td>
</tr>
<tr>
<td>Tyr</td>
<td>Tyrosine</td>
</tr>
<tr>
<td>WB</td>
<td>Western blot</td>
</tr>
</tbody>
</table>
Publications, presentations and awards arising from this thesis

Publications
A PDK1-dependent regulation of PLCy1 activation is essential for cancer cell migration and invasion.
Raimondi C, Maffucci T, Falasca M. (Submitted)

Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic beta cells.

A phosphoinositide 3-kinase/phospholipase Cy1 pathway regulates fibroblast growth factor-induced capillary tube formation.

Phospholipase Cy1 is required for metastasis development and progression.

Boyden Chamber (Book chapter)
Falasca M, Raimondi C, Maffucci T.
Due: July 29, 2011

Targeting PDK1 in cancer (Review)
Claudio Raimondi and Marco Falasca
Current Medicinal Chemistry (in press)

Awards
2010 – Wellcome Trust Value in People Award 2010/11 supporting the project “Targeting PDK1 in breast cancer metastases” for 6 months.
2010 – Best emerging investigator poster presenter award – Breast Cancer Campaign Scientific Conference 2010 at the Royal Society (London)
2009 – Best poster award – Away-day-meeting for Diabetes and Metabolic Department, Queen Mary’s University
2008 – Best poster award – William Harvey Day, Queen Mary’s University
Chapter 1
Introduction
Chapter 1:

Introduction

1.1 Phosphoinositides

Phosphoinositides are phospholipids within cell membranes. The general structure of the phosphoinositides comprises two fatty acid chains linked to a glycerol moiety and to a water soluble inositol head-group, which can undergo differential phosphorylation (Figure 1.1).

![Phosphatidylinositol](image)

**Phosphatidylinositol**

**Figure 1.1:** Structure of phosphatidylinositol, the compound for the synthesis of the whole family of phosphoinositides

The inositol group may be phosphorylated in different positions generating all the different components of the phosphoinositide family (Figure 1.2). Some phosphoinositides, such as the PtdIns(3,4,5)P$_3$, play a role as second messenger. Several protein domains are able to bind the different phosphoinositides such as PH, FYVE, PX, PHD, FERM, GRAM, ENTH and ANTH domains. Nowadays it is well understood the role of phosphoinositides as second messengers and their role in cell signalling in healthy and pathological conditions.
Phosphoinositides metabolism is strictly controlled in cells since activation of signalling molecules has to be well defined both temporally and spatially. Some phosphoinositides, such as PtdIns(3,4)P2 and PtdIns(3,4,5)P3 are absent in resting cells and are synthesised only upon cellular stimulation. This process involves protein kinases and protein phosphatases, the last in general involved in switching off the signalling. Phosphoinositides are involved in many cellular processes, and dysfunction of their metabolism is observed in several diseases such as cancer and diabetes (Wymann and Schneiter, 2008).

1.1.1 Phosphatidylinositol-4,5-bisphosphate, PtdIns(4,5)P2

Phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] represents 0.5% of total membrane lipids (Stephens et al., 2000). The major synthetic route of PtdIns(4,5)P2 is the phosphorylation of PtdIns4P at the 5-position by PtdIns4P 5-kinases (PIP5K) (van den Bout and Divecha, 2009). Three different classes of PIP5K have been identified: PIP5Kα, PIP5Kβ and
PIP5Kγ. A minor synthetic route is represented by the synthesis through the action of PtdIns5P 4-kinases that phosphorylate PtdIns5P in position 4 (Rameh et al., 1997; Clarke et al., 2010). PtdIns(4,5)P$_2$ has been extensively studied since different second messenger are generated from this phosphoinositide. Indeed PtdIns(4,5)P$_2$ is the main substrate of the PI3K family which produces the second messenger PtdIns(3,4,5)P$_3$. PtdIns(4,5)P$_2$ is also the substrate of Phospholipase C family members (PLCs). PLCs cleave the polar head group of PtdIns(4,5)P$_2$ generating diacylglycerol (DAG) and Inositol-(1,4,5)-trisphosphate (InsP$_3$), which are second messengers that activate PKC and stimulate calcium release from internal stores (Irvine et al., 1984; Berridge and Irvine, 1989). PtdIns(4,5)P$_2$ has many functions within cell signalling. Some of its functions, closely related to this thesis, are described in the following chapter.

### 1.1.1.1 PtdIns(4,5)P$_2$ and cytoskeleton remodelling

PtdIns(4,5)P$_2$ plays an essential role in the regulation of cytoskeleton remodelling by binding to protein such as cofilin, profilin, gelsolin. This interaction binds these proteins to the plasma membrane in a mechanism that prevents its activation. Hydrolysis of PtdIns(4,5)P$_2$ by phospholipase C (PLC) enzymes (Van Rheenen et al., 2007) releases these proteins from the plasma membrane in a well-defined spatial and temporal manner, stimulating actin polymerization. The actin binding proteins (ABP) cofilin interacts with monomeric and filamentous actin promoting actin filament disassembly and severing actin filaments. The actin filament severing activity contributes to create new barbed ends promoting new polymerization-competent filaments (Adrianantoandro and Pollard, 2006; Pavlov et al., 2007). Similarly, PtdIns(4,5)P$_2$ is involved in regulation of profilin and gelsolin, which play a central role in cytoskeleton remodelling and actin dynamics. The interaction between PtdIns(4,5)P$_2$ and profilin inhibits the activity of profilin as actin-monomer sequestering, stimulating actin polymerisation and cytoskeleton remodelling (Saarikangas et al., 2010). In particular profilin stimulates the incorporation of globular actin
in the actin filaments promoting their elongation. In parallel the ARP2/3 complex (Actin Related Proteins) associates to the side of a “Mother” filament creating a new nucleation site which initiates a branching filament (Nurnberg and Grosse, 2011). Equally, PtdIns(4,5)P$_2$ inhibits gelsolin actin filament severing activity by recruiting this protein to the plasma membrane (Saarikangas et al., 2010).

1.1.1.2 PtdIns(4,5)P$_2$ and membrane trafficking

PtdIns(4,5)P$_2$ is also directly involved in exocytosis (Martin et al., 1998), acting on plasma membrane proteins such as Ca$^{2+}$-dependent activator protein for secretion (CAPS) and on vesicle proteins such as synaptotagmin (Di Paolo and De Camilli, 2006). Furthermore, PtdIns(4,5)P$_2$ appears to be required in the ATP-dependent priming process of neurosecretory vesicles. During the exocytosis PtdIns(4,5)P$_2$ is locally and transiently depleted by a PLC-dependent hydrolysis and is not detected on the membrane of the fusing granules (Hammond et al., 2006; Hammond and Schiavo, 2006).

Exocytosis is often coupled to compensatory endocytosis, which is dependent on PtdIns(4,5)P$_2$. Compensatory endocytosis can occur through a clathrin-mediated mechanism or through alternative mechanisms which do not involve complete vesicle fusion or clathrin-mediated vesicle recycling (Gundelfinger et al, 2003). PtdIns(4,5)P$_2$ interacts with some endocytic clathrin adaptors such as AP-2, P180/CALM and epsin and binds to many other endocytic factors such as dynamin, which controls the fission reactions. Other actions of PtdIns(4,5)P$_2$ in endocytosis reflect its effects on the actin cytoskeleton, which is implicated in all internalization pathways (Di Paolo and De Camilli, 2006).
1.1.2 Phosphatidylinositol-3,4,5-trisphosphate, PtdIns(3,4,5)P$_3$

Phosphatidylinositol-3,4,5-trisphosphate, PtdIns(3,4,5)P$_3$, is a well characterised second messenger. Indeed PtdIns(3,4,5)P$_3$ is barely detectable in resting normal cells but its amount increases transiently in stimulated cells. PtdIns(3,4,5)P$_3$ levels increase upon activation of some members of the family of enzymes phosphoinositide 3-kinase (PI3K), which phosphorylates PtdIns(4,5)P$_2$ on position 3. PI3K is a family of enzymes, comprising eight mammalian isoforms grouped into three classes and PtdIns(3,4,5)P$_3$ is the main *in vivo* product of class I isoforms. Class I A consists of a catalytic subunit and a regulatory subunit. The catalytic subunits consist of p110$\alpha$, p110$\beta$, or p110$\delta$, and are the product of three genes *PIK3CA*, *PIK3CB* and *PIK3CD*. The regulatory subunits consist of p85$\alpha$, p85$\beta$ or p55$\gamma$. Class I B consists of only one catalytic subunit, p110$\gamma$, and two regulatory units, p84 and p101. *PIK3CA* is frequently mutated in cancers, and around eighty percent of these mutations occur in the helical or kinase domain of the enzyme leading to gain of function p110$\alpha$ activity (Courtney et al., 2010; Wong et al., 2010).

The levels of PtdIns(3,4,5)P$_3$ are negatively regulated by the phosphatase tensin homology protein (PTEN), which dephosphorylates PtdIns(3,4,5)P$_3$ in position 3 and therefore switches off the PI3K-activated pathway. PTEN is the second most frequently mutated gene in human cancer following *TP53* (Yuan and Cantley, 2008; Kok et al., 2009; Carracedo and Pandolfi, 2008). The lipid phosphatase activity is critical for PTEN tumour suppressor function. Therefore loss of PTEN activity leads to uncontrolled activation of the PI3K pathway, and the subsequent accumulation of PtdIns(3,4,5)P$_3$ leads to cell transformation.

1.1.2.1 PtdIns(3,4,5)P$_3$-dependent AKT and PLC$\gamma$1 activation

Accumulation of PtdIns(3,4,5)P$_3$ has been observed in many cancers. For this reason the PtdIns(3,4,5)P$_3$-dependent pathway has been intensively studied. The main effector activated downstream of PtdIns(3,4,5)P$_3$ is the protein kinase PKB/AKT, which controls different cellular functions.
AKT possesses a pleckstrin homology (PH) domain which specifically binds PtdIns(3,4,5)P$_3$ and PtdIns(3,4)P$_2$, both produced by PI3K. The PH domain- PtdIns(3,4,5)P$_3$ interaction recruits AKT to the plasma membrane and this interaction causes a conformational change leading to its activation (Alessi et al., 1997; Sarbassov et al., 2005; Bellacosa et al., 2005; Calleja et al., 2007). At the plasma membrane, 3-phosphoinositide-dependent-protein-kinase-1 (PDK1) and mammalian target of rapamycin (mTOR), in particular the mTOR complex 2 (mTORC2), phosphorylates AKT at its residues in Thr308 and Ser473 respectively. The phosphorylation of AKT by PDK1 is PtdIns(3,4,5)P$_3$-dependent (Alessi et al., 1997). In particular PDK1 possesses a PH domain which binds PtdIns(3,4,5)P$_3$. This interaction allows AKT and PDK1 to co-localise at the plasma membrane and it is required for optimal phosphorylation of AKT (Waugh et al., 2009). Mice expressing a PDK1 mutated form unable to bind phosphoinositides present a strongly reduced AKT activation, insulin resistance and hyperinsulinaemia (Bayascas et al., 2008). Once phosphorylated, AKT activates different downstream effectors. AKT is involved directly and indirectly in many cellular processes, such as cell proliferation, growth and cell motility. For example the AKT-induced FOXO phosphorylation leads to the inhibition of the transcription of p21KIP and retinoblastoma-like-2, both inhibitors of cell cycle progression, and therefore it promotes progression through the cell cycle (Manning et al., 2007; Zhang et al., 2011). Furthermore activated AKT phosphorylates the pro-apoptotic Bcl-2 family member BAD, which is inactive in the phosphorylated form, and MDM2 that induces p53 degradation (Wymann 2008; Duronio 2008). PtdIns(3,4,5)P3-mediated AKT activation leads to stimulation of cell growth through mTOR activation, which is one of the major effectors in tumourigenesis. Also PtdIns(3,4,5)P$_3$ contributes to cell migration and cytokinesis. Indeed, another downstream effector of PtdIns(3,4,5)P$_3$ is Phospholipase C gamma 1 (PLCγ1) that translocates to the plasma membrane after cellular stimulation with growth factors such as EGF or PDGF in a PtdIns(3,4,5)P$_3$ dependent manner (Falasca et al., 1998). PLCγ1 plasma membrane
translocation is triggered by the PH domain which specifically binds the PtdIns(3,4,5)P₃ and is essential for its activation.

1.2 Phospholipase C (PLC)

Historically, phospholipase C (PLC) was identified as an important enzyme involved in phosphoinositide metabolism (Hokins 1953, Michell 1975). It was only in the 80’s that the link between the water soluble PLC product Ins(1,4,5)P₃ and the release of calcium from intracellular stores was identified (Streb et al., 1983; Irvine et al., 1986). Several different PLC isoforms are currently known (see chapter 1.2.5), sharing common regions/domains, called X and Y flanked by EF motifs, which form the conserved catalytic domain. However different protein modules, such as PH domains or other protein binding modules are specific to each distinct isoform and are responsible for the different mechanisms of enzymatic activation and regulation. The following chapters will focus on the functions of domains common to all PLC isoenzymes.

1.2.1 Catalytic domain

The PLC isoenzymes catalyze the hydrolysis of the phosphodiesteric bond between the phosphoinositol headgroup and diacylglycerol (Figure 3A) (Bunney and Katan, 2010). The catalytic domain possesses alternating α-helices and β-sheets and resembles an incomplete triose-phosphate-isomerase (TIM) α/β barrel (Figure 1.3B). The enzymatic reaction is catalysed by specific aminoacids in the catalytic domain which are conserved among the different family members (Hondal et al., 1998). In particular, production of a cyclic-1,2-inositol,4,5-bisphosphate intermediate is catalysed by histidine 392, which binds to the proton of the 2-Hydroxyl of the inositol headgroup residues that acts as general base creating a cyclic intermediate (Essen et al., 1997). This intermediate is quickly hydrolysed in Ins(1,4,5)P₃, while His-311 protonates the DAG leaving group (Figure 1.3A). The catalytic domain has been shown to be
able to bind calcium ions. Calcium binding has been reported to be essential for catalytic activity since single mutation of the calcium binding Glu-341 within the TIM barrel inhibits calcium binding to the catalytic domain impairing enzymatic activity (Cheng et al.1995).

Figure 1.3: A) Enzymatic reaction catalysed by PLC isoenzymes (adapted from Bunney and Katan, 2010); B) Crystal structure of PLCδ1 (PH domain excluded) (Rebecchi et al, 2000)
1.2.2 EF Motifs

The N-terminal domain consists of an EF motif, a Helix loop Helix domain found in all the PLCs and common to calcium binding proteins. PLC isoforms can have up to four EF domains organised in paired units (\(N_{\text{term}}-\text{EF}_1-\text{EF}_2-\text{EF}_3-\text{EF}_4-C_{\text{term}}\)) (Figure 1.4). The role of PLC EF domains in calcium binding is controversial. Indeed the EF\(_3\) and EF\(_4\) motifs do not show metal binding during structural analysis. EF\(_1\) and EF\(_2\) contain calcium ligands (Essen et al., 1996). However there is no evidence showing that EF motifs in PLC isoforms bind to calcium ions. Deletion of EF\(_3\) and EF\(_4\) in PLC\(\delta_1\) completely blocks PLC enzymatic activity, indicating that this protein domain is essential for the correct function of the catalytic activity together with the TIM barrel domain (Nakashima et al., 1995).

![Figure 1.4: Structure of EF motifs of PLC\(\delta_1\) isoform (Essen et al., 1996)](image)

1.2.3 C2 domain

The C2 domain is a protein module of ~120 aminoacids present in different enzymes such as PKCs cPLA\(_2\) and PLCs. C2 domains possess 8 antiparallel \(\beta\)-sheets, which define three loops essential for calcium
binding (Figure 1.5). It has been proposed that C2 domain of PLCs can interact with phospholipids facilitating the tethering to the plasma membrane of the enzymes. Two possible mechanisms have been proposed: the bridging mechanism that involves calcium ions being sandwiched between the C2 domain and the phospholipid (Swairjo et al. 1995). Alternatively, it has been proposed that calcium binding does not cause conformational changes but it is essential for electrostatic potential change essential for a calcium-mediated binding of the target molecule (Newton et al., 1995). Therefore the C2 domain, together with the PH domain when present, could represent a second site for the binding of phosphoinositides important for the correct orientation of the catalytic domain (Bunney and Katan, 2010).

![Figure 1.5: Structure of the C2 domain of PLCδ1 (Essen et al., 1996)](image-url)
1.2.4 PH domains

The PH domain was first identified in the protein pleckstrin, the main substrate of PKC. Currently several proteins have been discovered containing the PH domain (Musacchio et al., 1993; Lemmon et al., 1996); among them PLCδ1, PLCγ1, PDK1 and AKT. The PH domain is a protein module consisting of ~120 amino acids with no catalytic activity. The sequence identities among the different PH domains are not sufficient to support structural homology. However it has been found that the secondary and tertiary structures are conserved among the different PH domains (Lemmon et al., 1995). Each domain consists of two nearly orthogonal antiparallel β-sheets of four and three strands and an amphipathic α-helix localised at the C-terminal portion of the domain (Figure 1.6). Each PH domain presents a well-defined charge polarisation. In particular the β1/β2, β3/β4 and β6/β7 loops represent the most variable region in length and sequence. These regions define the positively charged portion needed for ligand interaction and recognition and define the binding pocket which presents the sequence motif KXₐ(K/R)XR (Ferguson et al., 1995). The lysine (K) and arginine (R) represent the positive charged core responsible for the interaction with the phosphate groups. The side chains are responsible for further interactions which defines the identity of the ligand and the binding affinity (Lemmon and Ferguson, 2000).
It has been noted that the majority of proteins hosting PH domains require membrane association to carry out their functions. The original idea was that PH domains were involved in protein-protein interactions, in similar manner to SH2 and SH3 domains (Gibson et al., 1994). Initial evidence suggested the βγ subunits of the heterotrimeric G protein as a potential PH domains target (Touhara et al., 1994; Tsukada et al., 1994). However in vitro experiments using lipid vesicles identified the phosphoinositides as the main target of PH domain (Harlan et al.1994). Since the original identification, other PH domains were shown to bind with high affinity and stereospecificity for specific phosphoinositides headgroups (Kavran et al., 1998). The PLC8 PH domain was identified to specifically interact with PtdIns(4,5)P2, leading to a plasma membrane recruitment of the enzyme and increasing its processivity (Garcia et al., 1995; Lemmon et al., 1995). However few PH domains, such us PLCδ1 PH domain, bind to phosphoinositides with high specificity. Most PH domains, such as PLCγ1 PH domain can bind several phosphoinositides with different affinity and low specificity. The phosphoinositides/PH domain interaction has been demonstrated to be required for protein translocation to the plasma
membrane. A 'tandem model' has been proposed as potential mechanism that stabilises a weak interaction of PH domain through a co-operation with other domains of the host protein (Maffucci and Falasca, 2001). The PLCγ1 PH domain was demonstrated to be essential for PLCγ1 plasma membrane recruitment and subsequent enzyme activation (Falasca et al., 1998), together with PLCγ1 interaction with the phosphorylated EGF receptor.

The PH domains bind to the phosphoinositide head groups but also to the soluble isolated head groups of phosphoinositides. The PH domain of PLCδ1, for example, binds to the soluble head group of PtdIns(4,5)P₂, D-myo-Ins(1,4,5)P₃. Similarly Grp-1 PH domain binds with high affinity to D-myo-Ins(1,3,4,5)P₄, the soluble PtdIns(3,4,5)P₃ head group. Interestingly, the isolated head group may show a higher affinity for the PH domain binding compared to the head group membrane-embedded. This is the case of Ins(1,4,5)P₃, which is able to bind to PLCδ1 PH domain with an higher affinity (K_D=0.21 μM) compared to PtdIns(4,5)P₃ (K_D=1.66 μM), leading to the displacement of PLCδ1 when Ins(1,4,5)P₃ is generated, in an auto-inhibitory mechanism (Lemmon et al., 1995; Kavran et al., 1998, Lemmon, 2008). The properties of PH domains to bind to the soluble phosphoinositide head groups opened the field for a novel strategy, aiming to antagonise the activation of PH domain containing proteins by inhibiting their translocation to the plasma membrane. Indeed since different PH domains present different affinities for different inositol phosphates, it may be possible to specifically block a particular membrane-targeted protein using inositol phosphate derivative compounds.

1.2.5 PLC Isoenzymes

Several PLCs are known, diverging for aminoacid sequence, structure, regulation and tissue localisation. In particular the PLC isoenzyme family
is composed of the following members, which are present in the tissues listed in Table 1.1.

<table>
<thead>
<tr>
<th>Member</th>
<th>Isoforms</th>
<th>Tissue expression (Suh et al., 2008)</th>
</tr>
</thead>
</table>
| PLCβ  | PLCβ1, PLCβ2, PLCβ3, PLCβ4 | PLCβ1: Brain, intestine, prostate, ovary  
PLCβ2: Mainly hematopoietic tissue; present in ovary and brain  
PLCβ3: Brain, liver, parotid gland, skin, ovary  
PLCβ4: Mainly brain |
| PLCγ  | PLCγ1, PLCγ2 | PLCγ1: ubiquitous  
PLCγ2: Hematopoietic tissue |
| PLCδ  | PLCδ1, PLCδ3, PLCδ4 | PLCδ1: Brain, lungs, muscles, testis  
PLCδ3: Brain, heart, muscles, testis, kidney  
PLCδ4: Ubiquitous with high levels of expression in brain, muscles and kidney |
| PLCε  | PLCε1a, PLCε1b | High expression in heart; present in brain, lungs, colon |
| PLCζ  | PLCζ | Sperm-specific |
| PLCη  | PLCη1, PLCη2 | High level in brain and kidney; low level in lungs, intestine and pancreas |

**Table 1.1:** PLC family members and respective tissue expression

Beside the tissue localisation, the most important difference among the PLC isoenzymes is the modality of their activation and their structure.
Schematic structures of the different PLC isoenzymes are illustrated in Figure 1.7.

Figure 1.7: Schematic representation of PLC isoenzymes structures showing the differences in protein domains present in the family members (adapted from Bunney and Katan., 2010)

Different extracellular stimuli activate distinct PLC isoenzymes through different molecular mechanisms. However some stimuli can activate different PLC isoenzymes simultaneously, which complicate the understanding of the role of each single isoform. In this chapter the main mechanism of activation of all PLCs, except PLC\(\gamma\), are described. PLC\(\gamma\) will be discussed in the following chapter 1.3.
PLCβ

The PLCβs are activated by the rhodopsin superfamily membrane receptors which respond to a plethora of stimuli. These receptors belong to the class of G-protein-coupled-receptor (GPCR) and activate G-proteins to activate signal transduction. Among the different PLCs, PLCβ, but not PLCδ or PLCγ, are activated by G-proteins (Rebecchi and Pentyala, 2000). The G-proteins form a heterotrimeric complex in the inactive GDP-binding state formed by Gα, Gβ and Gγ subunits. Upon stimulation of the receptor, the Gα subunit is activated through exchanging GDP with GTP. This event causes the dissociation of Gα from Gβγ. The GTP-bound Gα subunit, together with the Gβγ heterodimer, activate PLCβ isoenzymes. It has to be pointed out that within the PLCβ isoenzymes, each enzyme shows different responsiveness to the different subunits, indicating a subtle regulation of their differential activation (Rebecchi et al., 2000). PLCβ1 is the least sensitive to Gβγ activation and PLCβ4 is completely insensitive to Gβγ (Figure 1.8). Recent works demonstrate that PLCβ can also be activated by the Rho-GTPase family member Rac, which is able to interact with the PH domain (Snyder et al., 2003).

Figure 1.8: Regulation of PLCβ by GPCR (Rebecchi et al., 2000)
**PLCδ**

A different mechanism controls the activation of PLCδ isoenzymes. PLCδs are the most sensitive to intracellular calcium variation compared to other PLC isoenzymes. PLCδ1, the most studied of its family, can be activated by calcium and in turn it can amplify the calcium signal. PLCδ1 can also be activated by α₁-adrenergic receptors through atypical G-protein (G₉) and by Gₛ coupled receptor agonists (Murthy et al., 2004) and RhoGAP which stimulates PLCδ1 activity up to 10-fold (Rebecchi et al., 2000).

**PLCε**

In 2001 a novel group of PLC was identified. PLCε isoenzymes are the newest and most complex PLC isoenzymes since they present the highest number of different protein domains, which regulate their activation (Kelley, et al 2001). PLCε is activated by Ras family members. In particular PLCε possesses two RA domains that associate with Ras and Rap1 and are essential for PLCε activation (Figure 1.9) (Song et al., 2002). Notably, Ras-mediated PLCε activation induces translocation of the enzyme to the plasma membrane, while Rap1-induced activation recruits the enzyme to the perinuclear region (Song et al., 2002). Furthermore the PLCε family presents a CDC25 homology domain. The CDC25 homology domain was first identified in the CDC25 protein isolated from *S. cerevisiae*, and possesses guanine nucleotide exchange (GEF) factor properties for RAS proteins. The CDC25 domain of PLCε has GEF activity towards RAP1, but not towards any other Ras members, therefore it is able to stimulate Rap1 GTP binding and activation which in turn activates PLCε activity and perinuclear translocation of the enzyme (Jin et al., 2001). In addition to Ras family members, PLCε are activated by a plethora of stimuli. Ligands able to bind GPCRs, such as lysophosphatidic acid or sphingosine-1-phosphate, can activate
PLCε isoenzymes together with PLCβ isoenzymes. Growth factors such as EGF, activate PLCε as well as the PLCγ isoforms (Citro et al., 2007).

Figure 1.9: Schematic mechanism of activation of PLCε showing the activation of the enzyme by GPCR through Gα subunit and RAP1 and by RTKs which are able to activate PLCε through activation of RAS and RAP1. The CDC25 homology domain of PLCε, illustrated in the figure, acts as a GEF for RAP1, increasing its activation, which in turn contributes to a sustained activation of PLCε.

**PLCζ**

PLCζ is a sperm-specific PLC isoform. Recombinant protein injected in egg cells causes calcium oscillation. PLCζ isoenzyme is the shortest of the family and lacks the PH domain. The lack of PH domain, important for phosphoinositide binding, raised the question of how the enzyme is able to maintain processive substrate hydrolysis. It has been shown that the C2 domain is sufficient for membrane tethering of the enzyme and its deletion inhibits calcium oscillations upon PLCζ activation (Suh et al., 2008).
PLC\textsubscript{\eta}

PLC\textsubscript{\eta} activation is still not completely understood. The plasma membrane localisation of the enzyme is independent from extracellular stimuli and is dependent on the PH domain. Indeed deletion of PH domain induces cytosolic localisation of the enzyme. Recent data showed that PLC\textsubscript{\eta}1 is involved in the signal amplification downstream of GPCR and is activated by intracellular calcium. Indeed LPA-induced calcium release was inhibited in PLC\textsubscript{\eta}1 knockdown cell lines (Kim et al., 2011).

1.3 PLC\textsubscript{\gamma}

The PLC\textsubscript{\gamma} subgroup includes two members: PLC\textsubscript{\gamma}1 and PLC\textsubscript{\gamma}2. PLC\textsubscript{\gamma}1 is ubiquitous, while PLC\textsubscript{\gamma}2 is mainly expressed in the hematopoietic system although it was originally identified in brain tissues (Rebecchi et al., 2000; Suh et al, 2008). The detailed structure of PLC\textsubscript{\gamma} is illustrated in Figure 1.10.

![Figure 1.10: Representation of PLC\textsubscript{\gamma} isoenzymes with their different protein domains and the position of known phosphorylation sites (Rebecchi et al., 2000).](image)

PLC\textsubscript{\gamma} isoenzymes possess some unique protein modules that are essential for enzyme regulation. The X and Y domains, together with the EF domain are common to the other PLC isoforms. As indicated in Figure 1.10 PLC\textsubscript{\gamma} members also present two SH2 domains, one SH3 domain, a split PH domain and the N-terminal PH domain (Rebecchi et al., 2000). This long region is inserted between the X and Y domains which form the catalytic domain and it has an important role in regulating PLC\textsubscript{\gamma} catalytic activity (Katan and Williams, 1998). The SH2 domain (Src homology
domain 2) is responsible for protein-protein interaction, recognising specific phosphorylated on tyrosine. Indeed the SH2 domains are essential for interaction with phosphorylated tyrosine residues in activated tyrosine kinase receptors, which dimerise upon ligand engagement and get auto-phosphorylated in tyrosine residues. The SH3 domain recognizes and interacts with proteins expressing polyproline sequences. PLCγ family members possess an N-terminal PH domain (see chapter 1.2.4) and a split PH domain. The N-terminal PH domain is essential for PLCγ1 activation and binds PtdIns(3,4,5)P3 (with a $K_D=1\mu M$) (Falasca et al.,1998). The synthesis of PtdIns(3,4,5)P3 increases the Ins(1,4,5)P3 production and the following intracellular calcium release, potentially via enhanced PtdIns(4, 5)P2 substrate availability due to PtdIns(3,4,5)P3-mediated recruitment of PLCγ1 to the plasma membrane through the PH domain (Bae et al., 1998; Rameh et al., 1998). The split PH possesses its two halves flanking the SH2-SH2-SH3 domains and its function is still not completely understood. Recent data showed that the split PH domain is required for the direct interaction of PLCγ1 with the transient Receptor Potential C3 (TRPC3) channel and is not involved in phosphoinositides binding (van Rossum et al, 2005) (Wen et al., 2006). However another report showed that the split PH domain of PLCγ1 is involved in phosphoinositides binding, in particular in PtdIns(4)P and PtdIns(4,5)P2 binding (Kim et al., 2004).

1.3.1. Growth factor-induced stimulation of PLCγ1

PLCγ family is composed of two members: PLCγ1 and PLCγ2. Although PLCγ1 is ubiquitary expressed, PLCγ2 is expressed mainly in the hematopoietic tissue. This introductory chapter will focus on PLCγ1 isoenzyme, which was the focus of my PhD project.

PLCγ1 is activated by different growth factors such as EGF, PDGF and FGF, which activate their respective tyrosine kinase receptors (TKR)
Engagement of the ligand to the TKR induces the dimerisation of the receptor and its auto-phosphorylation in tyrosine residues. The phosphorylated receptors recruit PLCγ1 and this allows TKRs to phosphorylate PLCγ1 in specific tyrosine residues. The protein-protein interaction between PLCγ1 and TKRs is promoted by the SH2 domain present in the PLCγ family, which recognizes the phosphotyrosine residues on the activated TKRs. Both SH2 domains are involved in the interaction, with a more specific role for the N-terminal SH2 compared to the C-terminal SH2 domain (Chattopadyay et al., 1999; Poulin et al., 2000). Indeed mutation of the C-terminal SH2 domain, which inhibits the SH2 binding to its target, causes a slight reduction of PLCγ1 phosphorylation and activation. On the contrary, mutation targeting the N-terminal SH2 completely inhibited PLCγ1 phosphorylation and activation. Therefore, the N-terminal-SH2 and the C-terminal-SH2 domains of PLCγ1 play different roles in PLCγ1 regulation (Stoica et al., 1998).

Growth factor stimulation induces PLCγ1 recruitment to the membrane and interaction with TKRs, which in turn phosphorylate PLCγ1 at specific tyrosine residues: Tyr 771, Tyr 783 and Tyr 1253. The phosphorylation is essential for PLCγ1 activation (Kim et al., 1990; Kim et al. 1991; Bunney and Katan, 2010) although plasma membrane recruitment through the PH domain is essential (Falasca et al., 1998). Mutation of Tyr 783 to phenylalanine (Phe) completely inhibits PLC activity upon EGF or PDGF stimulation. On the contrary substitution of Tyr 1253 or Tyr 771 causes limited or no inhibition. These data indicate that phosphorylation at Tyr 771 and Tyr 1253 is dispensable, whereas phosphorylation at Tyr 783 is essential for PLCγ1 activation (Kim et al., 1991; Sekiya et al., 2004). Evidence showed that PLCγ1 is maintained in an auto-inhibitory conformation that keeps the enzyme in an inactive form in the absence of extracellular stimulation. The inhibition is promoted by the X-Y linker, constituted by SH2-SH2-SH3 domain that occludes the access of the substrate to the catalytic domain. In particular it has been demonstrated...
that a minimal inhibitory protein module consists of the C-terminal-SH2 and that phosphorylation of Tyr 783 is essential for relieving of the auto-inhibitory interaction (Gresset et al., 2010) (Figure 1.11). A relative stabilising contribution to the auto-inhibitory interaction has been attributed to the split PH domain. Indeed mutation of this domain slight increases the activity of the purified PLCγ1 enzyme \textit{in vitro} (Gresset et al., 2010).

\begin{figure}[h]
  \centering
  \includegraphics[width=\textwidth]{figure11.png}
  \caption{Relief of the auto-inhibitory interaction. The catalytic domain (represented in grey) is inhibited by the interaction with the C-SH2 (purple cylinder). Phosphorylation of the TRK provides the docking site for the N-SH2 (blue cylinder). The following phosphorylation (red sphere) induces a conformational change that releases the catalytic domain from the auto-inhibitory interaction (Gresset et al., 2010).}
\end{figure}

\subsection*{1.3.2 PI3K and PLCγ1 activation}

The mechanism described in the previous chapter explained the mechanism of PLCγ1 activation by TKRs. However it has to be noted that the recruitment to the membrane is not only due to the interaction of N-
terminal-SH2 with the receptor. The PLCγ1 PH domain is essential for the growth factor-induced membrane translocation of PLCγ1. As described in chapter 1.2.4, it has been shown that PLCγ1 PH domain specifically binds to the PI3K product PtdIns(3,4,5)P3 (Falasca et al., 1998). Specifically, mutation of the β3/β4 loop of the PH-PLCγ1 completely abolishes the membrane translocation of PH-PLCγ1 upon PDGF stimulation. Therefore the PH domain is essential for PLCγ1 plasma membrane recruitment (Falasca et al., 1998).

By expressing the GFP-tagged PLCγ1 PH domain in live cells, it is possible to follow the growth factor-induced translocation of the PH domain in living cells. The GFP-PH translocation to the plasma membrane starts within 3-5 minutes from stimulation with PDGF and becomes more evident within 15 minutes. It localizes with ruffles-like structures and gradually disappears from the plasma membrane after 30 minutes from stimulation (Falasca et al., 1998). Inhibition of PI3K using the irreversible PI3K inhibitor wortmannin blocks the PDGF-induced translocation of overexpressed recombinant GFP-PH-PLCγ1. This study demonstrated that there is a crosstalk between PLCγ1 and PI3K pathway and added important information to understand the mechanism of PLCγ1 activation (Figure 1.12). Furthermore the observation that PH/PtdIns(3,4,5)P3 interaction is essential for PLCγ1 activation suggested the possibility of inhibiting PLCγ1 activation using molecules that block PLCγ1 translocation by competing with this interaction.
Figure 1.12: Crosstalk of PI3K/PLCγ1: PLCγ1 and PI3K are activated by growth factors. Binding of PtdIns(3,4,5)P₃ to PLCγ1 the PH domain and the interaction of SH2 domains of PLCγ1 with phosphotyrosine of TKRs lead to translocation of PLCγ1 to the plasma membrane and its activation (Falasca et al., 1998).

1.3.3 PLCγ1 activation and integrins

Extracellular Matrix Components (ECM) represent the main tissue’s mechanical support and a barrier for cell migration. ECM components provide the substrates for cellular migration triggering outside-in signalling promoting cell migration. Integrins are a family of glycoproteins, composed of α-subunits and β-subunits, which are responsible for cellular interaction with ECM components. Integrins form specific heterodimers with different binding specificity to ECM components. Each heterodimer presents an extracellular domain required for ECM component engagement and an intracellular domain responsible
for the propagation of the outside-in signal (Figure 1.13) (Friedl and Wolf, 2003).

![Diagram of integrin heterodimer](image)

**Figure 1.13:** Representation of integrins heterodimer (adapted from Cooper, 2000).

The outside-in signal activated by engaged integrins leads to activation of downstream pathways that control survival and migration. The focal adhesion kinase (FAK) is phosphorylated after integrin engagement with ECM components. FAK presents a FERM domain able to interact with growth factor receptors and the β-integrin subunit. Following integrin engagement FAK gets autophosphorylated at Tyr 397, the main phosphorylation site of the protein (Sieg et al., 2000). This activated conformation promotes the interaction with the kinase Src which is mediated by the Src SH2 and SH3 domains that recognise FAK phosphotyrosine and FAK proline-rich sequence respectively (Thomas et al., 1998; Frame et al., 2010). Therefore ECM-integrin engagement activates FAK and Src together with other effectors such as PI3K and ERK, promoting cell survival and cellular migration. PLCγ1 is also able to
interact with the phosphorylated form of FAK through its C-terminal SH2 domain. This interaction stimulates the tyrosine phosphorylation of PLCγ1 and its enzymatic activity, although FAK is not directly involved in PLCγ1 phosphorylation (Zhang et al., 1999). ECM-integrins engagement activates PLCγ1, as indicated by PLCγ1 tyrosine phosphorylation in cells seeded on Matrigel or fibronectin (Langholz et al., 1997; Tvorogov et al., 2004) and it is important for cell migration and changes in morphology upon integrin engagement (Kassis et al. 1999; Jones et al., 2005). Indeed, an integrin-blocking antibody inhibits PLCγ1 phosphorylation. Similarly, PLCγ1 inhibition through specific siRNAs or using the pan-PLC chemical inhibitor U73312 blocks the integrin induced cellular morphology change and cell migration. It has been demonstrated that the ECM-integrin induced PLCγ1 activation occurs downstream of Src kinase, which phosphorylates PLCγ1 in Tyr 783. Indeed inhibition of Src with the specific Src-inhibitor PP2, blocks Ins(1,4,5)P3 production and calcium release (Jones et al., 2005) (Figure 1.14). Furthermore PLCγ1 and Src co-immunoprecipitate in a complex together with GIT1, that acts as a molecular adapter between PLCγ1 and Src (Haendler et al., 2003).
Figure 1.14: Model of ECM-integrin-induced PLCγ1 activation (adapted from Jones et al., 2005)

1.3.4 Biological functions of PLCγ1

In the previous chapter the different modalities of PLCγ1 activation were described. This chapter will focus on the role of PLCγ1. Mice PLCγ1−/− are not viable and die after the first week of gestation. In particular mice PLCγ1−/− develop normally at E8.5, but at E9.5 are markedly reduced in size and die in the following stages. These data indicate that PLCγ1 plays an essential role in development (Ji et al., 1997). Fibroblasts isolated from these embryos proliferate normally upon addition of different mitogenic factors but fail to mobilize calcium upon EGF stimulation (Ji et al., 1998). However other reports showed that PLCγ1 promotes cell growth in fibroblasts in a catalytic-independent mechanism (Huang et al., 1995). In particular the SH3 domain of PLCγ1 has been reported to interact with the Ras exchange factor SOS1, promoting Ras activation (Kim et al., 2000).
Similarly the SH3 domain of PLCγ1 interacts with the protein kinase Jak2 in a process implicated in the modulation of growth hormone signalling (Choi et al., 2006). Several lines of evidence suggest a catalytic-independent role of PLCγ1 as guanine nucleotide exchanger (Ye et al., 2002; Choi et al., 2004) and also as a key regulator of agonist-induced Ca^{2+} entry (Patterson et al., 2002). Analysis of mouse embryos revealed that PLCγ1 is essential in angiogenesis. Embryos PLCγ1−/− showed no erithropoiesis, reduced vasculogenesis and reduced levels of vascular endothelial growth factor (VEGF) receptor expression (Liao et al., 2002). Similarly, mutation of the PLCγ1 orthologue causes defects in arteries formation (Lawson et al., 2003) in zebra fish. In umbilical vein endothelial cells (HUVEC), FGF-2 activates PLCγ1 in a PI3K-dependent manner. In these cells pharmacological inhibition or downregulation of PLCγ1 inhibits the FGF-2 induced cell migration and the tubulogenesis in vitro (Maffucci et al., 2009). Altogether these data indicate that, although PLCγ2 is the PLC isoform specifically expressed in the hematopoietic tissue, PLCγ1 is essential in early stage of development and the two isoforms have not overlapping roles.

It has been reported that PLCγ1−/− fibroblasts show a significant decrease in fibronectin-induced adhesion compared to normal fibroblasts (Tvorogov et al., 2005). Furthermore inhibition of PLCγ1 by siRNA or pharmacological inhibition affects cell morphology of cells seeded on ECM components such as Matrigel. In particular both HUVEC endothelial cells and cancer cells such as BE (colon carcinoma) and DU145 (prostate cancer) showed a rounded morphology when plated on Matrigel upon PLCγ1 knockdown or after treatment with U73122 (Jones et al., 2005). PLCγ1 plays an important role in cell movement regulation and cytoskeleton remodelling upon integrin engagement or growth factor stimulation. Inhibition of PLCγ1 reduces growth factor-induced cell motility in cancer cell lines and endothelial cells (Kassis et al., 1999; Maffucci et al., 2009). EGF-induced motility has been extensively investigated in cancer cell lines. EGF stimulation induces cytoskeleton
rearrangement, stimulating actin filament polymerisation (Chan et al., 1998). As described in chapter 1.1.1.1 PLC\(\gamma\)1 is involved in the regulation of actin polymerisation activating actin binding proteins (ABPs) such as cofilin, profilin and gelsolin through hydrolysis of PtdIns(4,5)P\(_2\) (Wang et al., 2007). PLC\(\gamma\)1 inhibition blocks the cofilin activity and inhibits the early actin polymerisation and the generation of new barbed ends (Figure 1.15) (Mouneimne et al., 2004). During chemotaxis, the asymmetric actin polymerization generates a cell polarity towards the stimulus, essential for chemotaxis and for cell directionality. Chemotaxis assays showed that the normal EGF-induced polymerisation of actin filaments at the leading edge of the cells, which induces a well-defined cell polarity, is completely blocked following inhibition of PLC\(\gamma\)1. Indeed cells treated with U73122 failed to develop a well-defined cell polarity indicating that PLC\(\gamma\)1 is essential for protrusion formation upon EGF stimulation (Jones et al., 2005). The activation of PLC\(\gamma\)1 at the leading edge is PI3K dependent. Indeed inhibition of PI3K pathway inhibits PLC\(\gamma\)1 translocation at the leading edge (Piccolo et al., 2002).

![Figure 1.15: Model of cofilin activation (adapted by Wang et al., 2007)](image_url)
1.3.5 Overview of the cell migration process.

The ability of cells to migrate and to move towards a chemo-attractant is an important process occurring in many physiological conditions such as embryogenesis, wound healing and the immune system response. Cell migration and invasion play also a very important role in cancer, allowing tumour cells to invade the surrounding tissue and eventually leading to dissemination of cancer cells during the metastatic process. Extracellular Matrix Components (ECM) represent the main tissue’s mechanical support and a barrier for cell migration. Integrins play an essential role in ECM-induced signalling (see chapter 1.3.3), and growth factors stimulate cell motility. During cell migration, integrins become locally enriched in regions of the plasma membrane defined as focal complexes which eventually evolve in focal contact regions (Burridge and Chrzanowska-Wodicka, 1992). The composition of focal complex depends on the relative abundance of the different ECM components and results in local enrichment of integrin heterodimers accordingly to the different ECM components available. Upon integrin engagement and growth factor stimulation, the cytoskeleton remodelling machinery becomes activated. In this process PI3K, PLCγ1 and the Rho family of small GTPase play an essential role stimulating cytoskeleton remodelling and the formation of cell protrusion at the leading edge of the cells (see chapter 1.1.1.1 and 1.3.4). The ECM-engaged integrins are able to associate with α-actinin, tensin, vinculin that bind integrins directly to the cytoskeleton, creating a direct link between focal adhesions and cytoskeleton (Figure 1.16-1,2) (Zamir and Geiger, 2001). These complexes are essential to generate the forces necessary to extend cellular protrusion. During the initial steps, when little adhesion is present at the leading edge, actin filament elongation extends the leading edge pushing the membrane in an outward direction. Movements within the ECM often require proteolysis of the ECM itself allowing the cells to create a path of migration. For this reason membrane-type matrix metalloproteinase enzymes are required for ECM digestion in order to create the space for cellular migration (Figure 1.16-3)
(Friedl and Wolf, 2003). Late the contraction driven by myosin II along the stress fibres leads to the contraction of the cell body towards the leading edge, pushing the cells forward (Figure 1.16-4). The coordinated sequence of these steps leads to the movement of the cell on the ECM or toward a chemo-attractant. Inhibition of one of these phases results in inhibition of cell migration and motility. As described in chapter 1.3.4, PLCγ1 is an important hub in cell motility regulation. Indeed its inhibition reduced cell motility upon growth factor and integrin-engagement stimulation, due to its important role in regulating the cytoskeleton remodelling through the activation of effectors such as Rac1 and cofilin (Li et al., 2009; Mouneimne et al., 2004; van Rheenen et al., 2007).

Figure 1.16: Model of cell migration summarising the process in 4 steps: 1-pseudopod protrusion at the leading edge, 2-formation of focal contact,
3- focalized proteolysis, 4-actomyosin contraction (Friedl and Wolf, 2003).

1.3.6 PLCγ1 and Rac1

The Rho GTPase family belongs to the Ras superfamily and has an important role in cytoskeleton rearrangement and actin polymerisation. The small GTPases are guanine-nucleotide-binding proteins which are in an “OFF” conformation when bound to GDP but switch to an “ON” conformation when bound to GTP. The cycling between the two forms is controlled by the activity of GEFs proteins (Guanine Exchange Factor), which induces the release of GDP from the small GTPase proteins and its replacement with GTP and GAPs (GTPase activating protein) which activate the GTPase activity and induce the hydrolysis of GTP to GDP. The Rho family presents, among other members, three subfamilies that control different processes within the cytoskeleton remodelling: Cdc42, Rac and Rho subclasses. In particular, Rho members are involved in formation of stress fiber and focal adhesion, Cdc42 in filopodia organisation and Rac in lamellipodia and membrane ruffles formation. Rac in particular activates the WASP and WAVE proteins that in turn activate the ARP2/3 complex and therefore induce actin nucleation (Haesman and Ridley, 2008). These structures are essential for cellular migration and motility. Both PLCγ1 and Rac1 have been shown to regulate cytoskeleton remodelling upon EGF stimulation (Wells et al., 2002; Ridley et al, 1992). A direct link exists between PLCγ isoforms and Rac1. While binding of Rac1 to the split PH domain of PLCγ2 is important for the Rac1-dependent activation of PLCγ2 (Walliser et al., 2008), the direct interaction of Rac1 with PLCγ1 promotes Rac1 activation (Jones and Katan, 2007). Indeed PLCγ1 associates with Rac1 upon EGF stimulation and promotes its activation. The SH3 domain of PLCγ1 is essential for this interaction and mutation of this domain abrogates Rac1 binding and its activation (Figure 1.17) (Li et al., 2009). Similarly, downregulation of PLCγ1 inhibits EGF- and serum-induced
activation of Rac1. It has been shown that PLCγ1 is a GEF specific for Rac1, which is consistent with the ability of PLCγ1 to activate Rac1. In particular the SH3 domain of PLCγ1 is responsible for the GEF activity. Indeed in vitro assay showed that PLCγ1 SH3 domain alone induces Rac1-GTP binding. (Li et al., 2009).

Figure 1.17: Model of EGF-induced Rac1 activation downstream of PLCγ1

1.4 Role of PLCγ1 in cancer

As a key downstream effector of EGF receptor (EGFR), PLCγ1 is likely to be involved in tumour progression. EGFR family members are often overexpressed in many cancers such as prostate, breast, head and neck cancers and many others (Agus et al., 2002; Scagliotti et al., 2004). Increased PLCγ1 expression was reported in breast carcinoma samples compared to healthy tissue, although this study did not connect the overexpression pattern to any particular stage of the disease (Arteaga et
In parallel other studies demonstrated the activation of PLCγ1 downstream of EGF. In particular, EGFR overexpression in fibroblasts induced PLCγ1 phosphorylation and increased motility upon EGF stimulation. Pharmacological inhibition of PLCγ1 or expression of a PLCγ1 dominant negative inhibited cell migration but it had no effect on EGF-induced mitogenesis, demonstrating the specific role of PLCγ1 in cell motility (Chen et al., 1994).

Increased cell motility plays an essential role in invasive cancers and metastasis. The role of PLCγ1 in cell invasion was assessed in vivo by injecting mice with DU145 prostate cancer cells expressing a PLCγ1 dominant negative mutant (PLCz). This dominant negative mutant of PLCγ1 inhibited primary tumour spreading and local invasion. Notably PLCγ1 inhibition had no effect on cell growth confirming the main role of PLCγ1 in cell invasion downstream of EGFR (Turner et al., 1997). Further in vitro invasion experiments using different breast and prostate cancer cell lines showed the broad role of PLCγ1 in cell invasion. Indeed pharmacological inhibition of PLCγ1 was able to inhibit in vitro Matrigel invasion in all the cell lines tested (Kassis et al., 1999), demonstrating the role of PLCγ1 in cell invasion. These results highlighted PLCγ1 as a potential target to inhibit carcinoma.

Although these reports provided a “proof of concept” that PLCγ1 can be targeted to inhibit tumour invasion, there was no clear in vivo proof of its importance in the metastatic process. The MMTV-PyVmT and TRAMP mice models, which respectively express the oncogenic Mice Mammary Tumour virus and the Polyoma middle T antigen, develop respectively breast cancer and prostate cancer and therefore represent a good model to study metastasis arisen from oncogene-induced primary tumour. The expression of breast- and prostate-localised PLCz dominant negative peptide had no effect on the primary tumour size but decreased the invasiveness of primary tumours and, most importantly, reduced formation of distant lung metastasis, showing the importance of PLCγ1 in
metastasis development (Shepard et al., 2007). A recent work published by our laboratory, in which I contributed as co-author, showed that downregulation of PLCγ1 had no effect on primary xenografted tumour whereas it inhibited the development of lung metastases derived from human breast cancer cell line MDA-MB-231 injected in the tail vein (Figure 1.18A) (Sala et al., 2008). In particular the downregulation of PLCγ1 in the injected MDA-MB-231 was achieved using specific shRNAs which were expressed in a stable or tetracycline inducible system. The shRNA represents a more specific system compared to the dominant negative system used in previous works. Furthermore the inducible downregulating system allowed us to downregulate PLCγ1 after the injection. Mice injected with breast cancer cells MDA-MB-231 stably downregulated for PLCγ1 showed inhibition of lung metastases development compared to mice injected with cell expressing PLCγ1 (Sala et al., 2008). To further understand the role of PLCγ1 in metastasis, mice were injected with MDA-MB-231 expressing the tetracycline inducible downregulating system targeting PLCγ1. Mice were not treated with tetracycline after the injection in order to maintain the expression of PLCγ1 in the cancer cells. Micro-metastases were detectable after 15 days from the injection. Therefore after 15 days from the injection, mice where treated with tetracycline, in order to activate the tetracycline-induced downregulation of PLCγ1 in the cancer cells. PLCγ1 downregulation induced regression of lungs metastases (Figure 1.18B). In fact, four of five lung tissues in both stable and inducible PLCγ1 knockdown were completely metastasis-free and only one mouse showed few metastases (Sala et al., 2008). These data showed that PLCγ1 is important in the early steps of metastases development and, more important, that it is required for metastatic development since its downregulation induces metastases regression. These data enhanced the importance of PLCγ1 in cancer cell invasion highlighted by previous work and suggested that PLCγ1 may represent a novel anti-metastatic strategy.
Figure 1.18: PLCγ1 is important for metastasis development and progression. A) Control MDA-MB-231 expressing a tetracycline inducible non-targeting sequence (3MUT) and MDA-MB-231 expressing a tetracycline inducible targeting shRNA for PLCγ1 (shPLCγ1), were injected in mice and lung metastases were assessed after 60 days from the injection. Downregulation of PLCγ1 protein level upon induction by tetracycline was assessed by western blot. B) Representative lung sections from untreated mice or mice treated with tetracycline after 14 days from injection are shown. Arrows indicate micrometastases (Sala et al., 2008).
1.5 The metastatic process

The initiating events in the arising of cancer are mutating oncogenic events, defined tumour initiating mutations that provide cells with enhanced proliferation rate, resistance to cell death and chromosomal and genetic instability (Figure 1.19-a,b) (Fidler, 2002). Mutation of EGFR and altered PI3K pathway, due to PI3K overexpression or inactive mutations of PTEN or its deletion are a well-established example of oncogenic events (Kok et al., 2009; Gonzalez-Angulo et al., 2011). In some cases tumour cells migrate from the primary tumour to distant healthy tissues initiating a second cancerous lesion called metastasis. Often metastasis remains dependent on such alterations, and inhibition of those pathways leads to tumour and metastatic regression. However, very often, metastases develop new mutations and become resistant to treatment, resulting in poor prognosis. Cells crossing the tissue boundaries find themselves in a different environment and altered pathways help these cells to survive and proliferate (Nguyen et al., 2009). The initiation of a novel tumour occurs in specific host organs whose microenvironment stimulates metastasis development. In particular physical characteristics of the organ structure and specific cytokines, determine the homing of metastatic cancer cells. For example expression of epiregulin, prostaglandin G/H, matrix metalloproteinase 1 (MMP1) and MMP2 in breast cancer cell lines has been implicated in breast cancer lung metastasis (Minn et al., 2007). The mutual relationship between the origin of cancer cells and the site for metastasis development was observed by Paget more than 100 years ago when he compared cancer cells to the “seed” and the specific host organ as the “soil” and highlighted the “conditio sine qua non” seed and soil has to be compatible (Fidler, 2002). The metastatic process can be subdivided into intravasation, survival in the circulation, extravasation and colonisation at distant site (Fidler, 2003; Nguyen et al., 2009). During this process, usually characterised by tumour-driven-angiogenesis, the tumour reaches the tissue boundaries allowing some cancer cells to enter the circulatory system (Figure 1.19-
c,d), during the intravasation phase. Cells entering the circulatory system undergo mechanical stress and they are targeted by the immune system. Therefore only few cells survive during this phase, which eventually is followed by extravasation. In this phase cells expressing extravasation genes such as metalloproteinases genes (MMPs) and CCL5 are characterised by enhanced ability to adhere to the blood vessel wall, to invade distant tissues and to initiate novel distant tumours (Figure 1.19-e) (Nguyen et al., 2009). It is well established that different steps are necessary for development of metastatic tumours and each step requires a highly selective process which selects cancer cells with metastatic characteristics. This is due to the fact that metastases are the results of a high selective process that selects populations of cancer cells presenting enhanced expression of metastasis initiating genes and metastasis progression-related genes which allows them to resist the environment of the newly colonised organ and often confers resistance to anti-cancer treatments. For example parathyroid hormone related protein (PTHRP) and interleukin 11 (IL-11) expression enable breast cancer cells to generate osteolytic metastases but they have no effect on primary tumour growth (Yin et al., 1999; Kang et al., 2003). The increased invasiveness and the ability of cancer cells to reach and colonise distant tissues are the main characteristics of metastasis. The tumour cell invasion role is a complex process whereby a group of epithelial-derived cells invade adjacent tissue in a coordinated fashion. The invasion is accompanied by cell proliferation and morphogenic differentiation. In this context the fact that PLCγ1 has been demonstrated to be essential for metastasis development and progression (chapter 1.4), but not for primary tumour growth, highlights PLCγ1 as an important determinant protein for metastasis development and a potential antimetastatic target.
Figure 1.19: Model of metastasis dissemination and initiation of a novel distant tumour (Fidler, 2002).
1.6 Breast cancer

In 2008 47,700 women were diagnosed with breast cancer in the UK (Official Cancer Research UK cancer statistical analysis). Breast cancer is a heterogeneous disease and therefore treatments have different outcomes according to the origin of the carcinoma and the tumour stage. The breast gland consists of lobules and ducts. In particular lobules present a luminal compartment surrounded by luminal cells. Ducts consist of ductal cells which define a tubular structure necessary for carrying the milk secreted in the lobules. Cancer cells can originate from both ducts (ductal carcinoma) and lobules (lobular carcinoma). Histopathological classification defines breast cancer as carcinoma in situ, when it is still limited by the basal membrane of the ducts and therefore it is not spread. The invasive carcinoma presents local infiltration of cancer cells and fixation of the tumour to skin and the underlying pectoralis fascia. Breast cancer-derived metastases may be found in lymph node, lungs, brain and bones. In general breast cancers are classified according to the tumour size (T), presence of nodule (N) and distant metastases occurrence (M). However molecular biology approaches, such as microarray analysis of breast cancer patient tissues, classify breast cancer on the basis of gene expression signature as: normal breast-like, ERBB2, basal-like and luminal-like breast cancer. In particular luminal breast cancer-like is associated with high levels of oestrogen receptor (ER), while normal breast-like, ERBB2, and basal-like breast cancers are associated with low level of ER (Perou et al., 2000; Sorlie et al., 2001). Tumours overexpressing ER depend on oestrogen for proliferation, therefore these tumours are responsive to hormone therapy. However selective pressure contributes to select ER cell populations, which are not dependent on oestrogen to proliferate and therefore are resistant to hormone therapy context. Generally in breast cancer, selective pressure contributes to the generation of ERBB2 and EGFR gene amplification. The overexpression of these receptors provides the tumour cells with enhanced growth and motility. EGFR and ERBB2 belong to the family of epidermal growth
factor receptors composed by EGFR/ERBB1, ERBB2, ERBB3 and ERBB4. Ligand binds to the extracellular domain, induces heterodimerisation and activates receptor autophosphorylation activating the downstream pathways. The ERBBs receptors present heterogeneous characteristics. ERBB2 for example possesses an extracellular domain but no ERBB2 ligand is known, while ERBB3 possesses a non-functional kinase domain. However ERBB3 seems to be essential for the tumorigenesis induced by ERBB2. Increased expression of ERBB3 potentiates the ERBB2 induced transformation, while ERBB3 loss inhibits ERBB2-induced transformation. Since the epidermal growth factor has a crucial role in breast cancer, specific drugs targeting the HERBB receptors were developed. For example, Trastuzumab is a monoclonal antibody that recognizes the extracellular domain of ERBB2 receptor, inhibiting the activation of the receptor (Molina et al., 2001). In the case of ERBB2 overexpressing metastatic breast cancers, Trastuzumab extended the progression-free and recurrence-free survival when combined with cytotoxic drugs like taxanes or cisplatin (Burstein et al., 2007). Trastuzumab and hormone therapy are a valid therapy in case of ER\(^+\) and ERBB2-overexpressing breast cancers. However about 15% of breast cancer tumours belong to the basal-like breast cancer subtype, which are also ER\(^-\). The almost totality of this subtype do not present expression of oestrogen, progesterone and ERBB2 receptors and therefore are called triple negative (Bauer et al., 2007). Triple negative cancer patients have poor prognosis and do not respond to endocrine therapies or ERBB2 targeting therapies. It has been demonstrated that triple negative phenotype correlates with mutation of the tumour suppressor BRCA1 and EGFR is often overexpressed in this tumour type. Clinical trials, which employ an EGFR targeting approach such as the tyrosine kinase inhibitor lapatinib and the EGFR-targeting antibody Cetuximab, showed a positive response when combined with genotoxic treatments such as carboplatin and DNA-damaging treatment (Cleator et al., 2007). The overall progress in breast cancer treatment and molecular mechanisms involved in breast cancer, early diagnosis and screening programs contributed to decrease
mortality rate of 37% compared to 1989 (Breast cancer UK, 2009). However, very little progresses has been done in curing metastatic breast cancer. Despite the therapeutic improvements about 30% of patients with breast cancer develop recurrent advanced metastases, indicating no significant advances in anti-metastatic treatment for metastatic breast cancer, and for metastasis spreading in general. Currently no effective anti-metastatic drugs are available and metastasis remains the main cause of cancer-related death.

1.7 3-Phosphoinositide-Dependent-Protein-Kinase-1 (PDK1) in cancer as potential therapeutic target

Cancer cell proliferation and survival is tightly regulated by hormones and growth factors that activate specific intracellular pathways inside the cell. Understanding the signalling pathways involved in these processes may help us to find predictive factors for tumour aggressiveness and develop new anticancer drugs. Among the different pathways, signals transmitted by the PI3K/AKT pathway have proven to be important for cell survival in many cell types (Chapter 1.1.2). Although Akt is considered to be one of the key enzymes regulating growth and proliferation of cancer cells, there is increasing evidence that Akt-independent pathways, downstream of PI3K activation, may also play a crucial role in driving tumour progression. In this respect, the existence of PDK1-mediated/Akt-independent pathways has been recently identified (Vasudevan et al., 2009). Despite the importance of PDK1 in cell signalling, less attention has been paid to this kinase for its role in cancer and as a therapeutic target.

1.7.1 Biological functions of PDK1

The role of PDK1 has been investigated in vivo in yeast, Drosophila (Casamayor et al., 1999; Cho et al., 2001; Lawlor et al., 2002) and mice.
In the examined organism the absence of PDK1 is lethal. Mice PDK1<sup>−/−</sup> lack branchial arches and exhibit problems in neural crest specification and forebrain development, and several disruptions in the development of a functional circulatory system, which eventually causes death at E9.5 (Lawlor et al., 2002). In order to study the role of PDK1 in development, hypomorphic mice for PDK1 were generated showing a reduced expression of PDK1 in all tissues. These mice showed a decreased body size of 40-50% compared to the wild type littermates, but showed no significant differences in the activation of AKT induced by insulin compared to their littermates. Analysis of organs revealed that the difference in size is due to a decreased cell size rather than reduction in cell number. Furthermore mice expressing a PDK1 mutated form unable to bind phosphoinositides present a strongly reduced AKT activation, insulin resistance and hyperinsulinaemia (Bayascas et al., 2008).

1.7.2 PDK1 in cancer

Hyperactivation of the PI3K/PDK1/AKT pathway is found in many human cancers. As described in chapter 1.1.2, PTEN is often mutated in human cancer and its absence causes a hyperactivation of the mitogenic signal promoted by PI3K, promoting tumourigenesis. The hypomorphic PDK1 mice model was a useful tool to investigate the role of PDK1 under increased PI3K signalling pathway. Hypomorphic PDK1 mutations in mice showed increased resistance to develop tumours when crossed with mice PTEN<sup>+/−</sup> indicating that PDK1 can be an important therapeutic target in cancers that present hyperactivation of the PTEN/PI3K/AKT pathway (Bayascas et al., 2005). PDK1 plays a pivotal role in breast cancer development. Increased copy number of PDK1 is often present in human breast cancer compared to normal breast epithelia and correlates with upstream PI3K pathway activation. In particular, increased copy number of PDK1 correlates with the presence of activating mutation of PI3K class 1 p110α or with ERBB2 overexpression (Maurer et al., 2009). Furthermore, using an RNA interference library targeting 779 kinases and related proteins, the PDK1 signalling pathway has been identified as a strong
determinant of sensitivity to multiple ER\(\alpha\) antagonists, including tamoxifen the most commonly used drug to treat breast cancer whose usefulness is limited by the development of resistance (Iorns et al., 2009; Peifer and Alessi, 2009). Whether PDK1 is essential for tumourigenesis initiation or it is required in later stages is still unclear. Overexpression of PDK1 in non tumourigenic breast epithelial cell line MCF10A does not alter cell growth and the normal multicentric morphology in three-dimensional culture conditions. Strikingly, co-overexpression of PDK1 and of the active mutant rat homolog of ERBB2 in MCF10A causes a profoundly distorted three-dimensional multicentric organization and confers increased cell motility regardless of the presence of chemo-attractant (Maurer et al., 2009). Indeed, PDK1 positively regulates ROCK1 in a kinase-independent manner. ROCK1 is a protein kinase involved in the phosphorylation of the myosin light chain and it is therefore involved in acto-myosin contractility. In particular promoting ROCK1 is essential for cell motility in three-dimensional conditions and \textit{in vivo}. Several studies have shown that upregulation of Rho-ROCK signalling in tumours is linked to increased invasion and metastatic potential (Pinner and Sahai, 2008). Noteworthy, the PDK1-dependent regulation of ROCK1 seems particularly important in three-dimensional environments. Interestingly, knock down of PDK1 has no effect on cell growth under standard tissue culture conditions in a panel of breast, colon, lungs and prostate cancer cell lines. However pharmacological inhibition of PDK1 or PDK1 knockdown inhibits cell growth in three-dimensional culture conditions on Matrigel or the anchorage-independent growth. Furthermore PDK1 inhibition inhibits Matrigel cell invasion in breast cancer cell lines, prostate cancer and melanoma (Pinner and Sahai, 2008; Nogashima et al., 2010), in line with data showed in this thesis.
1.7.3 PDK1-dependent pathways

3-phosphoinositide-dependent-protein kinase 1 (PDK1) is a kinase belonging to family of the AGC kinases. The AGC kinase family includes serine and threonine kinases with high identity of their catalytic domain to cAMP-dependent protein kinase 1 (PKA), cGMP-dependent protein kinase (PKG) and protein kinase C (PKC). The AGC kinases possess a conserved bi-lobed structure which defined the catalytic domain. The amino-terminal small lobe and the carboxy-terminal large lobe sandwich one ATP molecule essential for the subsequent substrate phosphorylation. Many AGC kinases possess two phosphorylation sites that regulate their activation: the activation loop, which is located within the kinase domain, and the hydrophobic motif which is located in a region adjacent to the catalytic domain. Phosphorylation of these sites increases the kinase activity and leads to enzymatic full activation. PDK1 was originally discovered in 1997 as the kinase responsible for the phosphorylation of AKT activation loop at the residue threonine 308, essential for enzyme activation (Alessi et al., 1997). Furthermore AKT phosphorylation at Thr308 was dependent in vitro on PtdIns(3,4,5)P\(_3\) concentration, linking PDK1 to the upstream activation of PI3K. PDK1 is a protein of 556 amino acids that possesses a catalytic domain and a PH domain. As a member of the AGC kinase, PDK1 shows a phosphorylation site in S241 which is located in the activation loop. The PDK1 activation loop is phosphorylated in resting cells and this event is not affected by growth factor stimulation. Phosphorylation of PDK1 at S241 is catalysed by an autophosphorylation reaction in trans, meaning that PDK1 is autophosphorylated by another PDK1 molecule (Wick et al., 2003). Therefore PDK1 kinase activity is constitutively active and regulation of PDK1-activated signalling involves other mechanisms. The first mechanism was discovered investigating the steps involved in AKT-T-loop phosphorylation in living cells. PDK1 is localised at the plasma membrane because of the interaction of its PH domain with the phosphoinositides PtdIns(3,4,5)P\(_3\), PtdIns(3,4)P\(_2\) and PtdIns(4,5)P\(_2\), with
the highest affinity towards the PI3K lipid products (Currie et al., 1999). The affinity of PDK1-PH domain for the PI3K products suggested a potential PI3K-dependent PDK1 membrane translocation. Although PDK1 membrane localisation has been largely investigated and supported, the dynamic of this localisation is controversial. Whether PDK1 translocates to the plasma membrane following growth factor stimulation, or it is constitutively localised to the plasma membrane is still debated. Growth factor-induced PDK1 membrane translocation was observed by confocal analysis (Anderson et al., 1998; Filippa et al., 2000). However another study employing high resolution electron microscopy analysis revealed a constitutive PDK1 membrane localisation without further translocation following growth factor stimulation (Currie et al., 1999). PDK1 membrane localisation is essential for AKT phosphorylation at Thr308. Growth factor-induced AKT membrane translocation leads to PDK1 and AKT co-localisation at the plasma membrane following PI3K activation, since both proteins bind PtdIns(3,4,5)P$_3$. AKT membrane recruitment causes conformational changes in AKT which allow the phosphorylation of AKT by PDK1 (Calleja et al., 2007) (Figure 1.20). Expression of a mutant AKT constitutively associated to the membrane resulted in full AKT phosphorylation at Thr308 in unstimulated cells (Andjelkovic et al., 1997), which may occur only in the presence of a membrane located PDK1 pool. On the contrary, mutation of the AKT-PH domain that abolishes AKT membrane recruitment strongly decreases AKT phosphorylation. Similarly, mutation or deletion of PDK1-PH domain strongly reduces AKT phosphorylation (Currie et al., 1999). PDK1-dependent AKT phosphorylation is therefore promoted by the co-localisation of both proteins to the plasma membrane, mediated by the interaction of the respective PH-domains with the PtdIns(3,4,5)P$_3$. 

65
A recent study reported that PDK1 exists as a homodimeric complex through PH domain interaction of two PDK1 monomers, and that this interaction is important in the regulation of AKT phosphorylation. Extracellular stimulation increases the basal homodimerisation in live cells in the cytosol and at the plasma membrane in a PI3K-dependent manner. Deletion of the entire PH domain or mutation of the threonine 513 within the PH domain, which is phosphorylated by PDK1 itself, inhibits the homodimer formation, favouring the monomeric PDK1 fraction and increases AKT Thr308 phosphorylation (Masters et al., 2010). This report identified the monomeric PDK1 form as a more active form in activating AKT compared to the homodimeric PDK1 form which resulted in an inhibited conformation. Therefore different mechanisms are
involved in AKT activation and the different steps showed above demonstrate a fine regulation of PDK1 pathway (Figure 1.20).

Although PDK1 was discovered for its ability to phosphorylate AKT, many other kinases are now known to act downstream of PDK1. For example the AGC kinases members serum glucocorticoid kinase (SGK), p70 ribosomal protein S6 kinases (S6K), p90 ribosomal protein S6 kinase (RSK), P21-activated kinases 1 (PAK1) and atypical protein kinase C (PKC) isoforms are known to be direct targets of PDK1, which phosphorylates specific serine/threonine residues of their activation loops (Mora et al., 2004). For this reason PDK1 has a main role in controlling cell proliferation, survival and cell motility and it has been termed “master AGC kinase”. The mechanism of activation of the PDK1-dependent kinases differs from the AKT activation mechanism. These protein kinases lack the PH domain but possess a hydrophobic motif that interacts with PDK1. The hydrophobic motif, also called PDK1 interacting fragment (PIF), lies in a conserved Phe-Xaa-Xaa-Phe/Tyr-Ser/Thr-Phe/Tyr sequence that undergoes phosphorylation in serine or threonine (Pearce et al., 2010). Phosphorylation of this site increases the binding of PDK1 to the hydrophobic motif, leading to the phosphorylation of the targeted kinases activation loop (Pullen et al., 1998; Alessi et al., 1998) (Figure 1.21). Mutagenesis of the hydrophobic motif decreases the PDK1-dependent phosphorylation of the activation loop. PDK1 is the only member of the AGC kinase family that lacks the hydrophobic motif, but structural analysis revealed that PDK1 presents a hydrophobic pocket, termed PDK1 interacting fragment pocket (PIF pocket), which is essential for PDK1 interaction with the hydrophobic motif of the targeted protein kinases (Biondi et al 2002). Mutations within the PDK1 PIF pocket abolish the binding of PDK1 to PKC, S6K and SGK1 and their subsequent phosphorylation and activation (Biondi et al., 2002). Therefore the PIF pocket represents a docking site that binds the PIF hydrophobic motif and promotes the phosphorylation of the activation loop of the targeted kinase.
**Figure 1.21:** Mechanism of activation of S6K and SGK kinases by PDK1 (adapted from Mora et al., 2004)

### 1.7.4 PDK1 as therapeutic target

Although several data showed that PDK1 plays an important role in cancer, no inhibitors were found to specifically inhibit PDK1. Many compounds able to inhibit PDK1 are small molecule inhibitors belonging to the class of ATP-competitive protein kinases inhibitors. These inhibitors compete for the ATP-binding to the kinase domain but often present off-target effects, being able to compete with the ATP binding of other protein kinases (Peifer and Alessi, 2008). Biochemical and structural data on the mechanism of action of PDK1 indicate that two additional
classes of PDK1 inhibitors could be exploited as druggable targets: the PIF pocket binding allosteric ligands and the PH domain competitors. A compound has been recently discovered in recent work performed by my group. The 2-O-Bn-InsP5 is an inositol derivative compound with specific PDK1 inhibitor activity presenting anticancer and pro-apoptotic properties \textit{in vivo}, able to block AKT Thr308 phosphorylation in cell lines and in excised tumours (Falasca et al., 2010). It has been proposed that inositol phosphates can bind PDK1 PH domain and retain this kinase in the cytosol, preventing Akt phosphorylation at Thr308 (Komander et al., 2004). New specific and potent inhibitors such as GSK2334470 (Najafov et al., 2010) and a pyridinonyl-based compound (Nagashima et al., 2010) were recently characterised and showed high selectivity and high potency in inhibiting PDK1. Therefore an increasing number of reports discovered the importance of PDK1 as a central hub in cancer development. However in the future it will be important to investigate \textit{in vivo} the pharmacological inhibition of PDK1 on tumour models, and eventually determine the pharmacokinetic and metabolic properties of specific PDK1 inhibitors identified for pre-clinical trials.

1.8 Inositol phosphates: promising lead compound for anticancer molecule development

Key enzymes such as AKT, PDK1 and PLC7 which are involved in cell proliferation, resistance to apoptosis and increased cell motility possess a PH domain that interacts with phosphoinositides and in particular with the 3-phosphorylated- phosphoinositides, in a mechanism that is essential for the enzyme activation. As described in chapter 1.2.4 it has been reported that PH domains can also bind to inositol polyphosphates, the soluble head-group of phosphoinositides. For instance Grp1-PH domain binds with high affinity the Ins(1,3,4,5)P4 with a KD of 27.3 nM and with lower affinity to other inositol polyphosphates (Lemmon et al., 1998). Similarly, structural studies showed that BTK-PH domain and AKT-PH domain
binds to Ins(1,3,4,5)P₄. BTK-PH domain interacts with 3-, 4- and 5-phosphates with the side chains of two acidic residues and with the backbone of the L1/L2 loop. This high number of contacts is sufficient to guarantee a stable interaction and accounts for the high affinity and specificity of the Btk PH domain for Ins(1,3,4,5)P₄ over Ins(1,4,5)P₃ (Maffucci and Falasca 2001). In the case of AKT PH domain, the interaction with Ins(1,3,4,5)P₄ leaves the 6-OH group exposed to the solvent, suggesting that the binding site could accommodate the phosphate group presented in the Ins(1,3,4,5,6)P₅ (Thomas et al 2003). These data suggested that inositol polyphosphates may be used as phosphoinositides antagonist, competing for binding the PH domain (Figure 1.22).

![Figure 1.22](image-url)  
**Figure 1.22:** Representation of the mechanism through which Ins(1,3,4,5,6)P₅ may inhibits AKT by competing with PtdIns(3,4,5)P₃ for binding AKT-PH domain.
It has been proposed that just as specific phosphoinositides activate different pathways in cells, specific inositol phosphates may block those pathways acting as specific antagonists (Berrie and Falasca, 2000). About 20 years ago it was discovered that a diet rich in inositol hexakisphosphate (InsP$_6$), named also phytic acid, correlates negatively with colon cancer (Vucenik et al., 2003). It was demonstrated that InsP$_6$ is internalized by cancer cells (Vucenik et al., 1994). Analysis of $^3$H labelled InsP$_6$ uptake and metabolism showed that InsP$_6$ is quickly uptaken in colon cancer cell lines and after 1 hour 56% of radioactivity is in InsP$_6$ form while the rest is in form of dephosphorylated inositol phosphates metabolic products (Sakamoto et al., 1993).

InsP$_6$ is a dietary supplement with antioxidant properties and it is also found in mammalian cells (Szwergold et al., 1987). InsP$_6$ has been found to be active in inhibiting tumour growth of leukemic hematopoietic cell line, breast, hepatoma, colon cell lines in vitro with different degrees of sensitivity accordingly to the cell lines (Shamsuddin et al., 1999; Singh et al., 2003). Furthermore InsP$_6$ showed protective effect for colon and breast cancer induced by different carcinogens and metastases formation in mice models injected with fibrosarcoma cells (Vucenik et al., 2003) and presents antiangiogenic properties in vitro and in vivo being able to inhibit tubulogenesis in vitro and blood vessel neogenesis induced by b-FGF in vivo (Vucenik et al., 2004). Treatment of Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice with InsP$_6$ in drinking water reduced the progression of prostate cancer lesions without any toxicity (Raina et al., 2008). All these evidences together points out that InsP$_6$ is able to prevent tumour growth and correlates with etiological evidences that diet rich in InsP$_6$-containing foods associates with protection against colon and prostate cancer (Vucenik et al., 2003). InsP$_6$ was shown to enhance the effect of Tamoxifen and Doxorubicin in breast cancer cell lines MDA-MB-231 and MCF7 and in breast cancer cells derived from primary tumour, in a synergistic manner in vitro, suggesting the potential usage of this compound as adjuvant therapy (Tantivejkul et
al., 2003). However the IC_{50} of InsP_{6} in inhibiting tumour cell growth \textit{in vitro} is between 1.26mM and 4.18mM according to the sensitivity of cancer cells. Although InsP_{6} treatment does not result in toxic effect in mice even at elevated concentrations (Ullah et al., 1990, Vucenik et al., 1995; Raina et al., 2008), it has to be noted that concentration of InsP_{6} (up to millimolar range) may result in reduced levels of multivalent cations and subsequent cell death due to its polyvalent cation-binding-properties (Torres et al., 2005). Moreover the high dose required to inhibit cell growth underlines a lack of molecular selectivity and specificity. One or more catabolic products of the InsP_{6} metabolism within the cells may be the InsP_{6}-derived active compounds responsible for the biological effects of InsP_{6}. This could also explain the high doses needed to inhibit tumour growth. It was recently demonstrated that \textit{in vivo} exogenous IP_{6} is rapidly dephosphorylated in plasma to inositol and to lower IPs (Eiseman et al., 2011). Moreover several lines of evidence suggest that the gut flora plays an essential role in InsP_{6} dephosphorylation and absorption. Indeed animals lacking the gut flora fail to incorporate detectable InsP_{6} (Wise and Gilburt, 1982; Sakamoto et al., 1993). These data suggest that although inositol phosphates present anti-tumour effects their effectiveness could be limited on tumour distant from the gastro-intestinal tract (Eiseman et al., 2011).

The effect of inositol phosphates has been tested \textit{in vitro} and \textit{in vivo} on tumour growth in the last 10 years. In particular among all the inositol polyphosphates, the inositol tetrakisphosphates Ins(1,4,5,6)P_{4} and pentakisphosphates Ins(1,3,4,5,6)P_{5} were found to inhibit cell growth and the anchorage-independent growth in breast cancer, ovarian and small cell lung cancer (SCLC) cell lines. Furthermore pre-treatment of cells with 50\mu M Ins(1,4,5,6)P_{4} blocked the growth factor-induced membrane translocation of overexpressed GFP-PH-AKT, indicating that this compound might be a selective inhibitor of PI3K/AKT pathway. Indeed, cell lines whose cell growth is PI3K independent and insensitive to the PI3K inhibitors LY294002 and Wortmannin, are also insensitive to
Ins(1,4,5,6)P₄ treatment (Razzini et al., 2000). Further work demonstrated that Ins(1,3,4,5,6)P₅ is the most potent inhibitor of PI3K/AKT pathway among the totality of inositol phosphates. Indeed Ins(1,3,4,5,6)P₅ induced apoptosis in ovarian cancer similarly to cisplatin and etoposide treatment and inhibited AKT S473 phosphorylation in ovarian and breast cancer cell lines that present increased activation of PI3K pathway. On the contrary proliferation of MDA-MB-231 and MCF7, which do not posses a constitutively activated PI3K/AKT pathway, were insensitive to Ins(1,3,4,5,6)P₅ treatment (Piccolo et al., 2004). In vivo experiments showed that Ins(1,3,4,5,6)P₅ blocks tumour growth in ovarian cancer cell line SKOV3 xenografted in mice and inhibits AKT S473 and T308 phosphorylation and also inhibits FGF-2-induced angiogenesis. Indeed Ins(1,3,4,5,6)Ps prevents cell migration and tubulogenesis induced by FGF-2 in human umbilical vein endothelial cells (HUVEC) both in vitro and in vivo through the inhibition of PI3K/AKT pathway which is also involved in the angiogenesis process (Maffucci et al., 2005). Therefore targeting PI3K/AKT pathway is an attractive therapeutic target as much as the possibility to use natural compounds such as Ins(1,3,4,5,6)P₅ or synthetic derivative compound in order to inhibiting this pathway.

Since mono therapy in cancer treatment showed limited effects, adjuvant therapies are often applied to cancer patient. In this prospective in vitro treatment of SKOV3 cells with Ins(1,3,4,5,6)P₅ and cisplatin, the main anticancer drug used for ovarian cancer treatment, showed a more than additive effects providing evidence that this compound is able to sensitise cancer cells to the cytotoxic anti-cancer drugs (Piccolo et al., 2004).

The constant research for novel PI3K/AKT pathway inhibitors, characterised by decreased toxic effects and improved potency and selectivity, induced my group in the last years to test inositol derivative compounds for their ability to inhibit the PI3K/AKT pathway. It was recently published that a benzene-tetrakisphosphate compound [Bz(1,2,3,4)P₄], an inositol phosphate surrogate, binds to AKT PH domain
with similar affinity to Ins(1,3,4,5)P₄ (Mills et al., 2007). Modification of the Ins(1,3,4,5,6)P₅ and analysis of X-ray structure of AKT PH domain showed that a tyrosine residue near the 6-OH of bound Ins(1,3,4,5,6)P₄ might interact with an aromatic group. As reported in Falasca et al., 2010, among different inositol phosphates tested on AKT activation, 2-O-Bn-InsP₅ resulted in AKT inhibition. In particular, 2-O-Bn-InsP₅ was more effective than Ins(1,3,4,5,6)P₅ in inhibiting growth and inducing apoptosis in SKBR3 and SKOV3 cell lines, which are sensitive to Ins(1,3,4,5,6)P₅ treatment. Strikingly, 2-O-Bn-InsP₅ induced apoptosis in Ins(1,3,4,5,6)P₅-resistant cell lines such as prostate cancer PC3, pancreatic cancer ASPC1 and breast cancer MDA-MB-468, inhibiting the phosphorylation of AKT in Ser473 and Thr308 in vitro. In vivo xenograft experiments using PC3 cells showed that 2-O-Bn-InsP₅ inhibited tumour growth and phosphorylation of AKT at Ser473 and Thr308, while Ins(1,3,4,5,6)P₅ had no effect on tumour growth and AKT phosphorylation. Kinase profiling showed that 2-O-Bn-InsP₅ is a very specific and potent inhibitor of PDK1 which is involved in AKT activation (Falasca et al., 2010).
Chapter 2
Materials and Methods
2.1 Cell culture

2.1.1 Cell lines

The cell lines used in the experiments performed in this thesis are listed in Table 2.1. Cells were available in the laboratory of Professor Marco Falasca unless otherwise stated.

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>Organ: mammary gland; breast</th>
<th>Disease: adenocarcinoma</th>
<th>Derived from metastatic site: pleural effusion</th>
<th>Cell Type: epithelia</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA-MB-231</td>
<td></td>
<td></td>
<td>The cell line originates from a pleural effusion of an earlier breast adenocarcinoma. MDA-MB-231 shows aneuploidy (modal number = 64, range = 52 to 68), with chromosome counts in the near-triploid range.</td>
<td></td>
</tr>
<tr>
<td>MDA-MB-435</td>
<td></td>
<td></td>
<td>A controversy originates about the true origins of these cells. MDA-MB-435 cell line was identified as breast cancer cells. Marker expression studies and genomic analysis questioned the breast origin and classified this cell line as melanoma cell line (Elison et al., 2002; Garraway LA). Recent update confirmed the MDA-MB-435 as a poorly differentiated breast tumour cell line with expression of both melanocytic and epithelial markers (Chambers 2009)</td>
<td></td>
</tr>
<tr>
<td>TSA</td>
<td>Organism: <em>Mus Musculus</em></td>
<td>Organ: mammary gland</td>
<td>TSA is an aggressive and poorly immunogenic cell line established from a moderately differentiated mammary adenocarcinoma that arose spontaneously in a multiparous BALB/c mouse.</td>
<td></td>
</tr>
<tr>
<td>A375M</td>
<td>Organ: Skin</td>
<td>Disease: Invasive melanoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEK293T</td>
<td>Organ: embryonic kidney</td>
<td>Cell type: transformed with adenovirus 5 DNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4T1</td>
<td>Organism: <em>Mus musculus</em></td>
<td>Organ: mammary gland</td>
<td>4T1 cell line is a mouse syngenic model of breast cancer. 4T1 produces highly metastatic tumors in BALB/c mice that can metastasise to the lung, liver, lymph nodes and brain while the primary tumor is growing in situ.</td>
<td></td>
</tr>
</tbody>
</table>
HUVEC | Organ: Human umbilical vein  
Cell type: Endothelial  
HUVEC are responsive to cytokine stimulation and are commonly used for physiological and pharmacological investigations.

2.1.2 Cell culture and propagation

MDA-MB-231 and Human embryonic kidney cells were cultured in DMEM growth media (Invitrogen) supplemented with 10% (v/v) Foetal Bovine Serum (FBS) (Invitrogen), Sodium Pyruvate 1% (v/v), 1X L-glutamine/penicillin/streptomycin (Invitrogen) and 0.1% gentamycin (v/v) (Invitrogen, UK). MDA-MB-435, 4T1, TSA and A375M were cultured in RPMI 1640 growth media (Invitrogen or PAA, UK) supplemented with 10% (v/v) Foetal Bovine Serum (FBS), Sodium Pyruvate 1% (v/v), 1X L-glutamine/penicillin/streptomycin and 0.1% gentamycin (v/v). Cells were seeded in tissue culture treated plastic 10 cm dishes or the appropriate 6 cm petri dishes, multi-well dishes (BD, UK) and grown in humidified incubator at 37°C in a 5% CO₂ atmosphere.

2.1.3 Cell amplification and passage

All cells lines were passaged when 80-85% confluent. Growth medium was aspirated and cells were washed twice in 5ml of sterile phosphate buffered saline solution (PBS) (PAA, Austria) for 20-30 seconds and then incubated with 3ml of trypsin (0.25%)/EDTA(0.2g/l) (PAA, Austria) solution to detach the cells. After 3-5 minutes, cells were harvested in 5ml of the appropriate complete growth media and gently pipetted up and down before being pelleted by centrifugation at 250g for 5 minutes at room temperature in 15ml or 50ml centrifuge tubes (Falcon-BD, UK). Cell pellets were resuspended in the appropriate growth media and re-plated as required in new tissue culture plates. Cells were passaged every 2-3 days. Growth media was changed every 48 hours when needed.
2.1.4 Cryo-conservation and recovery of cell lines

Cells in a 10 cm petri dishes were detached when 80-85% confluent. Cells were washed in 1X PBS and incubated with 3ml of trypsin (0.25%)/EDTA(0.2g/l) solution to detach the cells. After 3-5 minutes, cells were harvested in 5ml of the appropriate complete growth media and recovered by centrifugation at 250g for 5 minutes at room temperature. Cell pellets were resuspended in 1ml of 90% FBS:10% DMSO (Sigma Aldrich, UK) freezing solution and the total volume transferred in cryovials (VWR) for cell storage in aliquots of 1ml per cryovial. Cells were wrapped in tissue paper and stored at -80°C in a polystyrene box for a time minimum of 24 hours up to 1 month before being transferred into liquid nitrogen for long term storage.

2.2 Molecular Biology

2.2.1 Proteins

2.2.1.1 Western blotting analysis

2.2.1.1.1 Protein sample preparation from cell lysates

Cell were plated in tissue culture treated 6 well plates. Cells were detached from 10 cm petri dishes when 80-85% confluent as described in chapter 2.1.3. The pellet was resuspended in 10 ml of growing media and an aliquot of 2 ml of the resuspended pellet was diluted in 10 ml of growing media. Then 2 ml of the diluted resuspension were added in each well of a 6-well plate. Alternatively 1 ml of the diluted resuspension was added in each well of a 12-well plate. When necessary, the day after being plated, cells were cultured in serum free growth media for 24 hours before stimulation and then lysed. Cells were washed twice in 1X PBS and lysed in 200μl of cold NP-40 lysis buffer (50mM Tris-pH 8.0; 50mM KCl, 1% (v/v) NP-40) containing 1X protease inhibitor
cocktail (Sigma-Aldrich, UK) and 1X phosphatase inhibitor cocktail II (Sigma-Aldrich, UK). Scrapers were used to detach the cells from the plastic dish and destroy cellular integrity. Lysate was collected in 1.5 ml tubes (VWR, UK) and cleared from cell debris and cell membrane by centrifugation at 10,000g for 3 minutes. The supernatant was transferred to a new 1.5 ml tube used for protein quantification and subsequent western blot analysis. Cell lysates were stored at -20°C or -80°C for long conservation.

### 2.2.1.1.2 Bradford protein assay

Protein concentration was determined by Bradford protein assay. Bovine Serum Albumin (BSA) (Sigma-Aldrich, UK) was used to establish a standard calibration curve for protein quantification. Table 2.2 shows a typical standard curve preparation. 1μl of lysate was added to 199μl of 1X Bradford solution (Bio-Rad, UK). The absorbance of the standards and of the samples was measured at 595 nm using a plate reader. A linear calibration curve was set using Microsoft Excel® plotting BSA concentration (X axis) and absorbance value (Y axis). The linear equation for the standard curve was calculated by the software. Standard curve with a minimum \( r^2 = 0.97 \) was used to determine sample protein concentration. The unknown protein concentration of the lysates was calculated using the following formula:

\[
\text{Abs} = mx + b
\]

Abs=Absorbance; m=slope of the line; x=protein concentration; b=Y intercept

Protein samples were diluted in 5X denaturing sample buffer (see Appendix 1.1) and heated at 95°C for 5 minutes. The denatured protein samples were used for Polyacrylamide Gel Electrophoresis (PAGE) and Western blot analysis. The denatured sample buffers were stored at 4°C or at -20 for short and long period storage respectively.
Table 2.2: BSA Standard curve protein concentration

<table>
<thead>
<tr>
<th>Standard curve</th>
<th>1X Bradford reactive</th>
<th>BSA 200 µg/ml (µl)</th>
<th>BSA (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>200</td>
<td>0</td>
<td>0 µg/ml</td>
</tr>
<tr>
<td></td>
<td>198</td>
<td>2</td>
<td>0.4 µg/ml</td>
</tr>
<tr>
<td></td>
<td>196</td>
<td>4</td>
<td>0.8 µg/ml</td>
</tr>
<tr>
<td></td>
<td>194</td>
<td>6</td>
<td>1.2 µg/ml</td>
</tr>
<tr>
<td></td>
<td>192</td>
<td>8</td>
<td>1.6 µg/ml</td>
</tr>
</tbody>
</table>

1X Bradford solution was prepared diluting 5X Bradford Bio-Rad protein assay solution (Bio-Rad Laboratories, UK) in ddH₂O.

2.2.1.1.3 Polyacrylamide Gel Electrophoresis (PAGE) and Western blot

Two dedicated glass plates were assembled in a gel electrophoresis apparatus (Bio-Rad Laboratories, UK). A 10% resolving polyacrylamide gel solution was prepared and poured between the two glass plates, overlaid with 1.5ml of water and left at RT for 20-25 minutes to polymerize. Then, the water was removed and a 5% stacking solution was added on top of the previously set resolving gel and cast with 10 or 15 sample combs on top. Polymerization was allowed at RT for about 30 minutes (see appendix 1.2 and 1.3).

After removing the comb, each well of the gel was washed with ddH₂O. Previously denatured protein samples were loaded on the gel and gel electrophoresis performed in 1X running buffer (Appendix 1.4). A constant
voltage of 120V was used for gel-electrophoresis. Electro-blotting from the gel onto a Protran® nitrocellulose membrane filter (Whatman, UK) was performed in 1X transfer buffer (see appendix 1.5) using a dedicated apparatus (Bio-Rad Laboratories). Transfer was performed at constant current of 400mA for 1 hour and 30 minutes at RT in presence of a dedicated icepack within the tank. The correct protein transfer was assessed by staining with Ponceau solution (Applichem GmbH, UK). The solution was incubated for 2 minutes at RT. Membrane were washed in ddH$_2$O in order to remove the excess of Ponceau solution and visualize protein staining.

2.2.1.4 Immunoblotting and analysis

Nitrocellulose membrane was incubated with a solution of 5% milk (w/v) (Invitrogen) in PBS-0.05%Tween-20 (v/v) for 30 minutes before being transferred in PBS-0.05%Tween-20 (v/v) solution containing the diluted primary antibody (table 2.3) and incubated at 4°C overnight in agitation. The following day the membrane were washed 3X for 10 minutes in PBS-0.05%Tween-20 (v/v) and incubated with agitation at RT for 1 hour with the appropriate peroxidase-conjugated secondary antibodies anti-mouse (GE Healthcare, UK) (1:8,000), anti-rabbit (Sigma-Aldrich, UK) (1:8,000) or anti-goat (GE Healthcare, UK) (1:20,000) diluted in PBS-0.05%Tween-20 (v/v). Membranes were then washed 3X 5 minutes in PBS-0.05%Tween-20 (v/v) and 1X 5 minutes in PBS before being incubated with ECL Plus Mix solution (Amersham Bioscience, UK) for 1 minute, sealed in a plastic sheet and exposed to chemiluminescence sensitive film (Kodak) in a dedicated cassette, usually from 15 seconds to 10 minutes.

Table 2.3: List of Antibodies used for WB

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Company</th>
<th>Catalog #</th>
<th>Host</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLC(\gamma)</td>
<td>Santa Cruz</td>
<td>SC-7290</td>
<td>Mouse</td>
<td>1:1000</td>
</tr>
<tr>
<td>pPLC(\gamma)</td>
<td>Cell signalling</td>
<td>2821</td>
<td>Rabbit</td>
<td>1:500</td>
</tr>
<tr>
<td>Protein</td>
<td>Antigen</td>
<td>Source</td>
<td>Catalogue number</td>
<td>Species</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------</td>
<td>-------------------</td>
<td>------------------</td>
<td>---------</td>
</tr>
<tr>
<td>PDK1</td>
<td>Cell signalling</td>
<td>3062</td>
<td>Rabbit</td>
<td>1:500</td>
</tr>
<tr>
<td>PLCγ2</td>
<td>Santa Cruz</td>
<td>SC-5283</td>
<td>Mouse</td>
<td>1:500</td>
</tr>
<tr>
<td>AKT 1/2/3</td>
<td>Santa Cruz</td>
<td>Sc-8312</td>
<td>Rabbit</td>
<td>1:1000</td>
</tr>
<tr>
<td>pAKT Ser473</td>
<td>Santa Cruz</td>
<td>Sc-7985</td>
<td>Rabbit</td>
<td>1:500</td>
</tr>
<tr>
<td>pAKT Thr308</td>
<td>Cell signalling</td>
<td>2965</td>
<td>Rabbit</td>
<td>1:500</td>
</tr>
<tr>
<td>ERK1/2</td>
<td>Santa Cruz</td>
<td>sc-135900</td>
<td>Goat</td>
<td>1:1000</td>
</tr>
<tr>
<td>Anti-HA</td>
<td>Sigma-Aldrich</td>
<td>H3663</td>
<td>Mouse</td>
<td>1:500</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Sigma-Aldrich</td>
<td>G9545</td>
<td>Rabbit</td>
<td>1:2500</td>
</tr>
</tbody>
</table>

2.2.1.2 Co-immunoprecipitation analysis

2.2.1.2.1 Co-immunoprecipitation analysis by Millipore Catch and release KIT 2.0 (Millipore, US)

Co-immunoprecipitation in overexpressing conditions was performed using HEK293 cells transfected with pOZ-PDK1 and PRK5-PLCγ1 constructs as indicated in “plasmid transfection” paragraph. Three six centimetre dishes were used for each co-immunoprecipitation. Cells were lysed using the NP-40 lysis buffer (50mM Tris-pH 8.0, 50mM KCl, 1% (v/v) NP-40) containing protease and phosphatase inhibitors. Protein lysates were cleared from cell debris by centrifugation step at 10,000 RPM for 3 minutes at 4°C. In parallel, spin columns from the kit were washed by adding 400μl of 1X catch and release wash buffer and centrifuged for 30 seconds at 2,000g. Then 500 μg of protein were loaded onto the spin columns together with 3μg of primary antibody or 3μg of IgG as negative control, and with 10μl of antibody capture
affinity ligand. 1X wash buffer was added to provide a final volume of 500 μl. Columns were incubated at 4°C overnight. The day after spin columns were centrifuged for 30 seconds at 2,000g and the flow-through collected. This fraction was used later to check the immunoprecipitation efficiency by western blot analysis. Spin columns were washed 3 times with 1X washing buffer and spun at 2,000g for 30 second for each wash. The immunoprecipitated complex was eluted in 70 μl of 1X denaturing sample buffer by centrifugation at 2,000g for 1 minute. The eluted fraction was heated at 95°C for 5 minutes before western blot analysis.

2.2.1.2.2 Endogenous co-immunoprecipitation analysis

Endogenous co-immunoprecipitation assay was performed using three confluent 10 cm petri dishes of MDA-MB-231, MDA-MB-435 and A375M. Cells were lysed using the NP-40 lysis buffer (50mM Tris-pH 8.0, 50mM KCl, 1% (v/v) NP-40) containing protease and phosphatase inhibitors. In both cases 1 mg of the whole protein lysed was mixed with 3 μg of anti-PLCγ1 antibody (Santa Cruz Biotechnology Inc., US) and incubated on a rotating wheel overnight at 4°C to a final volume of 700 μl in IP buffers. The following day the mix was centrifuged at 10,000g for 3 minutes and transferred to a new clean tube. The mixture was then incubated with 30 μl of protein G Sepharose 4 fast flow (GE Healthcare, UK) and incubated on a rotating wheel at 4°C for 1 hour. Beads were centrifuged at 2,000g for 1 minute. Then, supernatant was removed and the beads were washed three times with IP buffer on a rotating wheel at 4°C for 5 minutes. Then beads were resuspended in 50 μl of 2X sample buffer and heated at 95°C for five minutes. The supernatant was analysed by SDS-PAGE electrophoresis and western blot.

2.2.1.3 GST-Pull down assay

Three sets of three 6-cm petri dishes, previously seeded with HEK293, were transfected respectively with PRK5-PCLγ1, pEBG2T-GST-PDK1 and pEBG2T-GST empty vector. 24 hours from transfection cells were lysed in lysis buffer (50mM Tris-pH 8.0, 50mM KCl, 1% NP-40) containing protease
and phosphatases inhibitors. Lysates were cleared by centrifugation at 10,000g for 3 minutes at 4°C. 500 μg of HEK293 overexpressing GST-empty vector and 500 μg of HEK293 lysate overexpressing GST-PDK1 were incubated separately with 20 μl of G4510 glutathione-Sepharose-beads (Sigma-Aldrich) for 1 hour at 4°C. The beads were washed 3X in washing buffer for 5 minutes at 4°C. Beads were incubated with 500 μg of protein lysate of HEK293 overexpressing PLCγ1 overnight on a rotating wheel at 4°C in a total volume of 1 ml in IP buffer. The following day beads were harvested and washed 3X with IP washing buffer and the beads resuspended in 50 μl of denaturing sample buffer and heated at 95°C for 5 minute (see appendix 1.1). Supernatant was analysed by SDS-PAGE electrophoresis and western blot.

2.2.2 RNA-interference

2.2.2.1 siRNA using Oligofectamine transfecting agent

Transient knock down of target proteins was achieved using siRNA duplex technology. siRNAs were purchased from Dharmacon, USA (Appendix 2.2). Transfection of MDA-MB-231 and MDA-MB-435 was performed using Oligofectamine™ (Invitrogen, UK) following the manufacturer’s instruction for transfection of adherent cells seeded in 6-well plates. 2X10⁶ cells/well were seeded the day before transfection in complete growth media and incubated at 37°C/5% CO₂. A mix (A) of 5μl siRNA duplexes (stock solution of 20 μM) and 180 μl of serum-free, penicillin-streptomycin-free Optimem™ (Invitrogen, UK) was prepared. In parallel a mix (B) of 7.5μl of Oligofectamine™ and 7.5 μl of serum-free, penicillin-streptomycin-free Optimem™ (Invitrogen, UK) was prepared. The two mixes were incubated for 7 minutes at RT. Subsequently the content of the tubes was mixed and incubated 25 minutes RT resulting (total volume of 200 μl). Cells were washed in 1X PBS solution and 800 μl of Optimem™ plus the 200 μl of transfecting mix were added to each well and incubated for 4 hours at 37°C
At the end of the incubation time, 500 μl of 30% FBS OptiMEM™ (v/v) were added to the 6 well and incubated overnight at 37°C/5%CO₂. The following day cells were washed with 1X PBS solution and incubated with normal growth media for the indicated time before the experiment. Cells transfected with a pool of non-targeting siRNA (Applied Biosystem/Ambion Inc., USA) were used at the same final concentration as negative control in all the experiments.

### 2.2.2.2 siRNA using Hiperfect reagent

Transient knock-down of target proteins was achieved using siRNAs in A375M cell line. Cells were transfected using Hyperfect® transfecting agent (Qiagen Ltd, UK) following the protocol provided by the manufacturer, optimised for transfection of adherent cells in 6-well plate. 2X10⁶ cells were seeded in 6 well plates and grown in complete RPMI growth media at 37°C/5%CO₂. The day after, 100μl of OptiMEM™ were mixed with 7.5 μl of 20μM siRNA stock solution and 18μl of Hyperfect® in a tube and mixed by vortexing for 5 seconds. The mix was incubated for 10 minutes at RT and then added to the growth media in the 6-well plate. The cells were incubated with the transfection complex overnight at 37°C/5%CO₂ and media was replaced the following day. Cells transfected with a pool of non-targeting siRNA (Applied Biosystem/Ambion Inc., USA) were used at the same final concentration as negative controls in all the experiments.

### 2.2.2.3 stable knock down using short hairpin RNA

#### 2.2.2.3.1 Stable knock-down of PLCγ1 using pSUPER™.retro vector-based shRNA

MDA-MB-231, MDA-MB-435 and TSA cell lines stable knock-down for PLCγ1 were previously generated in the lab using the pSUPER™.retro vector-based RNAi system (Oligoengine Inc. USA). A 19 nucleotide sequence derived from the mRNA PLCγ1 transcript were cloned in the vector
following the vector instruction. A 3 point-mutated non-targeting sequence was cloned in the vector and used as control for all the experiments (see table 2.4)

Table 2.4: The PLCγ1 targeting sequence cloned in pSUPER.retro vector together with the position in the cDNA is indicated. 3-point mutation of the control non-targeting sequence is indicated in RED.

<table>
<thead>
<tr>
<th>PLCγ1 targeting sequence: GAACAACCGGCTCTTCGTC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Position in cDNA 2791nt of 5205</td>
</tr>
<tr>
<td>3MUT control non-targeting sequence: GAACAACCGACGTTTCGTC</td>
</tr>
</tbody>
</table>

2.2.2.3.2 Inducible knock-down of PLCγ1 using pSUPERIOR™ vector-based shRNA

Inducible downregulation of PLCγ1 was achieved using the (Oligoengine Inc. USA) vector-based system. MDA-MB-231 cells expressing the inducible downregulating system was previously generated in the lab. These cells express the tetracycline repressor encoded by the vector pCDNA™6/TR (Invitrogen) and the pSUPERIOR vector-based RNA. The targeting sequence and the control non-targeting illustrated in table 2.4, were cloned in the pSUPERIOR.retro.puro as indicated by the manufacturer.

2.2.2.3.3 Stable downregulation of PDK1 using pSUPER vector-based shRNA.

Stable downregulation of PDK1 was achieved using the pSUPERIOR™.retro.puro. The PDK1 targeting sequence was designed based on PDK1 targeting sequence used by Sahai et al., 2008. A Pair of forward and reverse oligonucleotides, which comprise identical motifs in an inverted orientation separated by a 9 nt spacer, were generated. The extremities were
designed in order to present BglII and HindIII sticky ends. A control non-targeting sequence was designed by mutating 5 nucleotides in the sequence (see table 2.5). 5 µg of vector were digested overnight with BglII and HindIII restriction enzymes (Fermentas, UK) according to the manufacturer’s instruction. The cut plasmid was run on 1% agarose gel and extracted from the gel using the Genejet™ gel extraction kit (Fermentas, UK) following the manufacturer’s instruction.

Table 2.5 The 21 target sequence in PDK1 mRNA molecule is indicated together with the position in the mRNA transcript. The target sequence is indicated in bold while the BglII and HindIII sites together with the 5-pointed mutation are indicated in grey.

| PDK1 targeting sequence: GACCAGAGGCCAAGAATTTTA |
| Position in mRNA 1658 nucleotide |

### Forward and reverse oligonucleotides designed to target PDK1 expression.

<table>
<thead>
<tr>
<th>Sense target sequence</th>
<th>Anti-sense target sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bgl II 5'- GATCCCGGACCAGGAGGCCAAGAATTTTA</td>
<td>TTCAAGAGATAAAATCTGCGCTGCTTTTTA-3'</td>
</tr>
<tr>
<td>Loop</td>
<td></td>
</tr>
<tr>
<td>Hind III</td>
<td></td>
</tr>
</tbody>
</table>

### Forward and reverse oligonucleotides designed with 5-point-mutation in order to generate a control non-targeting sequence.

<table>
<thead>
<tr>
<th>Sense target sequence</th>
<th>Anti-sense target sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bgl II 5'- GATCCCGGACAGAGGCTCAAGAATTTTA</td>
<td>TTCAAGAGATCAATCTGCTGCTTTTTA-3'</td>
</tr>
<tr>
<td>Loop</td>
<td></td>
</tr>
<tr>
<td>Hind III</td>
<td></td>
</tr>
</tbody>
</table>
2.2.3 DNA

2.2.3.1 Ligation and transformation

Inserts were ligated in a previously digested vector mixing insert and linearized vector at a 3:1 molar ratio. 1 unit of T4 ligase (Fermentas, UK) was mixed with 50 ng of vector and the insert together with 2μl of 10X T4 ligase buffer and made up to a final volume of 20 μl. The ligation reaction was incubated at RT overnight. Control reactions were performed without the inserts.

The generated constructs were transformed in DHα strain bacterial cells. Bacteria were thawed on ice for 20 minutes. 5 μl of ligation mixture were added to the cells and incubated on ice for 20 minutes. Cells were heat-shocked at 42°C for 60 seconds and held directly on ice for 30 seconds. 500 μl of pre-warmed LB media was added to the bacteria and the mixture was incubated at 37°C for 1 hour in agitation at 200 rpm. Then cells were spun down at 500 g for 3 minutes and resuspended in 250 μl of LB before being plated on LB-agar plates (LB media with 1,5% (w/v) bacteriological agar) containing 100 mg/ml ampicillin or 100 mg/ml Kanamycin according to the resistance conferred by the vector. The inoculated plates were incubated overnight at 37°C.

2.2.3.2 DNA digestion

Fastdigest® enzymes (Fermentas, UK) were used for all the restriction reactions. 1 μg of vector was digested mixing 1 μl of enzyme together with 2 ml of 10X fastdigest® buffer in a final volume of 20 μl. The Digestion reaction was performed for 30 minutes at 37°C. DNA digestion was assessed by agarose gel electrophoresis.
2.2.3.3 Plasmid preparation

Plasmids were extracted and purified from bacteria using the spin miniprep kit (Qiagen, UK) for small-scale plasmid preparation, or the QIA filter plasmid maxi kit (Qiagen, UK) for the large-scale plasmid preparation.

2.2.3.4 Miniprep

For small-scale preparation, resistant colonies obtained from the inoculated plates were picked individually using sterile tips and grown overnight in 5 ml of LB media at 37°C with agitation (200 rpm) containing the appropriate antibiotic for selection. The DNA plasmid was then extracted following the manufacturer’s instructions.

2.2.3.5 Maxiprep

For large scale preparation 300 ml of LB media supplemented containing the appropriate antibiotic for selection were inoculated with 2 ml starter culture, prepared as indicated in “miniprep” section, and incubated with agitation (200 rpm) overnight at 37°C. Plasmids were extracted according to the manufacturer’s instructions.

2.2.3.6 Agarose-gel electrophoresis

A 1% agarose (Sigma, Aldrich, UK) (v/w) solution in 1X TAE buffer (see appendix 1.6) was prepared heating the solution until the total amount of agarose was dissolved. The solution was cooled down at RT for 10 minutes. Ethidium bromide was added to a final concentration of 0.5 μg/ml and the mixture was poured into a gel-casting tray, cast with sample combs and left to set at RT. The set gel was transferred on an electrophoresis apparatus filled with 1X TAE buffer. The samples were diluted in 5X loading buffer (New England Biolabs, UK) and loaded on the gel in parallel to 5 μl of 1-KB ladder (Fermentas, UK) for size comparison. The gel was run at 100 V for 30-60 minutes and DNA visualised under UV transillumination.
2.2.3.7 Plasmid transfection

Transfection of mammalian cells was performed using Lipofectamine™ (Invitrogen, UK) following the manufacturer’s instructions. The amount of Lipofectamine™ and DNA was optimized according to the cell line used (Table 2.5). A “mix A” and a “mix B”, containing respectively Lipofectamine™, Optimem™ and DNA/ Optimem™ were prepared as illustrated in Table 2.6. The two mixes were incubated separately at RT for 15 minutes before being mixed and left to incubate for further 15 minutes at RT. Cells were washed with 1X PBS and incubated with the mix plus serum free Optimem™ to the final volume indicated. After 4 hours, cells were washed in 1X PBS and incubated in complete growth media for 24 hours or 48 hours depending on the experiment.

Table 2.6: Transfection protocol optimized for HEK293 and MDA-MB-231 in different culture dishes/plate

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Plate</th>
<th>Lipofectamine/Optimem (Mix A)</th>
<th>DNA/Optimem (Mix B)</th>
<th>Total Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEK293</td>
<td>6 cm dishes</td>
<td>10 µl/200 µl</td>
<td>5 µg/200 µl</td>
<td>2 ml</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>12-well plate</td>
<td>2 µl/50 µl</td>
<td>1 µg/50 µl</td>
<td>500 µl</td>
</tr>
<tr>
<td></td>
<td>6 cm dishes</td>
<td>12 µl/200 µl</td>
<td>5µg/200 µl</td>
<td>2 ml</td>
</tr>
</tbody>
</table>
2.2.3.8 Polymerase chain reaction (PCR)

25 ng of plasmid was used as template using the “Maxima® hot start PCR master mix 2X”. A typical PCR reaction is illustrated in table 2.7 and 2.8.

Table 2.7: Typical PCR master mix

<table>
<thead>
<tr>
<th></th>
<th>Sample</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maxima® hot start PCR master mix 2X</td>
<td>25 µl</td>
<td>25 µl</td>
</tr>
<tr>
<td>Forward primer (100 mM)</td>
<td>0.5 µl</td>
<td>0.5 µl</td>
</tr>
<tr>
<td>Reverse primer (100 mM)</td>
<td>0.5 µl</td>
<td>0.5 µl</td>
</tr>
<tr>
<td>Template DNA</td>
<td>5 µl</td>
<td>-</td>
</tr>
<tr>
<td>H2O</td>
<td>19 µl</td>
<td>24 µl</td>
</tr>
<tr>
<td><strong>Total Volume</strong></td>
<td>50</td>
<td>50</td>
</tr>
</tbody>
</table>

Table 2.8: Typical thermal-cycler program for PCR

<table>
<thead>
<tr>
<th></th>
<th>Temperature (°C)</th>
<th>Time</th>
<th>Cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial denaturation/enzyme activation</td>
<td>95</td>
<td>4 min</td>
<td>1</td>
</tr>
<tr>
<td>Denaturation</td>
<td>95</td>
<td>30 sec</td>
<td>35</td>
</tr>
<tr>
<td>Annealing</td>
<td>57</td>
<td>30 sec</td>
<td></td>
</tr>
<tr>
<td>Extension</td>
<td>72</td>
<td>40 sec</td>
<td></td>
</tr>
<tr>
<td>Final extension</td>
<td>72</td>
<td>10 min</td>
<td>1</td>
</tr>
<tr>
<td>Hold</td>
<td>4</td>
<td>Indefinite</td>
<td></td>
</tr>
</tbody>
</table>
2.2.4 RNA

2.2.4.1 RNA extraction

Total RNA was extracted from 2X10^5 cells seeded on 6 wells multiplate using the RNeasy kit (Qiagen, UK) following the manufacturer's instructions.

2.2.4.2 RNA Reverse transcription

Total RNA was retro-transcripted using the SuperScript II reverse transcriptase kit (Invitrogen, UK). 1 µg of RNA was diluted in a mix containing oligod(T) and random primers (25mg/ml), dNTP mix (0.5 mM) to a final volume of 12 µl. The mix was heated to 65 degrees for 5 minutes in a PCR thermal-cycler block and quickly moved on ice. A mix of 1X first strand buffer, DTT (5mM) and RNase OUT (40 units) (Invitrogen, UK) was added and the mix was heated at 42°C for 2 minutes in a PCR thermal-cycler, where 200 units of SuperScript II reverse transcriptase were added to the reaction. The PCR thermal-cycler was programmed as follows:

Table 2.9 RNA retrotranscription program indicated in manufacturer’s instruction

<table>
<thead>
<tr>
<th>SuperScript II thermal-cycler program</th>
<th>Temperature (°C)</th>
<th>Time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>70</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>(until tube collection)</td>
<td></td>
</tr>
</tbody>
</table>

2.2.4.3 Real Time quantitative Polymerase Chain Reaction (RT-qPCR)
For quantitative PCR 100 ng of cDNA was mixed with 12.5 μl of 2X Maxima® SYBR green/Fluorescein qPCR master mix (Fermentas), 2.5 μl of 10μM stock solution of forward and reverse primers to a final volume of 25 μl. The ABI 7500 Real-Time PCR system was programmed as indicated in Figure 2.1. For each qPCR reaction a fragment from GAPDH cDNA was amplified as internal control. Relative quantification of gene was calculated using the relative ddCT analysis mode of the ABI 7500 Real-Time PCR system software.

Figure 2.1: Thermal-Cycler protocol for RT-qPCR reaction using the 7500 ABI 7500 Real-Time PCR system software
2.3 Imaging methods

Zeiss LSM Meta 510 or Zeiss LSM 510 inverted equipped with 405 nm, 488 nm, 543 nm, 594 nm lasers were used for all the fluorescence studies.

2.3.1 Ruffling Assay

Cells were seeded on coverslips (VWR, UK) \( (1 \times 10^5 \text{ per coverslip}) \). Cells were starved overnight and then stimulated with 10% serum supplemented media or EGF (20ng/ml). After two washes in cold 1X PBS, cells were fixed in 4% paraformaldehyde for 30 minutes at room temperature. Cells were permeabilized in 1XPBS/0.25% Triton-X-100 for 2.5 minutes at RT. Unspecific staining was prevented blocking the coverslips with a solution 1X PBS/0.1% BSA for 30 minutes at RT. Alexa Fluor 594-Phalloidin (Invitrogen, UK) was added at 1:1000 dilution in PBS and incubated for 1 hour at 37°C. Hoechst 33342 5µg/ml (Sigma-Aldrich, UK) was added for nuclei staining. Coverslips were mounted on glass slides using the anti-fade Vektashield (Vector Laboratories, UK) and incubated for 1 hour at 4°C. Samples were analysed using Carl Zeiss™ confocal microscope LSM 510 Meta equipped with a 63X oil objective. DAPI was excited with laser 405nm wavelength while Alexa Fluor 594 dye was excited at 594nm and emission was measured at 620nm. All images were processed using LSM Image browser from Zeiss.

2.3.2 Calcium measurement Assay

The fluorescent calcium indicator, Fluo-4 AM (Invitrogen, UK), was used to measure changes in intracellular calcium. \( 4 \times 10^5 \) cells were seeded on a bottom-glassed chamber for confocal live microscopy (Labtech Ltd, UK). The following day, cells were starved in serum free medium overnight. In case of siRNA transfection, cells were transfected in a 6 well-plate (chapter 2.2.2.1, 2.2.2.2) and 24 hours after transfection they were detached and seeded on the bottom-glassed chambers as described above. The following day each well
was incubated with 200 µl of HBSS (Invitrogen, UK), containing 0.5% BSA (Sigma-Aldrich, UK), 2mM CaCl₂ (Sigma-Aldrich, UK), 4µM Fluo-4 for 45 minutes at 37°C/10%CO₂. After loading, cells were washed twice in HBSS 0.5% BSA 2mM CaCl₂ and left in the same solution for 30 minutes for de-esterification of the Fluo-4-AM dye. Where indicated inhibitors were added during the de-esterification step for a total time of 30 minutes. The samples were protected from light during all the passages. The samples were moved in the confocal facilities and analysed using the LSM 510 inverted confocal microscope equipped with a chamber for live imaging at 37°C supplied with 5% CO₂ using a 20X objective. ZEN Carl Zeiss software was used for acquisition. The confocal was set in a time lapse acquisition mode acquiring a picture every 1.27 seconds, recording the fluorescence emitted by the Fluo-4 using a 505-545 nm pass-band filter. After recording basal fluorescent for 20 seconds cells were then stimulated with EGF (20ng/ml) and fluorescent was measured for 10 minutes. Analysis of fluorescence intensity was performed with ZEN™ Carl Zeiss software. Specifically, thirty cells were gated and variation of fluorescence intensity was measured for each sample. The average of intensity per time point was calculated and a chart of fluorescence on time was generated.

2.3.3 Incorporation of Fluorescein-conjugated InsP₅ (2-FAM-InsP₅)

MDA-MB-231 cells were seeded on coverslips in 12-well dishes at 60% of confluence and pre-treated with the indicated inhibitors for 2 hours. Cells were incubated with 2-FAM-InsP₅ (25 µM) (provided by Professor Potter, Bath University, UK) or fluorescein (25 µM) (Sigma-Aldrich) with or without the inhibitors for the indicated times. In the case of MDA-MB-231 transfected with siRNA targeting ABCC1 and ABCC5 and a scrambled non-targeting sequence, cells were seeded in a 12-well plate at a density of 50% of confluence, after 24 hours from transfection. Cells were then incubated with 2-FAM-InsP₅ or fluorescein for the indicated time points. In all cases cells were fixed in paraformaldehyde 4% (v/v) for 20 minutes and mounted on glass
slides. Fluorescence was measured by confocal analysis using an LSM 510 meta exciting the dye with the 488 laser with a 505-515 nm filter. Cell fluorescence was measured using the Carl Zeiss LSM software. Intracellular fluorescence was measured gating 40 cells for each time point of the experiments and mean fluorescence calculated.

2.3.4 Forster Resonance Energy Transfer by acceptor photo-bleaching

Direct protein–protein interactions were visualized using FRET whereby energy from an excited donor is transferred to an acceptor in very close proximity. The measurement of the energy transfer was monitored by following the fluorescence emission of the donor–acceptor couple and gave a reasonable approximation of the proximity and interaction between the two molecules, assuming that the emission spectrum of the donor overlapped with the excitation spectrum of the acceptor. The efficiency of this process was used to estimate the proximity and thus the interaction between PLCγ1 and PDK1 in MDA-MB-231 cells in overexpressing conditions.

Cells were seeded on coverslips in a 12-well plate at a density of 50% of confluence. Cells were co-transfected with PRK5-PLCγ1 and pOZ-PDK1 and after 24 hours from transfection cells were serum deprived overnight. The following day, cells were stimulated with a solution of DMEM + EGF (50 ng/ml) at the indicated time points before being fixed in paraformaldehyde 4% (v/v) for 30 minutes at RT. Cells were permeabilized in 1X PBS/0.25% Triton-X-100 for 2.5 minutes at RT. Unspecific staining was prevented by blocking the coverslips with a solution 1X PBS/0.1% of BSA for 30 minutes at RT. Primary antibodies anti-mouse-PLCγ1 (Santa Cruz Biotechnology, US) and anti-rabbit-PDK1 (Cell Signaling Technology Inc., USA) were diluted 1:50 in 50 μl/coverslip of 1X PBS/0.1% of BSA. The day after cells were washed 3X in 1X PBS/0.1% BSA and incubated with secondary antibodies anti-mouse-Alexa488 (Invitrogen, UK) and anti-rabbit Alexa555 (Invitrogen, UK) (The spectra of the two secondary antibodies are showed in Figure 2.2).
Figure 2.2: Donor and acceptor spectra generated with Fluorescence spectra viewer tool (http://www.invitrogen.com/site/us/en/home/support/Research-Tools/Fluorescence-SpectraViewer.html)

Cells were then washed 3X with 1X PBS and mounted on glass coverslips using Vectashield mounting media. Spectral imaging analysis was performed on Carl Zeiss LSM 510 meta. Cells were imaged with excitation $\lambda=488$ nm and $\lambda=543$ laser line and emission spectra were collected respectively in two different channels of the PMT detector. Reference spectra were generated from coverslips incubated separately with the two Alexa-conjugated secondary antibodies alone in order to generate single positive samples and all data were corrected for crosstalk and background fluorescence. The FRET efficiency was measured by acceptor photo-bleaching according to the method by Guillaud et al., 2008 where the de-quenching of the donor emission is a direct measure of the FRET efficiency. Cells were imaged with $\lambda=543$ nm laser line to visualise PDK1 (acceptor) fluorescence and $\lambda=488$ nm laser line to visualize PLC$\gamma$1 (donor) fluorescence. A selected area of the cell was repeatedly
photobleached with $\lambda = 543$ nm laser line at full power for 1 minute and FRET efficiency was measured as the increase (or dequenching) of PLCγ1 fluorescence after photo-bleaching in the selected area. All fluorescence measurements were performed in MetaMorph software (Molecular Devices Inc., US).

Two independent areas in the bleached zone and one area in the non-bleached zone were analysed in parallel to ensure that the FRET efficiency values were not artefacts due to the photo-bleaching protocol. FRET efficiency was calculated using the following equation:

$$E = \left[1 - \frac{(\text{Donor.before} - \text{BCK.before})}{(\text{Donor.after} - \text{BCK.after})}\right] \times 100$$

Donor.before = fluorescence intensity of PLCγ1 before photobleaching

BCK.before = background intensity before photobleaching

Donor.after = fluorescence intensity of PLCγ1 after photobleaching

BCK.after = background intensity after photobleaching. As a negative control, GFP was used as donor, was used to validate the system.

2.3.5 Forster Resonance Energy Transfer by FACS

MDA-MB-231 were transfected with pOZ-PDK1 and PRK5-PLCγ1 either individually or in combination. 48 hour after transfection cells where detached by incubating with 1X PBS + 0.2% EGTA (w/v) solution for 20 minutes. Cells were spin at 1,200 RPM for 5 minutes and resuspended in 1 ml of media serum free supplemented with EGF (50 ng/ml) for 5 and 10 minutes. Cells where then fixed in 2% paraformaldehyde solution for 15 minutes. Cells were pelleted at 1,200 RPM for 5 minutes and permeabilized in 1XPBS/0.25% Triton-X-100 solution for 2.5 minutes at RT. Cells were centrifuged at 1,200 RPM for 5 minutes and resuspended in 1X PBS/0.1% BSA blocking solution for 30 minutes at RT. Cells were then pelleted at 1,200 RPM for 5 minutes and
resuspended in 400 µl blocking solution containing anti-PLCγ1 or anti-PDK1 antibodies either individually or in combination (Table 2.10). Cells were incubated overnight at 4°C. The following day cells were centrifuged at 1,200 RPM for 5 minutes and washed three times for 5 minutes in blocking solution before being resuspended in 500 µl of blocking solution and read with a Canto II FACS (Becton, Dickinson BD; UK)

Table 2.10: Plasmids, primary and secondary antibodies used for FRET experiments by FACS:

<table>
<thead>
<tr>
<th>Constructs</th>
<th>Primary antibodies</th>
<th>Secondary antibodies (Alexa-555/Alexa-488 conjugated)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pCDNA (Negative control)</td>
<td>-</td>
<td>Alexa 488 (anti-mouse)</td>
</tr>
<tr>
<td>pCDNA (Negative control)</td>
<td>-</td>
<td>Alexa 555 (anti-mouse)</td>
</tr>
<tr>
<td>pOZ-PDK1 (Single positive)</td>
<td>anti-PDK1(R)</td>
<td>Alexa-488 (anti-rabbit)</td>
</tr>
<tr>
<td>pOZ-PDK1 (Single positive)</td>
<td>anti-PDK1(R)</td>
<td>Alexa-555 (anti-rabbit)</td>
</tr>
<tr>
<td>PRK5-PLCγ1 (Single positive)</td>
<td>anti-PLCγ1(M)</td>
<td>Alexa-488 (anti-mouse)</td>
</tr>
<tr>
<td>PRK5-PLCγ1 (Single positive)</td>
<td>anti-PLCγ1(M)</td>
<td>Alexa-555 (anti-mouse)</td>
</tr>
<tr>
<td>pEGFP/PRK5PLCγ1</td>
<td>anti-PLCγ1(M)</td>
<td>Alexa-555 (anti-mouse)</td>
</tr>
<tr>
<td>pEGFP/pOZ-PDK1</td>
<td>anti-PDK1(R)</td>
<td>Alexa-555 (Anti-rabbit)</td>
</tr>
<tr>
<td>pOZ-PDK1/PRK5-PLCγ1</td>
<td>anti-PLCγ1(M)</td>
<td>Alexa-488 (anti-rabbit)</td>
</tr>
<tr>
<td>pOZ-PDK1/PRK5-PLCγ1</td>
<td>anti-PLCγ1(M)</td>
<td>Alexa-555 (anti-mouse)</td>
</tr>
<tr>
<td></td>
<td>anti-PDK1(R)</td>
<td>Alexa-488 (anti-rabbit)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alexa-555 (anti-mouse)</td>
</tr>
</tbody>
</table>

Cells were gated according to forward and sideward scatter (FSC/SSC). All samples were excited with 488 nm laser and emission measured at 555 nm. The single positive samples stained with Alexa-555 conjugated secondary antibodies allowed to measure the background emission of the dye when excited with the 488 nm laser. The single positive samples stained with Alexa-488 conjugated secondary antibodies allowed removing of bleed-through fluorescence of the donor (Alexa-488) in the FRET channel by adjusting the photomultiplier tube (PMT) voltages and compensating for Alexa-488 and Alexa-555 dyes to specifically assess FRET in double positive cells. Cells co-transfected with pEGFP and PLCγ1 or PDK1 were used as negative controls of FRET. Data
2.4 Cell Biology

2.4.1 Cell counting

Cells were seeded in 12-well plates at a density of $1 \times 10^5$. Cells were grown in 10% FBS supplemented growth media or in serum-free media. When indicated cells were treated with inhibitors. In all the experiments described cells were washed with 1X PBS and detached by incubating with trypsin (0.25%)/EDTA (0g/l) (PAA, Austria) solution. Trypsin was neutralized by adding 1 volume of growth media supplemented with 10% FBS (v/v) and the cell suspension was transferred in 1.5 ml Eppendorf tube (VWR, UK). Cells were centrifuged at 4,000g for 5 minutes. The supernatant was then removed and the pellet was resuspended in 150 µl of growth media. Cells were manually counted using a Burker chamber. 10 µl of cell suspension were added into the Burker chamber. All fields delimited by the grid of the chamber were counted and cell number calculated according to the formula:

$$\text{Cells number/ml} = \frac{1}{n} \sum_{i=1}^{n} x_i \times 10,000$$

2.4.2 Migration and invasion assay

2.4.2.1 Cell migration assay

MDA-MB-231, MDA-MB-435, TSA, 4T1 and A375M cell lines were cultured overnight in 6 wells multi-dishes and serum starved overnight before the experiment. Polycarbonate transwell insert 8.0 µm diameter pores, 10mm diameter (Nunc, Thermo Scientific, UK) were coated overnight at 4°C with a solution of 10µg/ml of Fibronectin (Sigma-Aldrich, UK) in 1X PBS. The following day the inserts were washed in PBS 1X for few seconds and
transferred in a blocking solution of DMEM or RPMI containing 0.5% BSA for 1 hour at 37°C. When indicated cells were pre-treated with inhibitors for 1 hour before being trypsinized and pelleted. The pellet was resuspended in 2ml of RPMI or DMEM 0.5% BSA according to the cell type. Cells were counted and a suspension of 10,000 cells in 150μl was homogenously added in the upper chamber. The lower chamber was filled with 500μl of RPMI or DMEM 0.5% BSA according to the cell type. Cells were allowed to migrate for 4 hours at 37°C 5% CO₂. Before fixing, non-migrated cells were removed from the upper surface of the porous membrane with a cotton bud. Cells underneath were then fixed in 4% paraformaldehyde solution for 20 minutes and washed in 3X in 1X PBS solution for 1 minute. Subsequently inserts were stained with 0.1% crystal violet solution (v/w) for 10 minutes, then washed 3X with 1X PBS and dried. Cells were counted using a Leica phase-light microscope using a 10X magnitude objective. A minimum of five fields per transwell were counted and an average of migrated cells/field was calculated.

2.4.2.2 Matrigel cell invasion assay

MDA-MB-231, MBA-MB-435, TSA, 4T1, A375M cell lines were cultured overnight in 6 well multi-dishes and serum-starved overnight before the experiment. The following day Matrigel pre-coated insert (8.0 μm diameter pores, 10mm diameter) were re-hydrated for 1 hour adding 500ul of RPMI or DMEM in the upper and lower compartment, according to the cell type to be seeded on the insert. When indicated, cells were pre-treated with inhibitors for the appropriated time before being detached from the 6-well dishes by trypsinisation. Cells were pelleted and resuspended in 2ml of 1%FBS DMEM or RPMI 1640 according to the cell type. Cells were counted and a suspension of 500μl of media containing 10,000 cells (60,000 in the case of MDA-MB-435) was seeded on the upper chamber of the insert. The lower chamber was filled with 500μl of 10% FBS RPMI or DMEM media according to the cell type used. Cell invasion was allowed for 36 hours. After 36 hours the upper face of the porous membrane was delicately cleaned with a cotton bud in order
to remove the non-invading cells. The cells that successfully invade the Matrigel were fixed in 4% paraformaldehyde solution (w/v) for 25 minutes. Inserts were washed 3X for 1 minute using 1X PBS solution. Cells were stained with 0.1% crystal violet solution (v/w) for 10 minutes, then washed 3X with 1X PBS and the dried. Cells were counted using a Leica phase-light microscope using a 10X magnitude objective. A minimum of five fields was counted per insert. Each invasion experiment was performed in duplicate and the average of invading cells/fields was calculated.

2.4.3 Inositol phosphate assay

Cells were seeded on 12-well plate at a density of 8×10^5 cells per well. AG 1-X8 analytical grade anion exchange resin (formate form, 200–400 mesh, BioRad, UK) was re-hydrated overnight in H_2O. The following day cells were labeled with 0.5 μCi/well [^3]H]myo inositol (PerkinElmer, US) in inositol free medium M199 (Sigma-Aldrich, UK). After 24 hours, cells were incubated in M199 containing 10 mM Hepes, pH 7.4 (Invitrogen, UK) and 20 mM LiCl (Sigma, UK) for 15 min before stimulation. A solution of M199 plus EGF (20 ng/ml) was prepared and used to stimulate the cells at the indicated time points.

Cells were then lysed with 1 ml of ice cold 0.1 M HCOOH. In parallel, 3 ml of the re-hydrated resin were added to each column and left to set for 5 minutes. Columns were washed with 10 ml of H_2O before loading the cell lysate. Free inositol was eluted and collected by elution with 10 ml of H_2O and radioactivity counted by liquid radioactivity counting. Columns were washed with 5 ml of H_2O. Glycophosphatidylinositol (GPI) were eluted using 5 ml of “solution A” containing (5 mM Na_2B_4O_7, 160 mM NH_4HCOO), collected and radioactivity counted by liquid radioactivity counting. After washing with 5 ml of solution A, inositol phosphates were eluted with 2 ml of NH_4HCOO 1M and radioactivity counted by liquid scintillation. Radioactivity measured in the inositol fraction was used to normalise the radioactivity content of the samples.
Inositol phosphate production was expressed as percentage of inositol phosphate produced compared to the control unstimulated sample.

### 2.4.4 [³H]InsP₅ incorporation assay

MDA-MB-231 transfected with siRNA targeting ABCC1 and ABCC5 and a scrambled non-targeting sequence were seeded in a 12-well plate at a density of 50% of confluence 24 hours after transfection. In case of treatment with the ABCC1 inhibitor MK571 MDA-MB-231 were pre-treated with MK-571 (40µM) for 2 hours in 10% FBS growth media at 37°C/5% CO₂. In the case of MDA-MB-231 transfected with siRNAs, cells were then incubated with 2 µl/well of [³H]InsP5 for 1 hour minutes. In the case of MDA-MB-231 pre-treated with MK-571 cells were incubated with [³H]InsP5 (2µl/well) for 2 second as basal incorporation and for 15 and 30 minutes. Cells were washed 3X with cold 1X PBS to remove the non-incorporated [³H]InsP5, then lysed on ice using 1 ml of HClO₄ 0.6M + 0.20 mg/ml Inositol Hexakisphosphate (IP6) solution and incubated on ice for 5 minutes. The whole lysate was diluted in 6 ml of scintillation liquid and radioactivity assessed by radioactivity counting. Radioactivity counts were normalized for the protein concentration of a duplicate 12 plate-dishes seeded and treated in parallel with “cold” InsP₅ as a duplicate. In the case of cells transfected with siRNAs incorporation was expressed as percentage of incorporation of scrambled after 1 hour of incorporation. In the case of cells treated with KM-571 incorporation was expressed as fold increase of basal incorporation.

### 2.5 Statistical analysis

Statistical analyses were carried out using the one-tailed, paired t-test using Microsoft Excel®.
Chapter 3

PLC\(\gamma 1\) is essential for cancer cell migration and invasion
3.1 Introduction

PLCγ1 is activated by integrins engagement to the ECM and it also plays an important role in growth factor-induced cell motility, being activated by tyrosine kinase receptors for EGF, FGFs, NGF, VEGF, HGF and IGF-1 (Wells et al., 2002). Recent evidence produced by our group confirmed the pivotal role of PLCγ1 in malignant cell invasion and its role in metastasis development and progression (Sala et al., 2008).

During metastasis, malignant cells are able to “escape” from the primary tumour through the circulatory or lymphatic system, invading distant healthy tissues to initiate a new malignant lesion. Cell motility is critical for this process to occur and the mechanisms involved in regulation of cell motility are the results of an intricate network of signals activated by different growth factors, chemo-attractant and ECM components in vivo. The first in vitro tool to study cell motility was built by Boyden, therefore it was called Boyden chamber and was initially used to study leukocyte chemotaxis. It consists of two medium-filled chamber separated by a microporous membrane (Falasca et al., 2011). Cells are seeded in the top compartment and allowed to migrate for an appropriate incubation time toward chemotactic agents present in the bottom chamber media, such as growth factors or ECM components used to coat the porous membrane. Since the cells migrate from the upper compartment to the lower one through a porous membrane, the Boyden chambers are also called transwell chambers. Once the cells pass through the membrane they remain adherent to it. For this reason the cells need to be fixed on the membrane and stained to allow quantification based on manual counting using a phase contrast microscope.

In order to investigate the role of PLCγ1 in cell migration and 3D Matrigel invasion in cancer cell lines, I performed cell migration and cell invasion assays using different cancer cell lines (breast and melanoma cell lines) upon PLCγ1 inhibition by chemical and molecular biology approaches. Cytoskeleton remodelling was also analysed in those cell lines in order to investigate a potential role of PLCγ1 in this process.
3.2 Results

Migration of breast cancer cell line MDA-MB-231 was analysed in vitro using the transwell assay. The transwell inserts used in this assay consist of a porous polycarbonate membrane with an average porous size of 8 μm. The inserts were coated with fibronectin, an ECM component, used as chemo-attractant. Cells were seeded in the upper chamber of the insert and allowed to migrate for 4 hours before being fixed in paraformaldehyde and stained with crystal violet. Cell migration was calculated by manual cell counting using a 10x magnification of a phase contrast microscope.

In order to determine the appropriate number of cells to be used in the assay, a preliminary experiment was performed using three different amounts of cells per transwell (5,000; 10,000; 20,000). Pictures in Figure 3.1A show representative fields of cell migrated on transwell insert. This experiment indicated that the optimal experimental condition to perform the assay was obtained when 10,000 cells were seeded on the inserts, which led to an average of 100 cells migrated through the porous membrane per fields, a reasonable number for the cell counting (Figure 3.1B).

A

Figure legend next page
Figure 3.1: (A) Pictures of transwell inserts after fixing and staining with crystal violet. Representative fields of insert seeded with 5000 cells (left) and 20000 cells (right). (B) Quantification of migrating cells by cell counting and expressed as number of migrated cells per field. The graph represents one experiment performed in duplicate in order to optimize the experimental conditions.

3.2.1 PLC activity is essential for MDA-MB-231 fibronectin-induced migration

In order to investigate the role of PLCγ1 in fibronectin-induced migration in MDA-MB-231 cells I decided to test the effect of the PLC inhibitor U73122 on cell migration. The inhibitor U73122 is a pan-PLC inhibitor that inhibits the lipase activity of all the PLC family components and has been show to inhibit cell motility (Jones et al., 2005). Since PLCγ1 is activated by fibronectin, the inhibitor was a useful tool to start investigating the involvement of PLCγ1 in fibronectin-induced migration. MDA-MB-231 were serum starved overnight
and pre-treated with U73122 (5μM) for 30 minutes before being plated on transwell inserts in the presence or absence of the inhibitor. Cells were allowed to migrate for 4 hours before being fixed. Migration of cells treated with the inhibitor was compared to control cells treated with the inactive analogue U73343. Migration of cells treated with the drug carrier (DMSO) alone was also determined. Cell migration was completely inhibited in MDA-MB-231 treated with U73122 (p=0.001). No inhibition of cell migration was detected in cells treated with the inactive analogue U73343 compared to cells treated with vehicle alone. This data indicated that PLC activity is essential for fibronectin-induced migration in MDA-MB-231 (Figure 3.2).

Figure 3.2: Effect of PLC inhibition on fibronectin-induced cell migration. Migration is expressed as migrated cells per field. Migration of MDA-MB-231 treated with U73122 was compared to cells treated with the inactive analogue U73343. Columns are the mean of 3 independent experiments performed in duplicate; bars S.E. *p=0.001
3.2.2 Effect of a PLCγ1 mutant form constitutively recruited to the plasma membrane on fibronectin-induced cell migration.

PLCγ1 plays an important role in cellular spreading on Matrigel in endothelial and cancer cells (Jones et al., 2005; Jones et al., 2007). As shown in Figure 3.2, inhibition of PLC activity leads to impaired fibronectin-induced migration in MDA-MB-231. PLCγ1 has been demonstrated to be involved in focal adhesion formation during cell motility and it is recruited to the leading edge of the cells during wound healing assay and cell migration (Piccolo et al., 2002). Therefore PLCγ1 recruitment at the leading edge of the cells is crucial to regulate cell motility and it is probably involved in controlling directional motility.

In order to assess the potential involvement of the PLCγ1 isoform in directional motility I decided to test the effect of overexpressing a constitutively membrane-recruited PLCγ1 mutant on fibronectin induced migration in MDA-MB-231. Since PLCγ1 is recruited to the plasma membrane at the leading edge, I hypothesised that a constitutively active form of PLCγ1 recruited all along the plasma membrane could affect directionality during the migration process. For this purpose MDA-MB-231 cells expressing a palmitoylated form of PLCγ1 (MDA-MB-231 PALM-PLCγ1), kindly provided by Dr. Bonvini, were analysed on fibronectin-induced cell migration transwell assay.

MDA-MB-231 cells expressing only the palmitoylation (MDA-MB-231 PALM) sequence were used as internal control in the migration experiments. Data indicated a significant reduction of fibronectin-induced migration in MDA-MB-231 PALM-PLCγ1 compared to MDA-MB-231 PALM (Figure 3.3), suggesting that overexpression of a mutant PLCγ1 constitutively associated to the plasma membrane affects the ability of cells to migrate towards fibronectin. These data further supported the hypothesis that recruitment of PLCγ1 to the leading edge of migrating cells is important for cell migration.
Figure 3.3 Cell migration in MDA-MB-231 expressing PALM-PLCγ1:

Number of migrated MDA-MB-231 (Parental) or cells expressing a palmytoylated PLCγ1 (PALM PLCγ1), or the palmytoylation sequence alone (PALM) is expressed as percentage of migrated MDA-MB-231 expressing the empty vector as control. Columns are the mean of three different experiments each of them performed in duplicate; bars S.E. **p=0.005
3.2.3 Downregulation of PLCγ1 expression using a pSUPERIOR construct containing specific shRNA targeting PLCγ1.

Since no PLCγ1 specific inhibitors are available, the best available molecular approach to assess the role of PLCγ1 activity in different cellular function was the generation of stable cell lines downregulated for PLCγ1 using short hairpin RNA (shRNA). pSUPERIOR.retro.puro vector containing unique 19 nucleotides sequence complementary to the mRNA transcript of PLCγ1 was generated previously in the lab (Sala et al., 2008) (see chapter 2.2.2.3.1; 2.2.2.3.2). The resulting transcript of the recombinant vector is predicted to fold back on itself to form a 19-base pair loop structure (shRNA) which is then cleaved in the cell to produce a functional siRNA. Three-point mutations in the 19 nucleotides sequence were introduced to generate an appropriate pSUPERIOR.retro.puro vector control (3MUT) (Sala et al., 2008). MDA-MB-435 and TSA cell lines were infected with pSUPERIOR.retro.puro 3MUT and pSUPERIOR.retro.puro shPLCγ1. Infected cells were kept in culture in the presence of puromycin. Western Blot (WB) analysis of cell extracts was performed to assess the expression level of PLCγ1 in cells expressing the targeting sequence shPLCγ1 and control cells 3MUT (Figure 3.4). Cells expressing the shPLCγ1 sequence showed a significant reduction in PLCγ1 protein levels compared to the 3MUT control cells.

![Figure 3.4 WB analysis of stable protein downregulation of PLCγ1](image)

**Figure 3.4 WB analysis of stable protein downregulation of PLCγ1:** PLCγ1 protein level was assessed by WB in cell lysates of MDA-MB-435 and TSA cell lines expressing the specific shRNA targeting PLCγ1 (shPLCγ1) and compared to expression in cells expressing the non-targeting shRNA (3MUT). PLCγ1 expression was assessed by immunoblot using a specific anti-PLCγ1
antibody. Immunoblot for ERK2 was used as control for equal loading. The position of the bands correspond to 155 KDa for PLCγ1 and 42 KDa for ERK2.

### 3.2.4 Inducible downregulation of PLCγ1 expression using a pSUPERIOR construct

The pSUPERIOR.retro.puro vector can be used as an inducible vector to produce siRNA in mammalian cells. The vector contains a tetracycline operator 2 (TetO$_2$) derived from E. Coli in the H1 promoter. The TetO$_2$ sequence acts as binding site for a homodimer of Tet repressor that, if present, blocks the transcription of the shRNAs. Therefore a previous transfection with the tetracycline repressor expressing vector is necessary to allow the binding of the Tet repressor to the TetO2 operator. The tetracycline repressor binds with high affinity to the operator sequence in the absence of tetracycline. Upon addition, tetracycline binds to the Tet repressor causing conformational changes to the repressor that impair the operator-repressor binding, eventually resulting in the transcription of the shRNA duplex that, once processed from the RNAi machinery of the cell, provides functional siRNA (Figure 3.5).

![Figure 3.5 Model of inducible protein downregulation using pSUPERIOR inducible system.](http://www.scbt.it/gene_silencers.html)
Therefore MDA-MB-231 cells were first transfected with a vector expressing the Tet repressor and selected to generate stable Tet repressor expressing clones. Subsequently, a selected clone was infected with the pSUPERIOR 3MUT and pSUPERIOR shPLCγ1 in order to generate cells with an inducible downregulation of PLCγ1 and the respective control. These cells were previously generated in the lab (Sala et al., 2008). As shown in Figure 3.6, MDA-MB-231 pSUPERIOR 3MUT cells show comparable PLCγ1 expression in the presence or absence of tetracycline addition indicating that the 3MUT sequence has no effect on the expression levels of PLCγ1. On the contrary, 24 hours of treatment with tetracycline of MDA-MB-231 pSUPERIOR shPLCγ1 cells induces a clear downregulation of PLCγ1 protein expression.

Figure 3.6 Inducible downregulation of PLCγ1: WB analysis of PLCγ1 protein level in cells expressing the TET repressor and a non-targeting shRNA (3MUT) or the targeting shRNA (shPLCγ1) in the presence or absence of tetracycline. ERK2 immunoblot was used as an equal loading control.
3.2.5 Cell invasion assay in breast cancer cells stably downregulated for PLC\(\gamma\)1 expression

The experimental conditions used in the transwell assays are very different from the physiological conditions encountered by cancer cells during the metastatic process. ECM and the basal membranes of organs represent the main barriers that cancer cells need to cross in order to locally invade the tissue of origin or to initiate a secondary tumour in a distant organ.

The Matrigel cell invasion assay more closely mimics the physiological conditions encountered by the cancer cells during ECM invasion. Matrigel is a mixture of ECM components produced by the Engelbreth-Holm-Swarm (EHS) murine sarcoma that has been used to study cell morphology on ECM components and the three-dimensional architecture in normal and malignant cell lines. The main components of Matrigel are laminin, collagen IV, entactin and perlecan; growth factors are minor components. In particular Matrigel exists in a growth factor rich composition, or in growth factor reduced composition. Matrigel can be applied on the inserts in its cold liquid form over transwell inserts and allowed to polymerise to form a gel with a defined three-dimensional structure.

The effect of PLC\(\gamma\)1 downregulation on three-dimensional invasion was investigated previously in the lab using MDA-MB-231 stably downregulated for PLC\(\gamma\)1 expression (Sala et al., 2008). I decided to perform Matrigel invasion experiments using other breast cancer cell models such as MDA-MB-435 and TSA stably downregulated for PLC\(\gamma\)1 expression. This allowed me to investigate the role of PLC\(\gamma\)1 in 3D invasion in different breast cancer cell lines. MDA-MB-435 and TSA expressing shRNA targeting PLC\(\gamma\)1 expression (shPLC\(\gamma\)1) or the 3MUT shRNA (sh3MUT) cloned in the pSUPERIOR.retro.puro were used for the assay. Cells were seeded on inserts pre-coated with Matrigel growth factor-reduced and fixed after the appropriate invasion time (see chapter 2.4.2.2). I observed that downregulation of PLC\(\gamma\)1 completely inhibited Matrigel invasion in MDA-MB-435 (p<0.05) and in TSA (p<0.01) compared to the respective controls. These data indicate that PLC\(\gamma\)1
is required for 3D-Matrigel invasion in the breast cancer cell lines analysed and that its downregulation severely impairs the cellular movements through the 3D-structure of the Matrigel (Figure 3.7).

**Figure 3.7 Analysis of Matrigel invasion in breast cancer cell lines:** 10,000 cells were seeded on Matrigel and allowed to invade for 36 hours. Cells that have invaded were fixed, stained with crystal violet and counted. Quantification of Matrigel cell invasion is expressed as percentage of invading cells. Columns are the mean of three independent experiments each of them performed in duplicate; bars S.E. *p<0.05; ** p<0.01
3.2.6 Cell invasion assay in melanoma cells transiently downregulated for PLCγ1 expression

In order to determine whether PLCγ1 has a role in invasion of different cancer cells, the effect of PLCγ1 downregulation in the highly invasive melanoma cell line A375M was investigated. Since A375M cells stably downregulated for PLCγ1 expression were not available, I decided to downregulate PLCγ1 transiently using specific PLCγ1-targeting siRNA. A375M were transfected with Hiperfect transfecting reagent (Qiagen) (see chapter 2.2.2.2). Optimisation of the protocol transfection was necessary in order to setup the experimental conditions. Once the protocol was optimised, the invasion on Matrigel of A375M transfected with siRNA for PLCγ1 or a non-targeting sequence (Scrambled) was determined. WB analysis of lysates of transfected cells was performed in parallel to each invasion experiment at the end of the assay to evaluate the effective downregulation of PLCγ1 protein expression as shown in Figure 3.8A.

Analysis of cells that have invaded demonstrated that downregulation of PLCγ1 protein expression strongly inhibits Matrigel invasion in A375M (p=0.001). These data confirm the importance of PLCγ1 in 3D cellular invasion and show that PLCγ1 is important for cell invasion not only in breast cancer cell lines but also in other models such as melanoma (Figure 3.8B).
Figure 3.8 (A) PLCγ1 transient downregulation in A375M assessed by WB using specific PLCγ1 antibody. (B) Matrigel cell invasion assay comparing A375M siPLCγ1 and A375 scrambled invasion rate. Cells were starved overnight 24 hours after transfection and then seeded on Matrigel-coated transwell for 36 hours before being fixed and stained. Columns are the mean of three different experiments performed in duplicate; bars S.E. *P=0.001

3.2.7 Analysis of cytoskeleton remodelling in MDA-MB-435

As described in chapter 1.3.4, PLCγ1 is involved in cytoskeleton remodelling and its inhibition induces a rounded morphology in endothelial and cancer cell lines which fail to form cell protrusion and to undergo cell spreading in response to integrin engagement (Jones et al., 2005). Previous experiments performed in the lab showed that EGF-induced membrane ruffles are inhibited in MDA-MB-231 cells downregulated for PLCγ1 (Sala et al., 2008). Therefore I decided to investigate the effect of PLCγ1 downregulation on cytoskeleton remodelling in other breast cancer cell lines. The effect of PLCγ1 downregulation on cytoskeleton remodelling was investigated using immunofluorescence staining of actin with Alexa®Fluor 594 phalloidin. Phalloidin is a molecule with high affinity for actin, belonging to the family of
Phallotoxins, which stabilizes F-actin preventing actin depolymerisation. Phalloidin-conjugated with the Alexa® Fluor 594 dye allows fluorescent visualization of actin cytoskeleton by excitation at 543 nm wavelength. MDA-MB-435 cells were serum starved overnight and then stimulated with EGF or media supplemented with 10% serum for 6 minutes before being fixed and examined with a confocal microscope. Serum and EGF stimulation induces formation of membrane ruffles and cytoskeleton protrusion (white arrows in Figure 3.9A) in both MDA-MB-435 3MUT and MDA-MB-435 shPLCγ1. However downregulation of PLCγ1 significantly reduced the percentage of cell processing membrane ruffles or cellular protrusion (Figure 3.9B). These data indicate that PLCγ1 is required for polymerization of new actin filaments underneath the plasma membrane, which is essential for membrane ruffling formation and growth factor-induced cytoskeleton remodelling.

Figure legend next page...
Figure 3.9: PLCγ1 is important for cytoskeleton remodelling: (A) Phalloidin staining of actin cytoskeleton in unstimulated and EGF- or Serum-stimulated MDA-MB-435. Arrows indicate membrane ruffles. (B) Quantification of membrane ruffles was performed on 4 independent experiments. At least 100 cells per experiment were counted and classified according to the presence or absence of membrane ruffles. Columns represent the average of four independent experiments ±SEM. Bar=10 μm,*p=0.05, **p=0.01.

3.2.8 Analysis of cytoskeleton remodelling in TSA murine breast cancer cell line

To determine whether PLCγ1 has a role in actin remodelling in other breast cancer cell lines, actin cytoskeleton staining was performed in TSA cells. Data revealed that serum-induced and EGF-induced membrane ruffle formation was strongly inhibited in TSA shPLCγ1 compared to control TSA 3MUT (Figure 3.10). Inhibition of membrane ruffle formation was more evident in this cell line than in the MDA-MB-435 (Figure 3.9A) but data in both cell lines demonstrated the role of PLCγ1 in EGF- and serum-induced actin remodelling.
Figure 3.10 (A) Phalloidin staining of actin cytoskeleton in unstimulated and EGF- or Serum-stimulated TSA. Arrows indicate membrane ruffles. Bar=10μm. (B) Quantification of membrane ruffling was performed in 4
different experiments in duplicate. At least 100 cells per experiments were counted and classified according to the presence or absence of membrane ruffles. Columns represent the average of four independent experiments. bars S.E., *p=0.05.

3.3 Discussion

The tumour is the second cause of death in adults. Surgical excision of the primary tumour can result in good prognosis. However, cancer cells can acquire metastatic capacity leading to the spreading of tumour in distant tissues often resulting in a poor prognosis. Metastatic tumours are often resistant to chemotherapy and non-responsive to treatment and therefore the metastatic stage in cancer disease represents the most serious condition. Cancer cells able to metastasise are the result of a selective process where cells with high ability to migrate and to invade the ECM are selected. Understanding the mechanism by which they migrate and can invade is therefore a key goal in cancer research. It has been widely accepted that PLCγ is involved in cell migration and cell invasion in vitro and in vivo. Previous works investigated how integrins (Tvorogov et al. 2004) and EGF stimulate PLCγ-mediated cell migration and invasion in different normal and cancer cell lines. Furthermore the use of specific siRNA targeting PLCγ1 expression underlined the importance of this specific isoform in cell spreading on different substrates such as fibronectin and Matrigel. The EGFR-PLCγ1 pathway plays an important role in cell motility and cancer invasion (Chen et al., 1994; Kassis et al., 1999). Indeed EGFR and ERB2 receptors have been linked to increased invasivity and poor prognosis in breast cancer patients, and inhibition of PLC using the pan-PLC inhibitor U73122 or EGFR inhibitor decreased breast cancer cell migration in vitro (Kassis et al., 1999) as confirmed in my experimental system (Figure 3.2).

Furthermore PLCγ1 is highly expressed in colon cancer, breast cancer and highly metastatic colorectal tumour cell lines (Nomoto et al., 1995; Smith et al., 1998). Especially, high levels of PLCγ1 were found in breast carcinoma
metastases compared to primary tumour (Sala et al, 2008), indicating that this enzyme is important for the metastatic process. Expression of a dominant-negative mutant of PLCγ1 in de novo-occurring carcinomas of the mammary or prostate gland mice models diminished lungs metastasis (Shepard et al., 2007). These data pointed at PLCγ as an important regulator of metastasis dissemination and suggested PLCγ as a potential therapeutic target to prevent metastasis formation. However it should be mentioned that all these studies were obtained using generic PLC inhibitors or a dominant negative mutant. My results were obtained using specific siRNA or shRNA that allowed the transient or stable downregulation of PLCγ1 expression in a panel of metastatic breast cancer cell lines and one cell line of a highly metastatic melanoma. The experiments described in this chapter were published in a Cancer Research paper together with parallel experiments performed by co-authors (Sala et al., 2008). Downregulation of PLCγ1 inhibited Matrigel cell invasion in vitro in all the cell lines, indicating that this enzyme has a role in cell motility and invasion in different cell lines (Figure 3.7; 3.8). It has been already shown that PLCγ1 is recruited to the leading edge of migrating cells in a PI3K dependent manner (Falasca et al., 1998; Piccolo et al., 2002) and that it is involved in integrin-induced cytoskeleton remodelling downstream of FAK activation (Zhang et al., 1999), which results in directional migration. In line with this, data in Figure 3.3 shows that the expression of a mutant PLCγ1 constitutively associated to the plasma membrane inhibits the fibronectin-induced cell migration, likely through a loss of cell directionality caused by lack of polarization of PLCγ1. Data in the literature have also demonstrated an important role of PLCγ1 in integrin-induced cell spreading and cytoskeleton remodelling. Mouse embryonic fibroblast (MEF) cells knocked-down for PLCγ1 showed rounded morphology and diminished RAC1 activation upon integrin engagement which is essential for membrane ruffles formation (Choi et al., 2007). Consistent with this we also reported a role of PLCγ1 in EGF-induced Rac1 activation (Sala et al., 2008). Similarly, I observed that downregulation of PLCγ1 in MDA-MB-435 and TSA breast cancer cells impaired ruffles formation upon EGF or serum stimulation (Figure 3.9-3.10),
indicating that PLCγ1 plays an essential role in cytoskeleton remodelling which is essential for protrusion formation in cancer cell lines in turn necessary to regulate cell motility. Taken together these studies highlighted PLCγ1 as a key molecular enzyme involved in cell motility in normal and in cancer cells. Interestingly PLCγ1 has been found overexpressed in different cancer type like prostate and breast cancer. Furthermore we reported that PLCγ1 was overexpressed in 50% of metastasis form breast cancer patients (Sala et al., 2008). Data showed in this chapter showed that PLCγ1 isoform is essential for cell invasion of breast cancer and melanoma cells on Matrigel. These data supported the hypothesis that PLCγ1 might have a role in the metastatic process. Indeed, based on these data, we performed in vivo metastasis assay using MDA-MB-231 cells expressing the stable and inducible system in order to downregulate PLCγ1 protein expression (Sala et al., 2008) and we demonstrated that PLCγ1 is important for both development and progression of metastasis (chapter 1.4).

Summary

Taken together these data demonstrated the main role of PLCγ1 in cell migration and in particular in cancer cell invasion in vitro. Furthermore data showed that PLCγ1 has a main role in growth factor-induced cytoskeleton remodelling, which may explain the eventual inhibition of cell motility. These data, published in a Cancer Research paper, demonstrated the role of PLCγ1 in metastasis and highlighted PLCγ1 as a potential target for anti-metastatic drug development.
Chapter 4

PLCγ1 is the main PLC isoform involved in EGF- and FGF- induced calcium release and InsP₃ production in MDA-MB-231 and endothelial cells
4.1 Introduction

The results described in chapter 3 demonstrated the essential role of PLCγ1 on cell migration, invasion and cytoskeleton remodelling. These data, together with our data indicating the key role in metastasis development and progression (Sala et al., 2008), suggested that targeting PLCγ1 may represent a novel key anti-metastatic strategy. In order to investigate the potential effect of PLCγ1 inhibition it was first necessary to find an unequivocal read out of the enzymatic activity of PLCγ1. PLCγ1 is activated by different growth factor like EGF, FGF and PDGF (Kim et al., 1990; Kim et al., 1991). Once activated PLCγ1 hydrolyzes PtdIns(4,5)P2 leading to accumulation Ins(1,4,5)P3 and diacylglycerol that in turn induce calcium release from internal stores and the activation of some protein kinase C (PKC) isoforms, respectively. Following the initial calcium release from the internal stores and plasma membrane depolarisation, store operating channels (SOC) situated on the plasma membrane allow the influx of calcium ions from the extracellular compartment providing a more sustained signal (Patterson et al., 2005M; Heo et al., 2006).

Analysis of cytoplasmic calcium variation provides an indirect read-out of IP3 production which is dependent from PLC activity. Molecular probes are available to measure calcium concentration in a fluorescence assay. In particular the fluorescent calcium probe Fluo-4 AM is extensively used to measure variation in the cytoplasm calcium levels on time. This is obtained using a confocal time lapse analysis exciting the probe with a 488 nm wavelength laser and measuring the emission at 515 nm.
4.2 Results

4.2.1 Effect of PLCγ1 downregulation on EGF-induced calcium release in MDA-MB-231

EGFR and HerB family receptors are often overexpressed in breast cancer and EGF stimulates activation of PLCγ1 in different types of cancer (Thomas et al., 2003; Price et al., 1999). Based on this, the effect of PLCγ1 downregulation on calcium variation upon EGF stimulation was determined in MDA-MB-231 cells.

As shown in Figure 4.1, calcium measurements were performed in MDA-MB-231 cells expressing the inducible system, described in chapter 3.2.4, in the absence (PLCγ1 expressed) or presence (PLCγ1 downregulated) of tetracycline. Cells were stimulated with EGF (50 ng/ml) after a pre-acquisition of 1 minute and the fluorescence was monitored for 8 minutes. ATP was added at the end of the experiment as positive control in order to determine cell viability. MDA-MB-231 not treated with tetracycline (-TET) responded in a fast-response manner to EGF stimulation. In contrast MDA-MB-231 downregulated for PLCγ1 (+TET) did not show any fluorescence variations after EGF stimulation. The calcium response induced by ATP was comparable in both MDA-MB-231 (-TET) and MDA-MB-231 shPLCγ1 (+TET) indicating that cells were equally viable for the duration of the analysis. This data indicated that PLCγ1 is essential for EGF-induced calcium mobilisation in MDA-MB-231 and suggested that other PLC members are not involved in EGF-induced calcium release in this cell line.
Figure 4.1: PLCγ1 is essential for EGF-induced calcium mobilisation:
Calcium mobilisation assay upon EGF stimulation: (A) Calcium increase in EGF-stimulated-MDA-MB-231 when PLCγ1 is expressed. Arrows indicate the
time point of EGF or ATP treatment. (B) Calcium increase in EGF-stimulated-MDA-MB-231 when PLC\(\gamma\)1 expression is downregulated by tetracycline treatment is not expressed following the induction of transcription of the specific shRNA. Arrows indicate the time point of EGF or ATP treatment. Graph is the average of three independent experiments.

4.2.2 Effect of PLC\(\gamma\)1 downregulation on EGF-dependent Inositol Phosphates accumulation

In order to validate the calcium measurement data obtained in MDA-MB-231 expressing the inducible system targeting PLC\(\gamma\)1, I used a complementary approach to assess PLC\(\gamma\)1 activity. As described in introductory chapter 4.1 the hydrolysis of PtdIns(4,5)P\(_2\) by PLC produces the second messengers Ins(1,4,5)P\(_3\) and DAG. Measurement of inositol phosphates production represents a direct read-out of PLC activity upon cellular stimulation. The assay specifically used in this set of experiments measures the production of all inositol phosphates species. However, since the inositol phosphates variation is mainly due to the Ins(1,4,5)P\(_3\) production generated by PLC activation and its degradation products, the assay is a direct read-out of PLC activation.

MDA-MB-231 cells expressing the inducible system were divided in two groups. One group was treated with tetracycline 24 hours before the labelling to induce PLC\(\gamma\)1 downregulation (+TET), whereas the second group was not treated with tetracycline and used as control (-TET). This second group therefore expressed PLC\(\gamma\)1 since the silencing system was not induced. Cells were then labelled using \(^3\)H-myo-inositol for 24 hours in inositol free, serum free media and then stimulated with EGF at different time points. Cells were lysed, inositol phosphates were separated by anion exchange chromatography and the total amount was assessed by liquid radioactivity counting. Downregulation of PLC\(\gamma\)1 (MDA-MB-231 shPLC\(\gamma\)1 +TET) strongly inhibited the EGF-induced inositol phosphates production at all time points compared to the control MDA-MB-231 sh PLC\(\gamma\)1 –TET (Figure 4.2). Taken together
calcium measurement assay and inositol phosphates production assay indicate that EGF stimulation specifically activates the \( \text{PLC} \gamma_1 \) isoform in MDA-MB-231 excluding any significant involvement of other PLC isoforms.

**Figure 4.2 Inositol phosphate assay**: MDA-MB-231 shPLC\( \gamma_1 \) (-TET) and MDA-MB-231 shPLC\( \gamma_1 \) (+TET) were stimulated with 50 ng/ml EGF for 1,3,5,7,10 minutes. Inositol phosphates accumulation was expressed as percentage of the respective basal. Graphs are the average of 4 independent experiments; bars S.E; \(*P<0.05\)

### 4.3 Discussion

In this chapter I described two assays used to analyse PLC\( \gamma_1 \) activity: the calcium mobilisation assay and the inositol phosphates assay. The calcium assay using the confocal microscope in a time lapse mode was rigorously optimised since it is composed of a step of incorporation of the Fluo-4-AM probe, followed by a de-esterification step. The optimal concentration of Fluo-4 to be used was determined empirically evaluating the number of fluorescent
cells after 1 hour of incubation with a solution 2mM and 4mM of Fluo-4. Only cells incubated with 4μM Fluo-4 showed detectable fluorescence. The cells were incubated in presence or absence of calcium at 2mM concentration. The absence of calcium caused cell detachment from the bottom glassed plate, indicating that calcium was essential for cell adhesion in MDA-MB-231. Because of this all subsequent calcium measurement were performed in the presence of extracellular calcium, therefore the analysed calcium variations were due to the overall flux of calcium across the membranes (internal store and extracellular Ca\(^{2+}\) influx). The inositol phosphate assay was used to validate data obtained by calcium release, since this method measures directly the production of inositol phosphates. Data obtained analysing the intracellular calcium mobilisation and the inositol phosphate production showed that down regulation of PLC\(\gamma_1\) completely inhibits EGF-induced calcium release in MDA-MB-231. As described in paragraph 1.2.5, PLC\(\varepsilon\) can also be activated by EGF. However the fact that PLC\(\varepsilon\) is mainly expressed in tissues such brain, colon and lungs and together with results obtained from calcium and inositol phosphates measurements rules out any contribution of this PLC isoform to the EGF-induced signalling in this particular model. Therefore PLC\(\gamma_1\) appears to be the only member of the PLC family necessary for EGF induced-calcium mobilisation in MDA-MB-231.

Summary

Calcium release assay revealed that PLC\(\gamma_1\) is the only PLC isoform involved in the EGF-induced signalling in MDA-MB-231
4.4 PLCγ1 siRNA interference inhibits FGF-2 induced calcium release in HUVEC cells

4.4.1 Calcium release assay upon FGF-2 addition

Angiogenesis is involved in different processes such as development, wound healing and tissue regeneration. It plays also an important role in disease such as arteriosclerosis and tumour growth. This process involves endothelial cells which are able to organise three dimensional capillary structures. Different growth factors play an important role in angiogenesis. The most investigated growth factor, the vascular endothelial growth factor (VEGF), has been related to pathological angiogenesis and has been the targeted for development of anti-angiogenic agents. The fibroblast growth factor family (FGF) is composed of 22 different factors. In particular it has been reported that FGF-2 is upregulated in different cancers. FGF induces activation of PI3K/AKT pathway, Src family tyrosine kinases and Ras pathway and it has been shown to activate PLCγ1. It was previously observed in my laboratory that downregulation of PLCγ1 strongly reduces the FGF-induced inositol phosphates accumulation in Human umbilical vein cells (HUVEC) (Maffucci et al., 2009). To further investigate whether FGF-2 was able to activate PLCγ1, I decided to analyse FGF-2-induced calcium mobilisation. The assay was first optimized for this cell line. Cells were labelled with FLUO-4 and stimulated with FGF-2 using the two different concentrations (50ng/ml and 100ng/ml) in order to find the optimal concentration. Changes in fluorescence were measured for 20 minutes. The first concentration failed to induce any detectable intracellular calcium release whereas stimulation with 100ng/ml FGF-2 induced a spiked-shape response as indicated in Figure 4.3. Cell viability was assessed at the end of the acquisition time measuring the calcium release upon ATP stimulation.
Figure 4.3 Intracellular calcium increase in serum starved HUVEC was determined as described in the Materials and Methods section. Cells were stimulated with 100 ng/ml FGF-2 and 1 mM ATP at the indicated times (arrows). Data are mean of values obtained from 4 independent experiments.

4.4.2 PI3K is required for FGF-2-induced calcium release

To gain further insight into the mechanism of FGF-induced activation of PLCγ1, I decided to investigate the potential role of PI3K in this process in HUVEC cells. As described in chapter 1.3.2 PI3K activation is essential for PLCγ1 translocation to the plasma membrane (Falasca et al., 1998). Therefore, I decided to investigate the effect of the reversible PI3K inhibitor LY294002 on intracellular calcium mobilisation. HUVEC cells were serum starved overnight and pretreated with LY294002 (10 μM) and FGF-induced calcium mobilisation was measured by confocal analysis. HUVEC cells treated with vehicle alone were used as control. Cell viability was assessed by ATP stimulation at the end of the assay. Data in Figure 4.4 shows that the FGF-2-induced calcium mobilisation was completely inhibited in HUVEC cells treated with LY294002 compared to control cells. These data indicate that PI3K is important also in FGF-2 induced PLCγ1 activation in endothelial cells.
Figure 4.4: PI3K is required for FGF-2-induced calcium release. FGF-2-induced calcium release in serum starved HUVEC untreated (blue line) or treated (pink line) with LY294002 (10 μM). Data are mean of values obtained from 2 independent experiments.

4.4.3 Effect of PLC\gamma 1 and PLC\gamma 2 downregulation on endothelial cell proliferation

Previous experiments performed by others in my laboratory showed that downregulation of PLC\gamma 1 inhibited inositol phosphates accumulation in endothelial cells. To investigate a potential aspecific effect of PLC\gamma 1-targeting siRNA on PLC\gamma 2 expression, I decide to investigate PLC\gamma 2 levels in HUVEC cells transfected with siRNA targeting PLC\gamma 1. In parallel, siRNA targeting PLC\gamma 2 were used to evaluate the effect of PLC\gamma 2 downregulation in endothelial cells. Data in figure 4.5A-B show western blot analysis of HUVEC cells transfected with siRNA targeting PLC\gamma 1 or PLC\gamma 2 or with scrambled siRNA as control. Data showed that PLC\gamma 1 was completely downregulated in cells transfected with siRNA targeting PLC\gamma 1, while PLC\gamma 2 levels were not affected. Similarly, transfection with siRNA targeting PLC\gamma 2 had no effect on
PLCγ1 expression indicating that the siRNA sequences used were isoform specific. In order to investigate the role of the PLCγ1 and PLCγ2 on cell proliferation in endothelial cells, cell counting experiments were performed after 24 hours and 48 hours from transfection. Data in Figure 4.5C show that downregulation of PLCγ1 had no effect on cell proliferation. On the contrary, HUVEC transfected with siRNA targeting PLCγ2 showed a significant decrease in cell proliferation compared to control cells or cells transfected with siRNA targeting PLCγ1. These data indicated that PLCγ1 and PLCγ2 play different roles in endothelial cells, with a main role of PLCγ2 in cell proliferation.

Figure 4.5: PLCγ2 but not PLCγ1 affects cell proliferation in HUVEC cells: A,B) Western blot analysis for PLCγ1 and PLCγ2 expression in HUVEC cells transfected with scramble, PLCγ1 or PLCγ2 siRNA. C) Cell counting of HUVEC transfected with scrambled, PLCγ1 or PLCγ2 siRNA after 24 and 48 hours of transfection. Data are expressed as percentage of scrambled cells and are mean ±SEM of values from 6 independent experiments.

4.5 Discussion

In this chapter I described experiments performed to understand the contribution of PLCγ1 signalling in endothelial cells (HUVEC). The mechanism of FGF-2-induced activation of PLCγ1 has been controversial.
Some studies reported a positive regulation of PLCγ1 phosphorylation by FGF-2 (Burgess et al., 1990), while other reported that FGF-2 is not able to phosphorylate PLCγ1 (McLaughlin et al., 2001). To investigate the FGF-2 induced PLCγ1 activation, I decided to measure the intracellular calcium mobilisation upon FGF-2 stimulation. FGF-2 stimulation induced an instant calcium increase in HUVECs cells. Furthermore, parallel experiments in my laboratory showed that downregulation of PLCγ1 inhibited inositol phosphates accumulation upon FGF-2 stimulation (Maffucci et al., 2009). Together these data demonstrated the main role of PLCγ1 in the FGF-2 response in endothelial cells. It was reported that PI3K activation is essential for PLCγ1 activation upon growth factor stimulation in cancer cells (Falasca et al., 1998; Piccolo et al., 2002). I therefore decided to investigate the potential role of PI3K in FGF-2-induced PLCγ1 activation. My data showed that treatment with PI3K inhibitors (LY294002 and Wortmannin) inhibited PLCγ1 activation. In particular, LY294002 treatment inhibited intracellular calcium mobilization and experiments performed in my laboratory by others showed that treatment with wortmannin inhibited inositol phosphates accumulation in cells stimulated with FGF-2. Therefore this data demonstrated that PI3K is essential for the FGF-2-induced PLCγ1 activation. Since PLCγ2 is mainly expressed in the hematopoietic tissue, I investigated the effect of PLCγ1 and PLCγ2 downregulation on cell viability. The effect on cell proliferation observed in HUVECs cells downregulated for PLCγ2, but not in cells transfected with PLCγ1 siRNA, shows that PLCγ1 and PLCγ2 had different functions in endothelial cells. These results are in line with different reports that showed the differential and not overlapping role of the PLCγ1 isoforms in the immune system (Regunathan et al., 2006).

Summary

Taken together these data demonstrate that FGF-2 induces PLCγ1 activation in a PI3K-dependent mechanism and identified the critical role of PLCγ1 in cell migration and tubulogenesis in endothelial cells and highlighted the non-overlapping functions of PLCγ1 and PLCγ2 (Maffucci et al., 2009).
Chapter 5
Effect of Ins(1,3,4,5,6)P$_5$ and 2-O-Bn-InsP$_5$ on cell migration, cell invasion and on PLC$\gamma$1 activity
5.1 Introduction

Inositol 1,3,4,5,6 pentakisphosphates (InsP$_5$) has been shown to possess anti-angiogenic properties and to induce apoptosis in ovarian cancer, lung and breast cancer cell lines (Piccolo et al., 2004; Maffucci et al., 2005). This compound is able to inhibit activation of the PI3K/AKT pathway activation preventing AKT phosphorylation (see introduction chapter 1.8). Since AKT PH domain not only binds phosphoinositides but also inositol phosphates such as InsP$_4$, it has been hypothesised that InsP$_5$ prevents AKT plasma membrane recruitment by binding to the AKT PH domain and therefore competing with PtdIns(3,4,5)P$_3$ and PtdIns(3,4)P$_2$ for the PH domain binding. As described in the introductory chapter 1.2.4, PLC$\gamma$1 possesses a PH domain reported to be important for its enzymatic activation. The PH domain of PLC$\gamma$1 recruits the enzyme to the plasma membrane in an essential step for its enzymatic activation, interacting with PtdIns(3,4,5)P$_3$ produced by PI3K. Therefore I hypothesized that InsP$_5$ could prevent PLC$\gamma$1 activation by competing with PLC$\gamma$1 PH domain binding to PtdIns(3,4,5)P$_3$ and therefore preventing its activation. As described in introduction chapter 1.3.4, PLC$\gamma$1 is involved in controlling cell migration and cytoskeleton remodelling and its pharmacological inhibition could block these processes. Therefore I decided to test the effects of InsP$_5$ on cell migration and Matrigel cell invasion on a panel of cancer cell lines.
5.2 Results
5.2.1 InsP$_5$ inhibits fibronectin-induced migration in MDA-MB-231

In order to determine the effect of InsP5 on fibronectin-induced cell migration of MDA-MB-231, I performed migration assay using transwell inserts previously coated with fibronectin. MDA-MB-231 cells were serum starved overnight and then pre-treated with InsP$_5$ (50 μM) for 30 minutes. Since InsP$_5$ is dissolved in H$_2$O, MDA-MB-231 cells treated with the same volume of H$_2$O were used as control. Cells were then seeded on the inserts and allowed to migrate for 4 hours before being fixed and counted. Data revealed that InsP$_5$ inhibits MDA-MB-231 fibronectin-induced migration by 60% indicating that InsP$_5$ inhibits the integrin-activated migration in this breast cancer cell line (Figure 5.1).

![Figure 5.1 InsP$_5$ inhibits fibronectin-induced migration](image)

*Figure 5.1 InsP$_5$ inhibits fibronectin-induced migration: Quantification of fibronectin-induced migration of MDA-MB-231 cells treated with InP$_5$.*
(50μM) compared to control cells treated with vehicle alone. Data are means ±SEM of values obtained from three independent experiments. *p<0.01

5.2.2 InsP5 inhibits cell invasion on Matrigel of MDA-MB-231

To investigate the effects of InsP5 on cancer cell invasion, Matrigel cell invasion assay was performed. MDA-MB-231 cells were serum deprived overnight and treated with the inhibitor for 30 minutes before being seeded on the transwell inserts pre-coated with Matrigel. Cells were allowed to invade the Matrigel for 36 hours before being fixed. InsP5 was maintained for the duration of the invasion experiment. MDA-MB-231 cells treated with H2O were used as control. Data revealed that InsP5 inhibits invasion of MDA-MB-231 cells on Matrigel by 38% compared to the control, indicating that InsP5 is not only able to reduce cell migration but also to inhibit 3D-Matrigel cell invasion (Figure 5.2).

![Graph showing inhibition of cell invasion by InsP5](image)

**Figure 5.2 InsP5 inhibits Matrigel invasion:** Quantification of 3D-Matrigel invasion of MDA-MB-231 cells treated with InsP5 (50μM) compared to control
cells expressed as percentage of control cells which invaded the Matrigel. Data are means ±S.E.M of values obtained from 3 independent experiments. *p=0.01

5.2.3 Effect of InsP5 on cell survival and proliferation in MDA-MB-231 Breast cancer cells

Since InsP₅ inhibits migration and invasion in MDA-MB-231, I decided to investigate the effect of the compound on cell proliferation and cell survival since these processes may affect cell motility. Furthermore it has been previously shown that InsP₅ induces apoptosis in ovarian, lung cancer and some breast cancer cell lines (Piccolo et al., 2004). A potential pro-apoptotic effect in MDA-MB-231 could also result in the inhibition of cell invasion rate on Matrigel. In order to determine any potential effect of InsP₅ on cell proliferation and cell survival, I performed cell counting experiments in MDA-MB-231 after 72 hours of treatment with InsP₅ in serum free and in serum conditions. Cells treated with H₂O were used as control. 15,000 cells per-well were seeded, treated with InsP₅ or carrier alone and counted after 72 hours treatment. Data shown in Figure 5.3 indicate that InsP₅ had no effect on MDA-MB-231 proliferation, in cells treated with InsP₅ in 10% serum for 72 hours of treatment. Similarly, no effect on cell survival was detected in cells treated with InsP₅ in serum free condition. These data indicate that InsP₅ does not affect cell proliferation and cell survival in MDA-MB-231 and that the effect seen on cell invasion is not dependent on changes in the proliferation or survival.
Figure 5.3: Cell counting of MDA-MB-231 after 72 hours of treatment with InsP$_5$ (50μM) in media supplemented with 10% serum or serum deprived media conditions. Data are means ±SEM of values obtained from 3 independent experiments in duplicate. No significant difference was observed.

5.2.4 InsP$_5$ inhibits Matrigel cell invasion in human and murine breast cancer cell lines

My previous experiments performed using MDA-MB-231 indicated that InsP$_3$ inhibits migration and invasion. I therefore decided to evaluate the effect of InsP$_3$ treatment on different cancer cell lines. I performed cell invasion assays on Matrigel using the human breast cancer cell line MDA-MB-435 and two singenic mouse models of breast cancer cell lines (TSA and 4T1). InsP$_5$ was maintained for the duration of the invasion experiment. Cells treated with H$_2$O for each cell line were used as internal controls. Data in Figure 5.4 show that InsP$_3$ decreased the percentage of cells that had invaded by 35% in MDA-MB-435 and TSA, compared to the respective control. Interestingly, 4T1 cells were more sensitive to the treatment with InsP$_5$ compared to the other cell lines.
used, showing an inhibition of invasion of 76%. Overall these data demonstrated that InsP₅ inhibits invasion of a panel of breast cancer cell lines.

Figure 5.4: InsP₅ inhibits cell invasion on Matrigel of MDA-MB-435, 4T1 and TSA treated with InsP₅. Invasion was expressed as percentage of cells treated with the vehicle alone which invaded the Matrigel (control). Data are means ±SEM of values obtained from 3 independent experiments in duplicate. *p=0.05; **p=0.005

5.2.5 InsP₅ does not affect cell proliferation and cell survival of MDA-MB-435, 4T1 and TSA.

In order to evaluate any potential pro-apoptotic effect of InsP₅ on MDA-MB-435, 4T1 and TSA cell lines, I analysed cell proliferation and cell survival on these cell lines, as previously described. Cell counting experiments were performed on cells treated with InsP₅ in 10% serum media and on cells treated with InsP₅ in serum free condition. Cells treated with vehicle (H₂O) alone
were used as controls for the experiments. Data in Figure 5.5 show that InsP$_5$ did not affect proliferation and survival in MDA-MB-435 and TSA (panel A,B). Similarly, no effect on proliferation of TSA was observed in cells kept in 10% serum upon InsP$_5$ (panel C, D). On the contrary the number of 4T1 cells after 48 hours or 72 hours treatment with InsP$_5$ in serum free condition was clearly reduced, suggesting an effect of the inositol phosphate on cell survival in this particular cell type. Nevertheless, since Matrigel invasion assays were performed in the presence of serum and InsP$_5$ does not affect cell proliferation in the presence of serum, we can conclude that the inhibition of invasion detected in the presence of InsP$_5$ is exclusively due to an impaired cell migration.

**Figure 5.5: Effect of InsP$_5$ on cell proliferation/survival:** Cell counting experiment assessing cell proliferation (10% serum) and survival (Serum free
condition) in, MDA-MB.435 (A), TSA (B) and 4T1 (C,D) after 72 hours of treatment with 50 μM InsP₅. Data are means ±SEM of values obtained from 3 independent experiments in duplicate.

5.2.6 InsP₅ inhibits internal calcium release In MDA-MB-231 and MDA-MB-435 cell lines.

Our data so far indicated that InsP₅ inhibits cancer cell invasion primarily through inhibition of cell migration. Since we have shown that PLCγ1 has a key role in regulating cell migration, I hypothesised that InsP₅ could affect PLCγ1 activity. Therefore to test this hypothesis, a calcium release assay was performed using MDA-MB-231 and MDA-MB-435 treated with InsP₅ and stimulated with EGF, since I previously demonstrated that this process is completely dependent on PLCγ1 in MDA-MB-231 (Figure 4.1). Cells were pre-treated with InsP₅ and intracellular calcium variation was assessed with confocal microscope analysis, as before. Data in Figure 5.6A show the calcium response in control MDA-MB-231, treated with vehicle alone. EGF stimulation induced a rapid increase in fluorescence generating an initial Ca²⁺ spike immediately after stimulation followed by calcium oscillations. In contrast, cells treated with InsP₅ showed a significant decrease of the initial spike and calcium oscillation, indicating that InsP₅ inhibits PLCγ1 activity (Figure 5.6B). Cell viability was assessed at the end of the assay by ATP stimulation (Figure 5.6C). Fold increase in fluorescence was calculated comparing the difference in fluorescence between basal and the highest fluorescence induced by EGF in three different experiments (Figure 5.6D) and confirming the strong inhibition upon InsP₅ treatment. Similarly, EGF induced a rapid increase in calcium in MDA-MB-435 (Figure 5.7A) which was completely inhibited in cells treated with InsP₅ (Figure 5.7B), indicating that InsP₅ inhibits EGF-induced intracellular calcium mobilization in different cell types. Fold increase in fluorescence was calculated as previously indicated (Figure 5.7D). Similarly, cell viability was assessed at the end of the assay by ATP stimulation (Figure 5.7C)
Figure 5.6 Effect of InsP$_5$ on EGF-induced intracellular calcium mobilisation in MDA-MB-231: A, B) Representative experiment of EGF-induced intracellular calcium mobilisation in untreated MDA-MB-231 and MDA-MB-231 treated with InsP$_5$ (50 µM). C) Representative ATP-induced intracellular calcium mobilisation. D) Quantification of intracellular calcium increase. Columns are the mean of three independent experiments; Bars S.E *P=0.01
Figure 5.7: Effect of InsP₅ on EGF-induced intracellular calcium mobilisation in MDA-MB-435: A,B) Representative experiment of EGF-induced intracellular calcium mobilisation in untreated MDA-MB-435 and MDA-MB-435 treated with InsP₅ (50 μM). C) Representative ATP-induced intracellular calcium mobilisation. D) Quantification of intracellular calcium increase. Columns are the mean of three independent experiments; Bars S.E *p=0.001
5.3 Discussion

Taken together these experiments demonstrated that InsP<sub>5</sub> is able to inhibit cell migration and Matrigel cell invasion in vitro in different metastatic cell lines. Furthermore Figure 5.6 and 5.7 showed that InsP<sub>5</sub> inhibits the EGF-induced intracellular calcium mobilization in breast cancer cell lines. Since, as shown in chapter 4.2.1 and 4.2.2 the EGF-induced calcium mobilization is completely dependent on PLCγ1 activity, it is possible to conclude that InsP<sub>3</sub> inhibits PLCγ1 activity. Due to the key role of PLCγ1 in cell motility, cytoskeleton remodelling and cell metastasis (Sala et al., 2008), it is tempting to speculate that InsP<sub>5</sub> may have anti-metastatic properties in vivo, since this compound is able to inhibit cell migration and invasion in vitro (Figure 5.1, 5.2, 5.4).

5.4 2-O-Bn-InsP<sub>5</sub> – a new synthetic compound based on InsP<sub>5</sub> structure

In the last years my lab has been focussed on finding alternative compounds based on InsP<sub>5</sub> structure, in collaboration with Professor Potter at the University of Bath. X-Ray crystallography data revealed that Akt PH domain possesses a tyrosine residue near the 6-OH of bound of Ins(1,3,4,5)P<sub>4</sub> that might interact with an aromatic group. Therefore InsP<sub>3</sub> analogues were designed not to alter the symmetry of the parental molecule. As described previously in the introduction chapter 1.8, 2-O-Bn-InsP<sub>3</sub> was more potent in inhibiting AKT phosphorylation and it was effective in cell lines resistant to InsP<sub>5</sub> treatment, indicating a more potent action of this synthetic InsP<sub>3</sub> derivative compared to its natural parental molecule.

Thus, I decided to test whether 2-O-Bn-InsP<sub>5</sub> was able to inhibit PLCγ1.
5.4.1 2-O-Bn-InsP₅ inhibits fibronectin-induced cell migration in MDA-MB-231

Data presented in chapter 5.1 shows that InsP₅ inhibits MDA-MB-231 fibronectin-induced migration. Based on this, I decided to investigate the effect of 2-O-Bn-InsP₅ on cell migration. Fibronectin-induced cell migration was measured in the same experimental conditions described in chapter 5.1. Cells were serum starved overnight and pre-treated with 2-O-Bn-InsP₅ (50μM) for 30 minutes before being plated on fibronectin-coated transwell inserts and allowed to migrate for 4 hours and then fixed in presence of the compound. Cells treated with vehicle alone were used as control. Data in Figure 5.8 shows that 2-O-Bn-InsP₅ completely blocked fibronectin-induced cell migration in MDA-MB-231 and that 2-O-Bn-InsP₅ has a more potent effect in inhibiting cell migration compared to the parental molecule (InsP₅) which inhibits fibronectin-induced migration by 60% (Figure 5.1).

Figure 5.8: 2-O-Bn-InsP₅ blocks fibronectin-induced migration: fibronectin-induced migration of MDA-MB-231 cells treated with 2-O-Bn-InsP₅ (50μM) compared to control cells treated with vehicle alone. Data are
5.4.2 2-O-Bn-InsP₅ inhibits cell migration in a dose-dependent manner

Considering that 2-O-Bn-InsP₅ show an inhibition of 90% in cell migration, I decided to test different concentrations of inhibitor on fibronectin-induced cell migration, to find the lower effective concentration. Experiments were performed using MDA-MB-231 treated with 2-O-Bn-InsP₅ at 5, 10, 25, 50 μM. Cells treated with vehicle alone were used as control. As shown in Figure 5.9, cells treated with 2-O-Bn-InsP₅ 10μM show already an inhibition of 80% compared to the control. These data demonstrate that 2-O-Bn-InsP₅ inhibit in a dose response manner and is already effective at the concentration of 10μM. Taken together these data showed that the synthetic InsP₅-derivative compound, 2-O-Bn-InsP₅, is more potent in inhibiting cell migration compared to the mother molecule.

Figure 5.9: 2-O-Bn-InsP₅ inhibits cell migration in a dose-dependent manner: MDA-MB-231 were pre-treated with 2-O-Bn-InsP₅ at different concentration (5, 10, 25, 50 μM). Control cells were pre-treated with H₂O as control. Data are means ±SEM of values obtained from 3 independent experiments.
5.4.3 2-O-Bn-InsP₅ inhibits cell invasion on Matrigel in different human and murine breast cancer cell lines

Data previously described showed that 2-O-Bn-InsP₅ inhibits fibronectin-induced cell migration in MDA-MB-231 more potently compared to InsP₅. Therefore I decided to investigate the effect of 2-O-Bn-InsP₅ on cancer cell invasion on Matrigel. Invasion assays were performed using MDA-MB-231, MDA-MB-435, TSA and 4T1 cell lines. The same experimental conditions described in chapter 5.2.3 and 5.2.4 were used. Briefly, cells were serum starved and pre-treated with 2-O-Bn-InsP₅ for 30 minutes before being seeded on Matrigel-coated transwell inserts and allowed to invade for 36 hours before being fixed. The compound was maintained for the duration of the invasion experiment. Cells treated with H₂O were used as control. Data in Figure 5.10 show that 2-O-Bn-InsP₅ strongly inhibits invasion on Matrigel in all the cell lines tested. In particular a 52.7%, 63.8%, 73.9%, 87.9% of inhibition was observed respectively in TSA, MDA-MB-435, MDA-MB-231 and 4T1. As indicated in Table 5.1, it is worth noticing that in each cell line 2-O-Bn-InsP₅ inhibited cell invasion on Matrigel more potently than InsP₅. Taken together these data suggested that 2-O-Bn-InsP₅ is able to inhibit cancer cell invasion even more efficiently than the parental molecule.

Table 5.1: Percentage of MDA-MB-231, MDA-MB-435, 4T1, TSA treated with InsP₅ 50μM or 2-O-Bn-InsP₅ 50μM that have invaded after 36 hours *p<0.05, **p<0.005. Matrigel invasion expressed as percentage of control cells that had invaded the Matrigel layer (average of 3 independent experiments).
Figure 5.10: 2-O-Bn-InsP₅ inhibits cell invasion on Matrigel: Cell invasion assay on Matrigel, expressed as percentage of cells that had invaded, assessed in the indicated cell lines treated with 2-O-Bn-InsP₅. Invasion was compared to control cells treated with H₂O. Data are means ±SEM of values obtained from 3 independent experiments. **p=0.005
5.4.4 2-O-Bn-InsP₅ does not affect cell proliferation and cell survival in MDA-MB-435, 4T1 and TSA cell lines.

As discussed before for InsP₅, the effect of 2-O-Bn-InsP₅ on cell invasion prompted us to evaluate a potential effect on cell proliferation and cell survival. Cell counting assay was performed on MDA-MB-231, MDA-MB-435, 4T1 and TSA after 72 hours of treatment with 2-O-Bn-InsP₅. Cells were treated with 2-O-Bn-InsP₅ in 10% serum supplemented media condition to measure changes in proliferation and in serum free condition to evaluate effects on cell survival. Cells treated with H₂O were used as control. Data in Figure 5.11A,B,E reveals that, similarly to InsP₅ treatment, 2-O-Bn-InsP₅ treatment had no effect on cell proliferation and cell survival in MDA-MB-231, MDA-MB-435 and TSA. Similarly, no change was observed in cell proliferation in 4T1 treated with 2-O-Bn-InsP₅ (Figure 5.11C). However, a decreased number of 4T1 cells was observed when treated in serum free condition (Figure 5.11D), indicating an effect on cell survival promoted by 2-O-Bn-InsP₅ treatment. Since the Matrigel cell invasion assay was performed in serum condition, I concluded that the effect seen upon 2-O-Bn-InsP₅ treatment on cell invasion was not due to effects on cell growth but to a decreased ability of the cells to invade.
Figure 5.11: Cell proliferation and cell survival upon 2-O-Bn-InsP₅ treatment: Cell counting performed on MDA-MB-231 (A), MDA-MB-435 (B), 4T1 (C,D) and TSA (E) treated with 2-O-Bn-InsP₅ (50µM) in 10% serum or serum free condition. Cell counting was performed after 72 hours (48 hours and 72 hours in 4T1). Data are mean ±SEM of three independent experiments.
5.4.5 2-O-Bn-InsP₅ inhibits calcium release response in MDA-MB-231 and MDA-MB-435 upon EGF stimulation.

To determine whether the effect of 2-O-Bn-InsP₅ on cell invasion is also due to inhibition of PLCγ₁, as for InsP₅, I decided to perform calcium release assay experiments on MDA-MB-231 and MDA-MB-435 treated with 2-O-Bn-InsP₅ and then stimulated with EGF. All experiments were performed following the same experimental conditions used to test the effect of InsP₅ described in chapter 5.2.6. Data in Figure 5.12 show that 2-O-Bn-InsP₅ completely inhibits the EGF-induced intracellular calcium variation in MDA-MB-231 (A) and MDA-MB-435 (B). These data indicate that 2-O-Bn-InsP₅ completely blocks PLCγ₁ activity upon EGF stimulation in both cell lines. Furthermore data indicates that the inhibitory effect of 2-O-Bn-InsP₅ is more potent compared to InsP₅ (Chapter 5.2.6).

![Figure 5.12: Calcium release assay](Figure legend next page)
Figure 5.12 Effects of 2-O-Bn-InsP₅ on intracellular calcium mobilisation. A) EGF-induced intracellular calcium mobilisation in MDA-MB-231 untreated (left) or treated with 50 μM 2-O-Bn-InsP₅ (right). Quantification of intracellular calcium increase (bottom). Columns are the mean of three independent experiments; Bars S.E *p=0.002  B) Calcium release assay in MDA-MB-435 untreated (left) or treated with 50 μM 2-O-Bn-InsP₅ (right). Quantification of intracellular calcium increase (bottom). Columns are the mean ±SEM of four independent experiments; *p=0.001.
5.4.6 2-O-Bn-InsP₅ inhibits PLCγ₁ tyrosine phosphorylation upon EGF stimulation

As discussed in chapter 1.3, different steps are involved in PLCγ₁ activation. The recruitment to the plasma membrane is essential for PLCγ₁ activation. Furthermore tyrosine phosphorylation of PLCγ₁ is essential for its enzymatic activation. Since 2-O-Bn-InsP₅ showed the highest inhibitory effects on cell motility, Matrigel cell invasion and EGF-induced PLCγ₁-mediated intracellular calcium release, I decided to focus on the mechanism through which 2-O-Bn-InsP₅ inhibits PLCγ₁ activity. Therefore I decided to investigate the potential effect of 2-O-Bn-InsP₅ treatment on PLCγ₁ tyrosine phosphorylation. In particular I decided to investigate the phosphorylation of the residue Y783 which is essential for PLCγ₁ enzymatic activity (Sekiya et al, 2004).

MDA-MB-231 cells were serum starved overnight and then pre-treated with 2-O-Bn-InsP₅ for 30 minutes. Cells were then stimulated with EGF for 3 and 10 minutes and lysed for protein extraction. MDA-MB-231 cells treated with H₂O were used as control. Western blot analysis was performed and phosphorylation of PLCγ₁ at Y783 residue was assessed using a specific antibody. Western blot analysis generated two bands corresponding to the phosphorylated form of PLCγ₁ as indicated by the manufacturer. GAPDH levels were measured in order to evaluate protein equal loading. A representative blot is shown in Figure 5.13. 2-O-Bn-InsP₅ strongly inhibits PLCγ₁ phosphorylation upon EGF stimulation compared to untreated cells. These data indicates that 2-O-Bn-InsP₅ can inhibit PLCγ₁ activation by blocking its tyrosine phosphorylation. Therefore the ability of 2-O-Bn-InsP₅ to inhibit PLCγ₁ phosphorylation provides a molecular mechanism for the reduced Matrigel invasion detected in cancer cell lines treated with 2-O-Bn-InsP₅, and possibly InsP₅, explaining the decreased activity of the enzyme observed by the intracellular calcium mobilization assay.
Figure 5.13: PLCγ1 phosphorylation is inhibited by 2-O-Bn-InsP₅ treatment: Western blot analysis of PLCγ1 phosphorylation at its residue Y783 in MDA-MB-231 untreated or pre-treated with 2-O-Bn-InsP₅ for 30 minutes before stimulation with 50 ng/ml EGF for 3 and 10 minutes. Blot representative of 4 independent experiments.

5.5 Discussion

As discussed in the introductory chapters increasing evidence showed that the inositol phosphates might compete with the binding of phosphoinositides to PH domains possessed by key proteins involved in cell proliferation, cell survival and motility such as AKT, preventing their activation. My laboratory has been focussed on developing inositol phosphates-based compounds and investigating their effects on the PI3K/AKT pathway. Data showed in chapter 3, together with data published in our recent report (Sala et al., 2008) demonstrate the pivotal role of PLCγ1 in cell migration and invasion and, more importantly, the requirement of PLCγ1 for metastases development and progression. In an effort to identify potential specific PLCγ1 inhibitors, I decided to investigate the effect on PLCγ1 activation of inositol phosphates treatment, hypothesising that they might compete with the PtdIns(3,4,5)P₃ for the binding of PLCγ1 PH domain, blocking the PI3K-dependent plasma membrane recruitment of PLCγ1 necessary for the activation of the enzyme.
This model was already demonstrated for AKT inhibition promoted by InsP₅ (Piccolo et al., 2004; Maffucci et al., 2005). I therefore investigated the effect of InsP₅ treatment on cell migration in MDA-MB-231 and cell invasion in a broader number of breast cancer cell lines (MDA-MB-231, MDA-MB-435, TSA, 4T1). Data showed a significant inhibition of cell invasion on Matrigel in all the cancer cell lines analysed (Figure 5.1, 5.2, 5.4). Noteworthy no difference in cell proliferation or cell survival (except 4T1 cell line) was observed in cells treated with InsP₅, excluding therefore the possibility that the effect on cell migration and invasion was due to decreased cell viability (Figure 5.3, 5.5).

It has to be noted that InsP₅ induced apoptosis mostly in cell lines with high level of AKT activation while it had low or no effect in cell lines with normal level of activation of PI3K/AKT pathway (Piccolo et al., 2004). MDA-MB-231 for example shows low level of AKT activation and treatment with InsP₅ has no effect on cell proliferation and survival. On the contrary SKOV3 possesses elevated levels of AKT activation and treatment with Ins(1,3,4,5,6)P₅ affects cell proliferation and cell survival (Piccolo et al., 2004). To investigate the potential inhibition of PLCγ1 by InsP₅ treatment, I performed calcium mobilisation assays upon EGF stimulation in MDA-MB-231 and MDA-MB-435. EGF-induced calcium mobilisation was inhibited in cells upon treatment with InsP₅ compared to untreated cells (Figure 5.6, 5.7). No difference in ATP-induced calcium mobilisation was observed upon InsP₅ treatment compared to the control. Since the EGF-induced calcium migration in MDA-MB-231 is completely dependent on PLCγ1 (Figure 4.1, 4.2), these data strongly suggested that InsP₅ inhibits PLCγ1 activation directly or indirectly.

The effect of InsP₅ treatment on cell migration and invasion prompted my group, in collaboration with Professor Potter (University of Bath) to develop novel molecules based on InsP₅ structure in the effort to improve its potency and specificity. The derivative 2-O-Bn-InsP₅ showed enhanced inhibitory properties towards AKT. Invasion assay on Matrigel showed that 2-O-Bn-InsP₅ was more efficient in inhibiting invasion compared to InsP₅ (Figure 5.8,
Intracellular calcium mobilisation showed that 2-O-Bn-InsP$_5$ completely blocked intracellular calcium release, indicating that this InsP$_5$ derivative was a more potent inhibitor towards PLC$\gamma_1$ compared to the parental molecule (Figure 5.12). Since PLC$\gamma_1$ phosphorylation status is essential for PLC$\gamma_1$ activity, I investigated whether 2-O-Bn-InsP$_5$ was able to inhibit the phosphorylation status of PLC$\gamma_1$. Analysis of EGF-induced tyrosine phosphorylation of PLC$\gamma_1$ showed that 2-O-Bn-InsP$_5$ inhibited PLC$\gamma_1$ phosphorylation at its residue Y783, which strictly correlates with the enzymatic activity (Figure 5.13). Taken together these data demonstrated that the inhibitor prevents PLC$\gamma_1$ phosphorylation and the following activation of PLC$\gamma_1$. However the mechanism by which 2-O-Bn-InsP$_5$ and InsP$_5$ inhibit PLC$\gamma_1$ is not well understood and different hypotheses must be further investigated. For example it cannot be excluded that the inhibitors compete with EGF binding to the EGFR, resulting in an inhibition of the downstream pathway.

In an effort to determine specificity and targets of these two compounds, an *in vitro* kinase screening was performed on InsP$_5$ and 2-O-Bn-InsP$_5$ (Falasca et al., 2010). The screening was performed by Select Screen™ Kinase Profiling Service supplied by Invitrogen. InsP$_5$ and 2-O-Bn-InsP$_5$ were tested *in vitro* on over 60 different kinases in order to assess their specificity and their inhibitory activity. 2-O-Bn-InsP$_5$ inhibits PDK1 activity with an IC$_{50}$ of 26.5 nM towards PDK1. Both compounds showed no effect on AKT1 and AKT2 kinase activity. These results suggested a potential link between PDK1 and PLC$\gamma_1$ in a mechanism that could involve PDK1 in PLC$\gamma_1$ phosphorylation directly or indirectly. However since PDK1 is a serine/threonine kinase, a direct involvement is unlikely. A recent report showed that PDK1 is involved in ROCK1 regulation in a kinase-independent mechanism which involves the direct interaction of PDK1 with ROCK1 at the plasma membrane (Sahai et al., 2008) promoting ROCK1 activity. Therefore a similar mechanism might be involved in PLC$\gamma_1$ regulation. This hypothesis was the basis for the experiments described in chapter 7.
Summary

Ins(1,3,4,5,6)P$_5$ and 2-0-Bn-InsP$_5$ show inhibiting PLC$\gamma$1 activity. This was assessed by calcium release assay and inositol phosphates incorporation in MDA-MB-231. Moreover 2-0-Bn-InsP$_5$ inhibits PLC$\gamma$1 Y783 phosphorylation. Both compounds, but more 2-0-Bn-InsP$_5$, inhibit cell migration and cancer cell invasion.
Chapter 6
Potential involvement of ABC transporters on inositol polyphosphates transmembrane transport
6.1 InsP$_5$ internalisation

My data so far demonstrated that 2-O-Bn-InsP$_5$ is able to inhibit PLC$_{\gamma1}$ phosphorylation at residue Y783 and to inhibit its enzymatic activity. Furthermore InsP$_5$ and 2-O-Bn-InsP$_5$ block cell migration and invasion in the panel of breast cancer cell lines tested, indicating that they may have anti-metastatic properties in vivo. The mechanism by which inositol polyphosphates are transported across the membrane has not been characterised. It has to be noticed that Ins(1,3,4,5,6)P$_5$ possesses five phosphates groups that confer a high negative charge to the compound. Therefore it is unlikely that Ins(1,3,4,5,6)P$_5$ can be transported by passive diffusion across the plasma membrane. It has been demonstrated that Ins(1,3,4,5)P$_4$ and Ins(1,3,4,5,6)P$_5$ are internalized by cancer cells (Razzini et al., 2000; Maffucci et al., 2005), and preliminary data produced by my group shows that inositol polyphosphates uptake is inhibited at 4°C suggesting an active transport mechanism. In order to investigate inositol polyphosphates uptake I used the 2-fluorescein-conjugated-InsP$_5$ (2-FAM-InsP$_5$) which was synthetized by our collaborator Professor Potter at the University of Bath. The fluorescein-conjugated compound gave the opportunity to follow its incorporation over time and visualise the dynamic of its incorporation inside the cells.

6.1.1 Time-course of InsP$_5$ uptake

MDA-MB-231 were seeded on coverslips and incubated with 25 μM FAM-InsP$_5$ prepared in DMEM supplemented with 10% serum for the indicated time points. As controls MDA-MB-231 were incubated with 25μM fluorescein for the indicated time and then fixed. Fluorescence intensity was measured using confocal microscopy. Figure 6.1A shows that 2-FAM-InsP$_5$ entered the cells and it was already detectable intracellularly after 5 minutes. In contrast, control cells treated with fluorescein did not show intracellular fluorescence at any of the indicated time-points (Figure 6.1B). These results indicate that InsP$_5$ is able to enter MDA-MB-231 cells, despite its polar nature, as already demonstrated for the ovarian cancer cell line SKOV-3 and for the Small Cell Lung Cancer cell line (Maffucci et al., 2005; Razzini et al., 2000).
Figure 6.1 Incorporation of 2-FAM-InsP₅ A) MDA-MB-231 were seeded on coverslips in a 12-well plate and incubated with 2-FAM-InsP₅ (25 μM) for the indicated times before being fixed. B) MDA-MB-231 cells were incubated with 25 μM florescein as appropriate control for the 2-FAM-InsP₅ uptake.
6.1.2 Probenecid and Glibenclamide inhibit 2-FAM-InsP₅ uptake

In 2009 Nagy et al. identified in Arabidopsis a membrane transporter belonging to the ATP-binding-cassette (ABC) transporter, involved in the inositol hexakisphosphates transport. The ABC transporters are involved in the trafficking of many substances and several lines of evidence established their role in cancer drug resistance. Indeed the multidrug resistance in tumour is associated with overexpression of certain ABC transporters which, for this reason, are called Multidrug Resistance (MDR) protein or Multidrug Resistance Proteins (MRP) (Glavinas et al., 2004). In particular ABCC1/MRP1, ABCB1/MDR1 and ABCG2 are the transporters mainly involved in the drug resistance process. It has been recently reported that that inositol hexakisphosphate is actively exported from the cytoplasm to the vacuole by the ABCC5 transporter (Nagy et al., 2009). In order to assess the possibility that ABC transporters may also be involved in inositol polyphosphates uptake in mammalian cells, I decided to test the effect of probenecid and glibenclamide, which are two inhibitors of ABC transporters, on inositol phosphates uptake. MDA-MB-231 cells were treated with the inhibitors in a dose dependent manner in order to find highest non-toxic concentration (table 6.1). Treatment with probenecid 5mM and 10mM and glibenclamide 600 μM and 1.5mM were toxic, resulting in cell death within one hour from the beginning of the treatment. Therefore hereafter the first effective non-toxic concentration was used for all the experiments. In particular cells were treated with probenecid 1mM and glibenclamide 150μM. MDA-MB-231 were pre-treated for 1 hour with probenecid and glibenclamide and then incubated with 2-FAM-InsP₅ for the indicated times in presence of the inhibitors before being fixed and fluorescence analysed by confocal microscopy. Figure 6.2 shows that treatment of MDA-MB-231 with both inhibitors reduced 2-FAM-InsP₅ intake for 5 and 10 minutes. This data indicated that transporters belonging to the ABC family could be involved in the uptake of InsP₅ in mammalian cells similarly to what was reported in Arabidopsis.
Table 6.1:

<table>
<thead>
<tr>
<th>Concentration Tested</th>
<th>Probenecid</th>
<th>500μM</th>
<th>1mM</th>
<th>3mM</th>
<th>5mM</th>
<th>10mM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glibenclamide</td>
<td>75μM</td>
<td>150μM</td>
<td>450μM</td>
<td>600μM</td>
<td>1.5mM</td>
<td></td>
</tr>
</tbody>
</table>

Figure 6.2: Time course of 2-FAM-InsP₅ uptake in untreated cells and in MDA-MB-231 treated with probenecid and glibenclamide. On the right a representative bright-field picture of untreated and treated cells is presented.
6.1.3 ABCC1 transporter is involved in 2-FAM-InsP₅ uptake

The ABC transporters are a family of trans-membrane transporters involved in export of different substances. Mice deficient in ABCG2, ABCB1 or ABCC1 are viable and fertile but are more sensitive to cytotoxic drugs, consistent with the role of ABC transporters in protecting cells from toxins (Wijnholds et al., 1998; Dean et al., 2005). At present no evidence shows that in mammalian cells ABC transporters are involved in the import process, but they have been characterised for their main role in drug export and multidrug resistance. The finding that ABC inhibition by probenecid and glibenclamide is able to block the uptake of 2-FAM-InsP₅ (Figure 6.2) showed that this class of transporter may be involved also in the import process of InsP₅, supporting the hypothesis that ABC transporter may be involved in the import of certain substances rather than export alone.

In order to further investigate the role of ABC transporters in inositol polyphosphates intake, I decided to investigate the role of the ABCC family members. In particular ABCC1 has been found upregulated in a variety of solid tumour such as lung, breast and prostate and it constitutes a negative prognostic marker for early stage breast cancer (Kartenbeck et al., 1996; Rudas et al., 2003).

The first approach was to use the ABCC1 specific inhibitor MK-571. MDA-MB1-231 cells were pre-treated with 40 μM MK-571 for 1 hour before being incubated with 2-FAM-InsP₅ for the indicated minutes. Figure 6.3A shows images of a representative experiment of four experiments. Decreased fluorescence was observed at 10, 15 and 30 minutes of 2-FAM-InsP₅ incorporation in cells treated with MK-571 compared to untreated cells, indicating that ABCC1 transported is involved in FAM-InsP₅ uptake. However it is worth noticing that cells treated with MK-571 inhibitor were able to uptake 2-FAM-InsP₅, although with a slower kinetic, indicating that ABCC1 is not the only transporter involved in the 2-FAM-InsP₅ intake (Figure 6.3B).
A

Untreated (minutes of 2-FAM-InsP₃)

0 5

0 5

10 15

10 15

30

MK-571 (minutes of 2-FAM-InsP₃)

0 5

0 5

10 15

10 15

30

Figure legend next page
**Figure 6.3: 2-FAM-InsP<sub>5</sub> is inhibited by MK-571:** A) Images of MDA-MB-231 untreated or pre-treated with 40 µM MK-571 and incubated with 2-FAM-InsP<sub>5</sub> at indicated time points. B) Quantification of 4 independent experiments. Graphs are means values ±S.E; *P<0.05

**6.1.4 ABCC1 is potentially involved in <sup>3</sup>H-InsP<sub>5</sub> uptake.**

In order to validate the data obtained using 2-FAM-InsP<sub>5</sub> uptake, incorporation experiments of <sup>3</sup>H-labelled InsP<sub>5</sub> were performed. MDA-MB-231 were seeded on a 12 well plate and left untreated or pre-treated with 40 µM MK-571 for 1 hour and then incubated with 50µM of “cold” InsP<sub>5</sub> supplemented with <sup>3</sup>H-InsP<sub>5</sub> (4,000 cpm/well) provided by our collaborator (Adolfo Saiardi, UCL). The amount of incorporated radioactivity was determined by liquid scintillation counting. The uptake of <sup>3</sup>H-InsP<sub>5</sub> was significantly decreased in cells pre-treated with the ABCC1 inhibitor compared to control cells (Figure 6.4). These data confirmed the results
obtained following the incorporation of the 2-FAM-InsP₃ and suggest that ABCC1 transporter is involved in the InsP₃ uptake.

Figure 6.4: \(^3\)H-InsP₃ incorporation is inhibited by MK-571: \(^3\)H-InsP₃ incorporation in MDA-MB-231 untreated (blue line) or treated with the ABCC1 inhibitor MK-571 (red line). Graphs are the mean of 3 independent experiments; bars S.E.M; *P<0.05
6.1.5 Downregulation of ABCC1, but not ABCC5, inhibits InsP$_5$ uptake in MDA-MB-231

In order to further investigate the role of ABCC1 in InsP$_5$ transport, I decided to determine the effect of ABCC1 downregulation using specific siRNA in MDA-MB-231. The effect of ABCC5 downregulation (another member of the ABCC family) on 2-FAM-InsP$_5$ and $^3$H-InsP$_5$ uptake was also investigated in order to assess the potential involvement of other family members in the uptake process.

MDA-MB-231 cells were transfected with siRNAs targeting ABCC1 or ABCC5 respectively. As controls, MDA-MB-231 transfected with a scrambled sequence were used. After 72 hours from transfection, cells were incubated with 2-FAM-InsP$_5$ for the indicated times before being fixed. Intracellular cell fluorescence was analysed in three independent experiments. Decreased fluorescence was observed in MDA-MB-231 transfected with siRNA targeting ABCC1 compared to cells transfected with scrambled siRNA. In particular a decrease of 50% was observed after 10 minutes of 2-FAM-InsP$_5$ incorporation. Representative images are showed in Figure 6.5A,B. MDA-MB-231 transfected with siRNA targeting ABCC5 transporter expression showed no difference in 2-FAM-InsP$_5$ incorporation compared to control (Figure 6.5C). These data suggest that ABCC1 is required for inositol pentakisphosphate transport and that its downregulation significantly decreases uptake of extracellular inositol pentakisphosphate (Figure 6.5D). Furthermore data suggest that ABCC1 may have a specific role in inositol pentakisphosphate active transport, since siRNA for ABCC5 does not affect its cellular intake.
Figure legend next page
Figure 6.5: Effect of siRNAs targeting ABCC1 or ABCC5 on 2-FAM-InsP$_3$ uptake: Representative images of MDA-MB-231 transfected respectively with
scrambled siRNA (A), siRNA targeting ABCC1 (B) or siRNA targeting ABCC5 (C) incubated with 2-FAM-InsP₃ for 1, 5 and 10 minutes. Statistical analysis (D) was performed measuring fluorescence of 30 cells per sample for each time point. Plots are the mean of three independent experiments; bars S.E.M.; *p<0.05

6.1.6 Downregulation of ABCC1 expression inhibits ³H-InsP₃ uptake

I then analysed the effect of ABCC1 downregulation on ³H-InsP₃ incorporation in MDA-MB-231. Incorporation of ³H-InsP₃ was assessed in parallel in MDA-MB-231 transfected with siRNA targeting the ABCC5 transporter. MDA-MB-231 transfected with a scrambled siRNA sequence were used as control. MDA-MB-231 were incubated for 1 hour with 50 μM “cold” InsP₃ and ³H-InsP₃ (5000cpm/μl), then lysed and analysed by liquid scintillation counting. Cells downregulated for ABCC1 showed a significant decrease in ³H-InsP₃ incorporation compared to scrambled cells. On the contrary ABCC5 knock down did not show any effect on the uptake process (Figure 6.6). These data confirmed the observation obtained by confocal fluorescence analysis suggesting the specific role of ABCC1 in InsP₃ uptake.

![Bar graph showing ³H-InsP₃ incorporation in scrambled, ABCC1, and ABCC5 siRNA treated cells.](image)

Figure legend next page
Figure 6.6: Effect of siRNAs targeting ABCC1 or ABCC5 on $^{3}$H-InsP₅ uptake

$^{3}$H-InsP₅ incorporation analysis in MDA-MB-231 transfected with scrambled siRNA, ABCC1 siRNA or ABCC5 siRNA and incubated with $^{3}$H-InsP₅ for 1 hour. Columns represent the mean average incorporation of 4 independent experiments, expressed as percentage of $^{3}$H-InsP₅ incorporation of scrambled cell lines; bars S.E.M; *p<0.05

6.1.7 Downregulation of ABCC1 and ABCC5 protein levels in MDA-MB-231

Downregulation of ABCC1 and ABCC5 in MDA-MB-231 levels was checked by Real-Time PCR after 72 hours from transfection. A scrambled non-targeting sequence was used as control. Figure 6.7 shows more than 80% decrease of ABCC1 and ABCC5 mRNA levels in cells transfected with the respective siRNA when compared with expression of control scrambled cells. Furthermore, no decrease in ABCC5 mRNA levels was detected in cells transfected with siRNA targeting ABCC1 and vice versa, indicating that the sequences used are specific for each transporter and are able to downregulate them with high efficiency.

Figure 6.7: Quantification of ABCC1 and ABCC5 expression: RT-PCR analysis of ABCC1 and ABCC5 mRNA levels in cells transfected with siRNA for ABCC1 and ABCC5 and control scrambled siRNA. Relative gene expression was
calculated using scrambled samples as calibrators and actin as a housekeeping gene. Columns are the mean ±SEM of three independent experiments

6.2 Discussion

Data presented in this chapter aimed to investigate the potential role of ABC transporters belonging to the ABCC family in inositol phosphate active transport in mammalian cells. My group showed that cancer cells uptake inositol polyphosphates (Razzini et al., 2000). Furthermore preliminary data show that inositol polyphosphates uptake is inhibited by incubating the cells at 4°C. However it is currently unknown which transporters are involved in this process. Although ABC transporters in mammals are involved in drug export and their overexpression confers drug resistance to cancer cells, it has been shown that ABCC family members are involved in the vacuole export of inositol pentakisphosphate (Nagy et al., 2009) in Arabidopsis. Furthermore evidence suggests that ABC transporters are involved in the import of anion abscisic acid into cells in plantae. Another report suggests the involvement of ABC transporters in the import of auxin (Terasaka K., et al., 2005). In principle there is no evidence suggesting that ABC transporters should not be involved in import/export process rather then export alone. Starting from this evidence, I decided to investigate the role of ABC transporters in inositol pentakisphosphates in cancer cells. Treatment of MDA-MB-231 with two generic ABC transporter inhibitors (probenecid and glibenclamide) inhibited 2-FAM-InsP₅ incorporation, indicating that ABC transporters may be involved in Ins(1,3,4,5,6)P₅ uptake (Figure 6.2). In particular treatment with MK-571, a specific inhibitor of ABCC1, inhibited uptake of 2-FAM-InsP₅ and of ³H-InsP₅ (Figure 6.3, 6.4). Similar results were obtained using siRNA targeting ABCC1 (Figure 6.5). It has to be noted that neither MK-571 treatment nor downregulation of ABCC1 completely inhibited InsP₅ uptake indicating that ABCC1 is not the only ABC transporter involved in this process. However downregulation of ABCC5 had no effect on InsP₅ uptake indicating that the inhibition observed upon ABCC1 inhibition may be specific and not all the ABCC family members are involved in this process. Although a more complete screening is required to assess the role of the ABC
family members in inositol phosphates uptake, my data indicate for the first time that in mammalian cells ABC transporters may be involved in inositol phosphate uptake and therefore suggest a potential involvement of ABC transporters also in cellular import. These data may also have important relevance in cancer therapy. Indeed ABC transporters have been found overexpressed in several cancers including pancreatic cancer (Konig et al., 2005; Hagmann et al., 2009). This family of proteins has an established role in chemoresistance or multidrug resistance. Work in my laboratory has recently unravelled a novel involvement of these proteins in cancer progression. Indeed it has been reported that ABCC1 transporter is involved in an autocrine loop by which cancer cells can stimulate their proliferation (Pineiro et al., 2010). In particular the phospholipid lysophosphatidylinositol (LPI) is synthesized by cancer cells, through the action of the enzyme phospholipase A2 (PLA$_2$), and exported by ABCC1. Once released, LPI can bind its receptor GPR55 (G-protein coupled receptor 55) and activate signalling pathways involved in cell proliferation (Pineiro et al., 2010). Inhibition of this ABC transporter-mediated autocrine loop can represent a novel strategy to block cancer cell proliferation. Indeed, blockage of activation of GPR55 or activity of the LPI transporter ABCC1 inhibits survival and proliferation of prostate and ovarian cancer cell lines. However, according to the data shown in this chapter, the overexpression of ABCC1 might increase the intracellular uptake of exogenous inositol phosphates such as InsP$_5$ or potential synthetic derivatives, resulting in increased sensitivity and cell death.

Summary

Data shown in this chapter indicates for the first time a potential involvement of ABC transporters and in particular of ABCC1 transporter in inositol phosphate uptake in mammalian cells. Taken together this data show a potential novel role for ABCC transporters in active cellular import and suggest a novel way of thinking ABC transporters, not only as transporter involved in drug resistance or autocrine loop but also as potentially marker to identify tumour responsiveness to specific anti-cancer treatment, such as inositol phosphates.
Chapter 7

PDK1-dependent PLCγ1 activation
7.1 Transient downregulation of PDK1 in MDA-MB-231, MDA-MB-435 and A375M

Results described in chapter 5.4.5 and 5.4.6 showed that 2-O-Bn-InsP₃ treatment is able to block PLCγ1 activity (Figure 5.13) and that it inhibits PLCγ1 phosphorylation at the residue Y783. Furthermore kinase profile assays provided in vitro evidence that 2-O-Bn-InsP₃ specifically inhibits PDK1. These data suggested that PDK1 might have a novel role on PLCγ1 regulation and activation. In order to investigate this hypothesis I decided to investigate the potential effect of PDK1 downregulation on PLCγ1 activity.

7.1.1 PDK1 protein downregulation in MDA-MB-231, MDA-MB-435 and A375M

Transient downregulation of PDK1 was achieved using specific siRNA targeting PDK1. MDA-MB-231, MDA-MB-435 cells were transfected with Oligofectamine transfecting agent, while A375M were transfected using Hypercent transfecting agent. In order to test the efficiency of PDK1 silencing, MDA-MB-231 lysates obtained after 48 hours and 72 hours from transfection were analysed by western blot analysis using a specific PDK1 antibody (Figure 7.1A). Efficiency of downregulation in A375M and MDA-MB-435 was assessed after 72 hours from transfection. Cells transfected with non-targeting siRNA were used as control. Western Blots in Figure 7.1B,C showed a reduced PDK1 expression after 48 hours compared to scrambled cells in MDA-MB-435 and A375M. PDK1 protein expression was downregulated after 72 hours from transfection in all the three cell lines, indicating that 72 hours are required for the efficient downregulation of this enzyme in all the three cell lines investigated.
Figure 7.1: Transient downregulation of PDK1: Expression levels of PDK1 after 48 and 72 hours from transfection with specific siRNA targeting PDK1 in MDA-MB-231 and after 72 hours in A375M and MDA-MB-435 cells.
7.1.2 Transient downregulation of PDK1 protein expression inhibits calcium release upon EGF stimulation

The observation that 2-O-Bn-InsP$_3$ inhibits PLC$_{\gamma}1$ activity (as assessed by EGF-induced calcium release) and that kinase profiling analysis revealed that 2-O-Bn-InsP$_3$ is a specific PDK1 inhibitor, prompted me to investigate whether PDK1 had a role in PLC$_{\gamma}1$ activation. Therefore I decided to determine the effect of PDK1 downregulation on PLC$_{\gamma}1$ activity in MDA-MB-231 and A375M using the intracellular calcium measurement assay upon EGF stimulation. As indicated in chapter 7.1, the most efficient downregulation was obtained after 72 hours of transfection with the specific siRNAs. Therefore the calcium measurement was performed after 72 hours from transfection. MDA-MB-231 and A375M siPDK1 were serum-starved overnight and loaded with Fluo-4-AM before analysis of calcium mobilisation induced by EGF stimulation. MDA-MB-231 and A375M transfected with a scrambled sequence were used as controls. The chart shown in Figure 7.2 indicates that EGF stimulation induced a fast response in MDA-MB-231 and A375M scrambled cells, leading to the peaks in the calcium pattern. Cell viability was assessed adding ATP to the cells towards the end of the assay, which generated peak at the end of the chart. Strikingly, EGF-induced calcium mobilisation was completely abrogated in MDA-MB-231 and A375M transfected with siRNA targeting PDK1. ATP-induced calcium mobilisation was comparable in cells transfected with scrambled or PDK1 specific siRNA, indicating no significant difference in cell viability. These data revealed for the first time a role of PDK1 in PLC$_{\gamma}1$ activation.
Figure 7.2 PDK1 downregulation inhibits EGF-induced calcium release: Calcium release assay performed on MDA-MB-231 and A375M transfected with siRNA specific for PDK1 or with a non-targeting sequence. Arrows indicate the time point of EGF and ATP stimulation. The chart is the mean of 4 independent experiments.
7.1.3 *Matrigel cell invasion is inhibited in Breast cancer and Melanoma cell lines upon PDK1 downregulation.*

As described in the introductory chapter 1.7, PDK1 is a key enzyme involved in promoting cell invasion. Calcium measurement showed that siRNA for PDK1 inhibits PLCγ1 activity as assessed by intracellular calcium mobilisation upon EGF stimulation in MDA-MB-231. Since both enzymes play an important role in cell invasion, I decided to investigate the effects of PDK1 downregulation on cell invasion on Matrigel using different invasive cancer cell types. MDA-MB-231, MDA-MB-435 and A375M were transfected with scrambled siRNA and siRNA for PDK1 and 72 hours after transfection cells were plated on Matrigel pre-coated transwells and allowed to invade for 36 hours. An aliquot of cells was seeded in parallel on 6-well plates to perform western blot analysis at the end of the invasion assay. Cells transfected with a scrambled siRNA sequence were used as control. Cell invasion on Matrigel was inhibited in all three cell lines upon downregulation of PDK1 compared to their respective control. In particular invasion was inhibited by 50% and 52% in MDA-MB-231 and MDA-MB-435 upon PDK1 knock down respectively compared to MDA-MB-231 and MDA-MB-435 scrambled cells (Figure 7.3). A375M showed the highest inhibition with a decrease in cell invasion of 70% compared to scrambled cells, indicating that PDK1 plays an important role in Matrigel cell invasion in several cancer types, and the inhibition is independent of the cell type used (Figure 7.3). These data showed that PDK1 is an essential enzyme for promoting cancer cell invasion, consistent with data in the literature (Primo et al., 2007; Pinner and Sahai, 2008; Finlay et al., 2009).
Figure 7.3 Cell invasion on Matrigel of MDA-MB-231, MDA-MB-435 and A375M downregulated for PDK1 expression: Invasion assay was performed after 72 hours from siRNA transfection and lasted 36 hours. Columns are mean of three independent experiments. Bars S.E; *p<0.05; **p<0.001

7.2 Generation of MDA-MB-231 stably downregulated for PDK1 expression

In order to further investigate the effect of PDK1 protein downregulation on PLCγ1 activation, I decided to generate stable MDA-MB-231 downregulated for PDK1. The rationale for this decision was the limitation of the transient transfection using siRNAs. Transient transfection interfering efficiency is variable among the different experiments. Furthermore transient interfering does not provide a homogenous population of cell downregulated for the targeted protein. In order to overcome these limitations I generated MDA-MB-231 cells expressing shRNA targeting PDK1 using specific targeting sequences cloned in the vector pSUPERIOR.retro.puro. Cells expressing the
construct were selected. This method allowed the selection of a more homogeneous population of cells downregulated for PDK1 expression.

The pSUPERIOR vector was used in concert with a pair of custom oligonucleotides that contained a unique 22-nt sequence derived from the mRNA transcript of PDK1 in order to induce gene suppression. The target sequence corresponds to the sense strand of the pSUPERIOR-generated siRNA, which corresponds to the complementary sequence within the mRNA. The forward and reverse oligonucleotides were annealed and cloned into the vector, between the unique BglII and HindIII enzyme sites. This strategy positions the forward oligonucleotides at the correct position downstream from the H1 promoter’s TATA box to generate the desired siRNA duplex.

7.2.1 Design of 22-nucleotide targeting sequence cloned in pSUPERIOR.retro.puro vector

The sequence of the targeting oligonucleotides includes the unique 22-nucleotide targeting sequence in both sense and antisense orientation, separated by a 9-nt spacer sequence. The 5’ end corresponds to the BglII site, while the 3’ end contains the HindIII corresponding nucleotides. The resulting transcript of the recombinant vector is predicted to fold back on itself to form a 22-base pair stem-loop structure.

The 22-nucleotide targeting sequence was designed based on the sequence published by Sahai et al, 2008 used for siRNA (Figure 7.4). The sequence was modified in the last nucleotide in order to remove the fifth T that would be otherwise recognized as a stop by RNA polymerase III aborting the transcription of the shRNA. A 5 point mutated sequence was generated and cloned in the pSUPERIOR.retro.puro vector as closest control. The 5’ end presents the BglII restriction site, while the 3’ end contains the HindIII corresponding nucleotides (Figure 7.4).
In order to insert the custom-designed oligonucleotides in the pSUPERIOR.retro.puro vector, I performed serial digestions of the pSUPERIOR.retro.puro vector with Hind III and BglII restriction enzymes. The serial digestions were performed separately in order to be certain of the restriction activity of each enzyme. After each digestion, plasmids were loaded on 1% agarose gel and analysed by electrophoresis.

The vector was first digested with Hind III overnight. Figure 7.5 shows the uncut plasmid on the left and the vector upon overnight digestion on the right.
Figure 7.5: pSUPERIOR.retro.puro not digested and digested with HindIII restriction enzyme.

The digested vector was purified and digested a second time with restriction enzyme BglII, in order to create complementary extremities for the insertion of the annealed custom oligonucleotides. As a control the parental uncut vector was digested with BglII alone in order to verify the activity of the restriction enzyme. Figure 7.6 shows that the vector was successfully double digested with HindIII and BglII as indicated by the second band at 1kb in the third lane on the right at 6.3kb and at 1Kb.

Figure 7.6: Digestion of the previously HindIII-digested pSUPERIOR.retro.puro using the restriction enzyme BglII (right lane). BglII activity was tested on uncut vector (middle lane).
7.2.2 Colony-PCR screening

In order to insert the 5Mut and the shPDK1 oligonucleotides in the vector, ligase reaction was performed overnight. Competent Top10™ bacterial cells (Invitrogen, UK) were transformed with the plasmids upon ligation. 20 Positive bacterial colonies for the 5MUT and 20 positive bacterial colonies for shPDK1 were picked up and screened by PCR. Primers provided by the manufacturer for PCR screening of positive colonies were used in order to screen the effective integration of the customer oligos in the double-cut plasmids. Positive colonies were predicted to give an amplification product of 482 bp. Figure 7.7 shows the amplification product of the 40 different colonies. Among the different positive colonies I choose the colonies listed in table 7.1 to proceed for plasmid purification and cell transfection.

![Colony PCR screening](image)

**Figure 7.7 Colony PCR screening**: Screening of positive colonies shows an amplicon at the predicted size of 483bp.
Table 7.1: List of colonies chosen for plasmid purification and following transfection for generation of cells stably downregulated for PDK1 and respective control.

<table>
<thead>
<tr>
<th>Colony number</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>5MUT</td>
</tr>
<tr>
<td>8</td>
<td>5MUT</td>
</tr>
<tr>
<td>25</td>
<td>shPDK1</td>
</tr>
<tr>
<td>26</td>
<td>shPDK1</td>
</tr>
<tr>
<td>27</td>
<td>shPDK1</td>
</tr>
<tr>
<td>39</td>
<td>shPDK1</td>
</tr>
<tr>
<td>40</td>
<td>shPDK1</td>
</tr>
</tbody>
</table>

7.2.3 Clones selection

MDA-MB-231 cells were transfected with plasmid constructs listed in table 7.1 and plated in selection media containing 1µg/ml puromycin after 48 hours after transfection. Five days later two clones from each transfection were picked up and plated in separate plate dishes and allowed to grow. Protein lysates obtained from the different clones were analysed for PDK1 protein expression levels by western blot using a specific PDK1 antibody. Only two clones (construct 39, clone number 1 and construct 39, clone number 2) showed a clear reduction in PDK1 expression, and will be referred to as shPDK1 Clone 1 and Clone 2. Construct 2 clone 1 and construct 8 clone 1 were chosen as scrambled and maintained in culture and will be referred to as 5MUT clone 1 and clone 2 (Figure 7.8A). Figure 7.8B shows a further western blot analysis of MDA-MB-231 5MUT clones and MDA shPDK1 clones after different passages in culture.
Figure 7.8: Stable downregulation of PDK1. A) Western blot analysis of PDK1 levels on the different clones at passage 1. B) Representative Western blot analysis of PDK1 after two cell passages in culture.
7.3 Effect of PDK1 protein downregulation on Inositol phosphates production

Intracellular calcium analysis experiments showed that transient protein downregulation of PDK1 using siRNA interfering inhibits intracellular calcium mobilisation upon EGF stimulation in MDA-MB-231 (chapter 7.1.2). In order to validate these results, I decided to investigate the inositol phosphate production in MDA-MB-231 shPDK1 “MDA-MB-231 shPDK1”. MDA-MB-231 5MUT cells were used as control for the experiments. Experiments were performed using the two clones previously selected in order to avoid any clone-specific effect in the analysis.

Cells were labelled with a $^3$H-myo-inositol for 24 hours in inositol free, serum free media and then stimulated with EGF at different time points. Cells were lysed, and total inositol phosphates were separated by anion exchange chromatography and the total amount assessed by liquid radioactivity counting. Accumulation of inositol phosphates was inhibited in both clones MDA-MB-231 shPDK1 compared to MDA-MB-231 5MUT (Figure 7.9A). This data were consistent with results obtained in the calcium mobilization assay and identify PDK1 as a new key protein in regulating PLCγ1 activity.
Figure 7.9: Inositol phosphates levels in MDA-MB-231 stably downregulated for PDK1: Inositol phosphates accumulation in MDA-MB-231 5MUT and shPDK1 previously incubated in $^3$H-myoinositol for 24 hours in inositol free, serum free media and then stimulated with 50ng/ml EGF for the indicated times before being lysed and analysed by liquid radioactivity counting. Data are means ± SEM of 4 independent experiments.; *p<0.05
7.4 The PDK1-dependent PLC\(\gamma\)1 regulation

7.4.1 Analysis of PLC\(\gamma\)1 protein level in MDA-MB-231 downregulated for PDK1

In order to understand the mechanism of PDK1-dependent regulation of PLC\(\gamma\)1 activity, I first determined whether downregulation of PDK1 affected PLC\(\gamma\)1 protein expression in MDA-MB-231. This experiment aimed to investigate any potential effect of the absence of PDK1 on PLC\(\gamma\)1 protein level due to changes at transcription level or protein stability. After 48 hours from transfection with specific PDK1-targeting siRNA or scrambled siRNA, cells were starved overnight and then stimulated with EGF at different times. Since PDK1 phosphorylates AKT at threonine 308 (Thr 308), I decided to check AKT phosphorylation to validate the efficiency of PDK1 downregulation. Western blot analysis showed that the decreased levels of PDK1 expression in MDA-MB-231 was mirrored by the inhibition of the EGF-induced threonine phosphorylation of AKT in “MDA-MB-231 siPDK1” compared to scrambled cells (Figure 7.10). No change in PLC\(\gamma\)1 expression was observed between MDA-MB-231 siPDK1 and control cells, indicating that PDK1 protein downregulation does not affect PLC\(\gamma\)1 expression and that the inhibition of PLC\(\gamma\)1 previously observed is due to an impaired PLC\(\gamma\)1 activation.
Figure 7.10: PLCγ1 expression in cells downregulated for PDK1: Western blot analysis of MDA-MB-231 transfected with scrambled siRNA or siRNA targeting PDK1 (siPDK1). Cells were treated with EGF for the indicated times 72h after transfection. Lysates were analysed using specific antibodies for the specified proteins. Blot representative of two independent experiments.

7.4.2 Effect of downregulation of PDK1 on tyrosine phosphorylation of PLCγ1 in MDA-MB-231

To gain further insight into the mechanism of PDK1-dependent PLCγ1 activation, I decided to investigate any potential effect of PDK1 downregulation on PLCγ1 post-translational modifications. As described in chapter 1.3.1, PLCγ1 phosphorylation is required for its enzymatic activation. In particular phosphorylation of tyrosine 783 (Y783) correlates with PLCγ1 activation. MDA-MB-231 transfected with a control scrambled siRNA or siRNA targeting PDK1 were starved overnight 48 hours after transfection and then stimulated with EGF for 3 and 10 minutes. Western blot analysis showed that tyrosine phosphorylation of PLCγ1 was inhibited after 10 minutes of EGF stimulation in MDA-MB-231 compared to scrambled cells (Figure 7.11A). No
changes were observed after a short stimulation of 3 minutes, probably due to
the not complete downregulation of PDK1. The efficiency of transfection was
assessed using a specific PDK1 antibody to test protein expression levels of
PDK1 in MDA-MB-231 and scrambled cells. These data indicate that
downregulation of PDK1 inhibits the EGF-induced tyrosine phosphorylation
of PLCγ1 at its residue Y783. Furthermore this data reveal a novel role for
PDK1 in the regulation of PLCγ1 activity through modulation of its tyrosine
phosphorylation. In order to validate the data obtained using transient siRNA
similar experiments were performed in MDA-MB-231 stably downregulated
for PDK1 expression. Cells were serum starved over-night, stimulated with
EGF for 3 and 10 minutes before being lysed. Phosphorylation of PLCγ1 was
strongly inhibited in cells expressing the shRNA targeting PDK1 compared to
control cells (Figure 7.11B) at all time points of EGF stimulation. The
discrepancy in the results obtained by transient and stable PDK1
downregulation may be explained by the partial silencing of PDK1 using
transient RNA interfering. On the contrary, a more efficient PDK1
downregulation was achieved in MDA-MB-231 expressing the shRNA
targeting PDK1, which showed a complete inhibition of PLCγ1
phosphorylation.
Figure 7.11: Western blot analysis of MDA-MB-231 downregulated for PDK1 (siPDK1 or shPDK1): A) Cells were treated with EGF 72 hours after transfection and overnight serum starvation. Phosphorylation of tyrosine 783 of PLCγ1 was assessed after 3 and 10 minutes of EGF stimulation (Representative Western blot of two independent experiments). B) MDA-MB-231 sh5MUT and MDA-MB-231 shPDK1 were treated with EGF for the indicated times and phosphorylation of PLCγ1 analysed. Lysates were analysed using specific antibodies for the specified proteins. Representative Western blot of 3 independent experiments.
7.5 Investigation of the mechanism of PDK1-mediated PLCγ1 activation

In order to further investigate the mechanism through which PDK1 regulates PLCγ1 I decided to investigate the hypothesis that the two enzymes could interact. To test this hypothesis I used different complementary approaches. First I tested whether the two proteins, either endogenous or over-expressed could co-immunoprecipitate.

7.5.1 Overexpression of PLCγ1 and PDK1 in HEK293 cells

To optimise the protocol of co-immunoprecipitation experiment, I first decided to perform the experiment using overexpressed PDK1 and PLCγ1. In these experiments HEK293 cells were chosen because of their high transfection efficiency. Cells were transfected using Lipofectamine (Invitrogen, UK) according to the manufacturer’s instructions. 48 hours after transfection, proteins lysates were collected and expression of exogenous PLCγ1 and PDK1 assessed by western blot. HEK293 showed a high rate of transfection using both plasmids. Western blot analysis showed an increased expression of PLCγ1 in overexpressing HEK293 cells (HEK293-PLCγ1) compared to HEK293 transfected with the empty vector (HEK293). PLCγ1 was detected using specific anti-PLCγ1 antibody (Figure 7.12 A).

The pOZ-PDK1 construct expresses an HA-FLAG tagged fusion protein. The HA and FLAG are two epitopes tags recognised by specific antibodies. Because of these flags the overexpressed PDK1 was predicted to be shifted compared to the wild type protein when run on acrylamide gel and then analysed by western blot.

Indeed Western blot analysis of HEK293 overexpressing PDK1 (HEK293-pOZ-PDK1) showed a high expression of the tagged PDK1 compared to control cells. Endogenous and exogenous PDK1 protein levels were assessed using a specific anti PDK1 and anti HA-antibody (Figure 7.12 B,C).
Figure 7.12: Overexpression of PLCγ1 and HA-Flag-PDK1 in HEK293 cells: A) Western blot analysis of HEK293 overexpressing PLCγ1 48 hours after transfection detected by a PLCγ1 specific antibody; B) Western analysis using the anti-PDK1 antibody of HEK293 expressing the HA-PDK1 tagged protein detected two bands which corresponded to the endogenous PDK1 (lower band) and to the recombinant protein HA-PDK1 (upper band); C) The overexpressed HA-PDK1 was detected using an anti-HA antibody in HEK293
7.5.2 Investigation of potential PLCγ1-PDK1 through co-immunoprecipitation analysis.

Once optimized the protocol of overexpression, co-immunoprecipitation experiments were performed using HEK293 cells overexpressing both PLCγ1 and the tagged fusion protein HA-FLAG-PDK1. Cells were transfected and 48 hours after transfection cells were lysed and immunoprecipitation experiments were performed using the Catch and release 2.0® kit (Millipore, US) (chapter 2.2.1.2.1). This kit allows reducing troubleshooting in setting experimental conditions, since the IgG affinity beads are already in a column in a fixed amount decided by the manufacturer. I decided to perform immunoprecipitation experiments using the anti PLCγ1 antibody (Santa Cruz Biotechnology, USA) validated for immunoprecipitation analysis according to the manufacturer’s datasheet. Immunoprecipitation with mouse IgG was performed in parallel as control. For each sample the lysates that did not bind to the PLCγ1 antibody-bead complex (unbound) was collected and loaded as a control. The immune-complex was detached from the beads using denaturing loading buffer after three washes, and loaded for western blot analysis (IP). Western blot analysis revealed an efficient immunoprecipitation of PLCγ1 in these experimental conditions. Furthermore the control IgG were unable to immunoprecipitate PLCγ1 (Figure 7.13). More importantly, a specific band recognised by the PDK1 antibody was detected in the PLCγ1-IP at the molecular weight of the HA-Flag-PDK1 fused protein. No PDK1 band was detectable in IgG-IP fraction indicating that the band was specific (Figure 7.13).
**Figure 7.13: Co-IP analysis of PDK1/PLCγ1 upon overexpression:** Co-IP analysis of overexpressed PDK1 and PLCγ1 using anti-PLCγ1 or mouse-IgG to immunoprecipitate. Immunocomplexes were analysed for the presence of PDK1 and PLCγ1. Representative western blot of two independent experiments.

Data shown in Figure 7.13 suggested that a specific protein-protein interaction occurs between PLCγ1 and PDK1. However low amount of PDK1 was immunoprecipitated using the PLCγ1 antibody. Furthermore no endogenous PDK1 was detected in these experimental conditions indicating that the protocol needed to be further optimised. Using different amounts of protein lysates and antibody did not improve the co-immunoprecipitation rates, suggesting that conditions of lysis and wash buffers need to be optimised. It has to be noticed that the PDK1 band showed in IP-PLCγ1 samples presents a slight shift compared to the fusion protein of the unbound-PLCγ1, suggesting a potential post-translational modification of the protein. Further investigation could highlight a potential post-translational modification of PDK1 involved in the novel PDK1-PLCγ1 interaction and in PLCγ1 regulation.
7.5.3 GST pull-down experiments

The second approach that I decided to use in order to investigate a potential PLCγ1-PDK1 protein-protein interaction was the GST-pull down assay. This second approach is a complementary method to investigate protein-protein interactions in overexpressing conditions. The assay allows the pull-down of interacting protein without the use of specific antibodies. In this assay one of the two proteins whose interaction has to be tested is cloned in a Glutathione-S-Transferase (GST) expressing vector and the resulting GST-fused protein is immobilised on Glutathione agarose beads. Lysate containing the second protein of the potential interaction is loaded on the beads, and this allows the two proteins to interact. Finally the immobilised protein and the potential associated protein(s) can then be dissociated from the beads. Any potential interaction can then be analysed by western blot.

For these experiments, a pEBG2T vector expressing the coding sequence of PDK1 fused with GST at N-terminal (GST-PDK1) was used. This vector allowed the expression of GST-fusion protein directly in mammalian cells HEK293. Lysates from HEK293 overexpressing the empty vector pEBG2T-GST (GST) were used as control. The GST-PDK1 fusion protein presents a shift of ~26 KDa compared to the wild type protein. Figure 7.14 shows the western blot analysis of lysates from HEK293 overexpressing PLCγ1(HEK293-PLCγ1) and HEK293 overexpressing GST-PDK1 (HEK293-GST-PDK1). GST-PDK1 was efficiently overexpressed in HEK293 and recognised by a PDK1 specific antibody as a band at 85 KDa. In parallel HEK293-PLCγ1 showed increased levels of PLCγ1 compared to HEK293-GST-PDK1 used as control for PLCγ1 expression in this particular case.
Figure 7.14: Overexpression of PLCγ1 and GST-PDK1 analysed by western blot using specific antibodies for PLCγ1 and PDK1. Note that addition of GST to PDK1 generates a band of ~85KDa.

7.5.4 GST pull down analysis of PDK1-PLCγ1 interaction

The GST pull down assay was performed using protein lysates from HEK293-GST and HEK293-GST-PDK1. Lysate from HEK293-GST was used as negative control for the experiments, since the GST alone should not interact with PLCγ1. Briefly, lysates from HEK293-GST and HEK293-GST-PDK1 were incubated with the agarose-glutathione beads for 1 hour and then incubated overnight with lysed collected from HEK293 overexpressing PLCγ1. Beads were then washed and proteins bound to the agarose beads were harvested in denaturing condition and analyzed by western blot analysis. Figure 7.15 shows a representative western blot of experiments performed using lysis buffer (50mM Tris-pH 8.0, 50mM KCl, 1% NP-40) for collecting cell lysates and for the washing steps. A band recognised by PLCγ1 antibody was detected when lysates HEK293-PLCγ1 were incubated with GST-PDK1 previously immobilised on the agarose beads. However a small band recognised by PLCγ1 antibody was detected also in the negative control (HEK-GST). The limited amount of PLCγ1 interacting with PDK1, together with the signal detected in the control suggested me that the technique was not
optimised. Nevertheless the result was encouraging to further optimise the assay.

![Figure 7.15: GST pull down: Western blot analysis of GST pull down assay of HEK293 overexpressing GST or GST-PDK1 incubated with lysate from HEK293 overexpressing PLCγ1. PLCγ1 and PDK1 were detected using specific antibodies. Representative western blot of 2 experiments.](image)

In an effort to find the optimal condition to detect the interaction, I decided to test different buffers for the incubation step. Three different buffers were prepared changing the ionic and detergent concentration (Table 7.2). The aim of this optimisation protocol was to preserve the PLCγ1-PDK1 interaction and remove the aspecific binding observed in the control.

Table 7.2:

<table>
<thead>
<tr>
<th></th>
<th>Buffer 1</th>
<th>Buffer 2</th>
<th>Buffer 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tris pH 8.0</td>
<td>50 mM</td>
<td>50 mM</td>
<td>50 mM</td>
</tr>
<tr>
<td>NaCl</td>
<td>300 mM</td>
<td>150 mM</td>
<td>50mM</td>
</tr>
<tr>
<td>NP-40</td>
<td>0.1%</td>
<td>1%</td>
<td>2%</td>
</tr>
</tbody>
</table>
HEK293-GST and HEK293-GST-PDK1 were lysed in lysis buffer (50mM Tris-pH 8.0, 50mM KCl, 1% NP-40) and incubated with agarose-glutathione beads for 2 hours using one of the buffers listed in table 7.2. After three washes, performed in the chosen buffer, lysate from HEK293-PLCγ1 was incubated overnight with the beads-bound GST-fused protein, in the corresponding buffer. Complexes were eluted in denaturing conditions after three washes and analysed by western blot. As shown in Figure 7.16 PLCγ1 was not detected in the complex when the incubation was carried out in buffer 1 (lanes 2-3). On the contrary, a clear band was detected when HEK293-PLCγ1 lysate was incubated with GST-PDK1 using the buffer 2 (lanes 3-4) and buffer 3 (lane 5-6), indicating that PLCγ1-PDK1 complex was preserved in these conditions. Moreover a very low aspecific signal was detected following incubation with GST alone. Coomassie brilliant blue staining was performed in order to evaluate proteins levels in the different samples. The arrows indicate GST-PDK1 and GST. The staining revealed no major difference in protein levels among the different samples. Taken together these data demonstrated that PLCγ1 can associate with PDK1, at least \textit{in vitro}. 
Figure 7.16: GST Pull-down optimisation protocol: WB analysis of GST pull down assay in cells expressing GST or GST-PDK1 and lysed with three different buffers (see table 3) (upper panel). Loading control was assessed by Coomassie staining of a gel run in parallel (lower panel). Representative Western blot of three independent experiments.
7.5.5 Co-immunoprecipitation analysis of endogenous PLCγ1 and PDK1 in MDA-MB-231

Co-immunoprecipitation and GST pull down experiments demonstrated for the first time that PLCγ1 can interact with PDK1 when overexpressed. To investigate the PDK1-PLCγ1 interaction at endogenous level, I decided to perform co-immunoprecipitation experiments of endogenous proteins from lysates of MDA-MB-231 stimulated with EGF and in full serum condition. Experimental conditions optimised in the pull-down assay were used. To this end, MDA-MB-231 were serum starved overnight and left untreated (control) or stimulated with EGF for 10 minutes. Alternatively, cells maintained in 10% serum supplied media were used. PLCγ1 and PDK1 were co-immunoprecipitated using the PLCγ1 antibody and immunocomplexes fractions assessed by western blot for PLCγ1 and PDK1. As shown in Figure 7.17, PDK1 was specifically immunoprecipitated by the anti-PLCγ1 in lysates from EGF-stimulated cells compared to non-stimulated cells or to cells maintained in serum condition. These data demonstrated that EGF induces association of PLCγ1 and PDK1. Data are consistent with previous results showing a reduced tyrosine phosphorylation of PLCγ1 after EGF stimulation in cells downregulated for PDK1 or treated with 2-O-Bn-InsP, suggesting that the interaction between PLCγ1 and PDK1 is necessary for PLCγ1 phosphorylation and the subsequent activation.

Figure 7.17 Co-immunoprecipitation of endogenous PDK1 and PLCγ1: MDA-MB-231 were left untreated or stimulated with EGF for 10 minutes or maintained in serum-supplemented media. Co-IP and western blot analysis
were performed using anti-PLCγ1 and anti-PDK1 antibodies. Representative Western blot of three independent experiments.

To further investigate the novel identified complex between PLCγ1 and PDK1, I decided to perform co-immunoprecipitation experiments in MDA-MB-435 downregulated for PLCγ1 expression (MDA-MB-435 shPLCγ1) and the respective control (MDA-MB-435 sh3MUT). The rationale was to investigate the potential PLCγ1/PDK1 complex in a second cell line and also to validate the specificity of the co-immunoprecipitation assay. Indeed, in principle, the co-immunoprecipitation analysis performed using the PLCγ1 antibody in cells lacking PLCγ1 should monitor potential aspecific immunoprecipitation. Cells were serum starved overnight and left untreated or stimulated with EGF for 10 minutes or with media containing 10% serum supplied media before being lysed. Immunoprecipitation assay was performed in the conditions previously described. Lysates were incubated with PLCγ1 antibody and immunoprecipitated fractions assessed by western blot for PLCγ1 and PDK1. Figure 7.18 shows that PLCγ1 was efficiently immunoprecipitated in MDA-MB-435 3MUT whereas no PLCγ1 (or reduced PLCγ1) was immunoprecipitated in MDA-MB-435 downregulated for PLCγ1 expression. These data demonstrate that PDK1 specifically interact with PLCγ1 and rule out any potential aspecific co-immunoprecipitation.
Figure 7.18: Co-immunoprecipitation of PDK1 and PLC\(\gamma\)1 in MDA-MB-435: MDA-MB-435 3MUT and MDA-MB-435 shPLC\(\gamma\)1 were left untreated or stimulated with EGF for 10 minutes or maintained in serum-supplemented media. Co-IP and western blot analysis are performed using anti- PLC\(\gamma\)1 and anti-PDK1 antibodies. Representative Western blot of three independent experiments.

7.5.6 FRET analysis of PLC\(\gamma\)1/PDK1 protein interaction by confocal imaging

To understand the dynamic of the interaction between PDK1 and PLC\(\gamma\)1, I decided to use the Fluorescence Resonance Energy Transfer (FRET) assay as described in chapter 2.3.4, in order to analyse the formation of the complex spatially and temporally. To this end MDA-MB-231 were co-transfected with plasmids to over-express both PLC\(\gamma\)1 and PDK1. As controls, MDA-MB-231 expressing a GFP-containing vector together with PLC\(\gamma\)1 plasmid and MDA-MB-231 expressing GFP-containing vector together with the pOZ-PDK1 plasmid were used. No FRET signal was expected to be detected in the control cells since no interaction occurs between GFP and PLC\(\gamma\)1 and between GFP and PDK1. Cells were starved overnight 24 hours after transfection and then left untreated or stimulated with EGF at different time points before being fixed. Immunofluorescence staining was performed using PLC\(\gamma\)1 and PDK1
specific antibodies (chapter 2.3.4) followed by FRET analysis. An increase in fluorescence in the donor channel was detected after acceptor’s photo-bleaching. Donor fluorescence was measured at the level of membrane protrusions (when present after EGF stimulation) and also in more cytoplasmic regions. The rationale was that since PLCγ1 translocates to the plasma-membrane after EGF stimulation and also it is localised at the leading-edge of motile cells, the PDK1-PLCγ1 complex could be enriched in the EGF-induced cell protrusions. Donor fluorescence was measured also in more central cytoplasmic regions. Images in Figure 7.19 show the fluorescence intensity of the donor before and after the photo-bleaching for each time point in specific chosen regions. The merged channel shows where the acceptor was photo-bleached. The lines indicate representative regions where donor fluorescence change was measured and value collected for statistical analysis. In particular the chart in figure 7.20 shows the donor fluorescence (green line) before and after photobleaching of the acceptor (red line) of representative regions at all time points. FRET occurred after 1 minute and 3 minutes of EGF stimulation, since at these time-points acceptor’s drop of fluorescence was coupled with an increased donor’s fluorescence. As indicated in Figure 7.21, photo-bleaching of the donor caused a significant increase of fluorescence in the donor channel after 3 minutes of stimulation with EGF, indicative of FRET. No changes in donor fluorescence were revealed in the internal cytoplasmic region after acceptor photo-bleaching, and no FRET was detected when PLCγ1 or PDK1 were overexpressed together with a GFP-containing vector, indicating that PLCγ1 and PDK1 associated after EGF stimulation, in well-defined region corresponding to cellular protrusions induced by EGF.
Figure 7.19: FRET images of MDA-MB-231 expressing exogenous PLCγ1 and PDK1: Donor pre-bleach and post-bleach fluorescence was measured in MDA-MB-231 overexpressing PLCγ1 and PDK1 after 1,3,5 and 10 minutes of stimulation with EGF in the areas indicated by the red line in each figure.
Figure 7.20: Graphs representing donor and acceptor fluorescence measured at each time points along the red line indicated in the corresponding figures showed in figure 7.19. Increased donor fluorescence after bleaching indicated FRET occurring in the measured area. Unstimulated MDA-MB-231 overexpressing PLCγ1 and PDK1 were used as control.
Figure 7.21: Quantification of FRET in MDA-MB-231: Chart indicates percentage of FRET in MDA-MB-231 expressing exogenous PLC\(_{\gamma 1}\) and PDK1 at the indicate times of EGF stimulation. Percentage of FRET was calculated in three independent experiments measuring donor fluorescence of 10 cells per experiment before and after acceptor bleaching. Percentage of FRET in cells co-expressing PLC\(_{\gamma 1}\) and GFP or PDK1 and GFP was used as basal FRET signal. Columns are the means ±SEM of percentage of FRET measured at protrusion level or in more central cytosolic regions.
7.5.7 FRET analysis of PLCγ1/PDK1 protein interaction by FACS analysis

To confirm the FRET data obtained by confocal analysis, I decided to perform FRET experiments using a different methodological approach. The FRET analysis described in chapter 7.5.6 was based on the increased fluorescence of the donor after photo-bleaching of the acceptor as read-out of occurring FRET. The methodology used to detect FRET using FACS analysis relies on increased fluorescence of the acceptor following donor excitation, without direct excitation of the acceptor itself. FRET occurs when donor’s and acceptor’s distance is less than 10 nm, resulting in increased fluorescence emission of the acceptor. Therefore the potential increase of acceptor fluorescence over background is due to FRET between donor and acceptor.

MDA-MB-231 cells were co-transfected with plasmids overexpressing PLCγ1 and PDK1. Cells were serum starved over night before being stimulated with 50ng/ml EGF. Background fluorescence of acceptor alone was measured as control. Furthermore acceptor fluorescence was measured in MDA-MB-231 expressing a GFP-containing vector together with PLCγ1 plasmid or pOZ-PDK1 plasmid, in order to calibrate the background fluorescence of the acceptor. Furthermore MDA-MB-231 cells were transfected with PLCγ1 or pOZ-PDK1 plasmid and labelled with donor or acceptor dye-conjugated antibodies. These measurements allowed the calibration of the instrument in order to avoid false-positive FRET signal from cross-talk artefacts. The acceptor emission profiles of untreated and EGF stimulated cells were compared to the acceptor profile obtained in cells stained for PDK1 and PLCγ1 respectively. As indicated in figure 7.22A unstimulated cells show an emission profile superimposable to the single positive sample. Cells stimulated with EGF present a shift in the acceptor emission profile indicating increased acceptor fluorescence subsequent to EGF stimulation. Analysis of the acceptor emission profiles shows that a slight increase in the acceptor fluorescence was detected in unstimulated MDA-MB-231 overexpressing PLCγ1 and PDK1 compared
to background level, although not statistically significant. On the contrary stimulation with EGF induced 30% increase of acceptor fluorescence (Figure 7.22B,C). These data indicate that EGF stimulation induces a fluorescence increase of the acceptor due to FRET occurring between PLCγ1 and PDK1, demonstrating that PLCγ1 and PDK1 interaction is induced by EGF stimulation.

**Figure 7.22: Quantification of FRET by FACS analysis:** A) The data display acceptor fluorescence of control and unstimulated cells (left) and control and EGF-stimulated cells (right) after correction of spectral bleeding of donor into the FRET (550 nm) channel. B) Fluorescence intensity over
time of acquisition of control, unstimulated and EGF stimulated cells. C) **Quantification of fluorescence in the FRET channels in MDA-MB-231** transfected with PLCγ1 or pOZ-PDK1 plasmid and labeled with acceptor-dye-conjugated antibody, or expressing a GFP-containing vector (donor) together with PLCγ1 plasmid or pOZ-PDK1 plasmid labelled with acceptor-dye-conjugated antibody. FRET was quantified also in MDA-MB-231 co-expressing PLCγ1 and PDK1 untreated or stimulated with EGF. Graph is the average ±SEM of three independent experiments.

### 7.6 Discussion

In order to test the hypothesis of a novel role of PDK1 in PLCγ1 regulation I decided first to investigate the role of PDK1 on PLCγ1 activation by measuring intracellular calcium and inositol phosphate accumulation upon EGF stimulation. Transient transfection of siRNAs is a powerful tool to downregulate the expression of targeted proteins. However, the results might be affected by intrinsic variability of the efficiency of transfection among different experiments and by a partial knock down. Therefore I decided to generate MDA-MB-231 expressing shRNA specific for downregulation of PDK1. The specific targeting sequence was cloned in the pSUPERIOR.retro.puro, which allows stable downregulation of the protein or inducible downregulation of the targeted protein if expressed in cells expressing the TET repressor. As described in the introductive chapter 1.7.2 increasing lines of evidence showed that PDK1 plays a main role in cell migration and invasion in normal and cancer cell lines. My data showed that transient downregulation of PDK1 inhibited cell invasion on Matrigel in MDA-MB-231, MDA-MB-435 and A375M indicating that PDK1 plays an important role in cell invasion in the cell systems used (Figure 7.3). Interestingly transient downregulation of PDK1 inhibited EGF-induced calcium mobilisation in MDA-MB-231 and A375M (Figure 7.2). Furthermore inositol phosphates accumulation assay was inhibited in two clones of MDA-MB-231 expressing shRNA targeting PDK1 (Figure 7.9). Since the EGF-induced calcium release is entirely dependent on PLCγ1 in
this cellular system, these data demonstrated that PDK1 is involved in PLCγ1 activity. Furthermore downregulation of PDK1 inhibited PLCγ1 phosphorylation in MDA-MB-231 which explains the inhibition of PLCγ1 activity (Figure 7.11). These data were consistent with the inhibition of PLCγ1 phosphorylation observed in cells treated with 2-O-Bn-InsP₃ upon EGF stimulation. These data therefore identified a novel role of PDK1 in PLCγ1 regulation and a common mechanism of regulation of cancer progression and metastasis development. Considering the importance of PLCγ1 in metastasis development and progression, the inhibiting effect of 2-O-Bn-InsP₃ on PLCγ1 activity and on cell invasion strongly suggests that this inhibitor might have anti-metastatic effects in vivo. PDK1 represents a good target in cancer and since it is involved in the regulation of proteins that have an important role in cancer cell biology such as AKT, S6K1, SGK1-3 and PKC. However for this reason PDK1 inhibition could result in side effects. Interestingly data in literature showed that hypomorphic mice did not show any specific phenotype but, when crossed with PTEN heterozygote mice are protected against tumour development (Bayascas et al., 2005). Therefore pharmacological PDK1 inhibition could result in primary tumour growth inhibition and more importantly in anti-metastatic effect.

Co-immunoprecipitation, GST pull-down and FRET analysis showed that PLCγ1 and PDK1 form a complex upon EGF stimulation, with an increased association upon growth factor stimulation. In particular confocal-based FRET analysis showed a significant increased association upon stimulation with EGF for 3 minutes in cell protrusion while FACS-based FRET analysis showed increased association upon EGF stimulation for 10 minutes. The different time response to EGF might be explained by the different conditions used for cell stimulation. Indeed for confocal-based FRET analysis adherent cells were stimulated at the different time points while for FACS-based FRET analysis cells were first detached and then stimulated with EGF in order to allow cell fixation for FACS analysis. Consistent with confocal-based FRET, co-immunoprecipitation analysis showed an increased association after 3 minutes stimulation with EGF. Taken together these data revealed a novel
protein-protein interaction between PLCγ1 and PDK1 essential for PLCγ1 activation and for cell motility.

Summary

Data shown in this chapter reveal a novel role of PDK1 in PLCγ1 activation, and demonstrated that PDK1 is essential in PLCγ1 activation. In particular PLCγ1 and PDK1 interact upon EGF stimulation and FRET analysis revealed that this association is increased at protrusion level. Furthermore, inhibition of PDK1 blocks PLCγ1 activation and inhibits PLCγ1 tyrosine phosphorylation.
Chapter 8
Concluding discussion and future studies
8.1 Discussion

The aim of my work was to investigate the role of PLC\(\gamma\)1 in cancer cell motility, with a particular interest in cancer cell migration and invasion, and the investigation of potential inhibitors that might prevent its activation. PLC\(\gamma\)1 has been extensively investigated in the literature and increasing lines of evidence suggested its role in cancer cell motility (Turner et al., 1997; Jonest et al., 2005; Shepard et al., 2007). Many previous reports used pan-PLC inhibitors or expression of a dominant negative mutant to understand the role of PLC\(\gamma\) in cancer, especially in tumour local invasion and metastases. Our recent report demonstrated that PLC\(\gamma\)1 is overexpressed in lymph node metastases from breast cancer patients (Sala et al., 2008) and is required for metastasis development and progression.

The experiments performed in this thesis improved the understanding of the role of PLC\(\gamma\)1 in cancer cell motility and invasion in vitro. In particular I investigated the role of PLC\(\gamma\)1 in breast cancer and melanoma cancer cell migration and invasion in vitro using specific siRNA and shRNA to inhibit PLC\(\gamma\)1. This approach minimised aspecific effects compared to previous reports that used expression of dominant negative mutant to investigate PLC\(\gamma\)1 role in cancer. In accordance with previous observation using dominant negative mutant, my data showed that downregulation of PLC\(\gamma\)1 in vitro inhibited cancer cell migration and cell invasion in vitro and its downregulation affected membrane ruffles formation and growth factor-induced cytoskeleton remodelling. Failure in cytoskeleton remodelling is probably the main reason for the inhibition observed in cell migration and cell invasion. These in vitro data were the basis for experimental metastasis using MDA-MB-231 performed by my group. These experiments demonstrated that PLC\(\gamma\)1 is required for metastasis development and progression and identified PLC\(\gamma\)1 as a novel therapeutic target. Over the last 20 years successful strategies have been developed to treat different types of cancer, although cancer remains the second cause of death in adults. However no significant improvement has been achieved in treatment of metastasis, which most of the
time results in resistance to all the available treatment and represents the first cause of death in cancer patients. At present no antimetastatic drugs are available. Several papers produced by my laboratory demonstrated that inositol phosphates can be used to inhibit AKT by impairing the AKT PH/PtdIns(3,4,5)P3 interaction, competing with PtdIns(3,4,5)P3 for the PH domain binding (Piccolo et al., 2004; Maffucci et al., 2005). Similarly, since PLCγ1 possesses a PH domain responsible for its membrane recruitment, blocking the PH domain interaction with its substrate could be a good strategy to impair the activation of this enzyme. Considering that PH domains can bind different inositol phosphates with a different range of affinity (Kavran et al., 1998; Maffucci and Falasca, 2001; Lemmon 2008), the hypothesis of finding inositol phosphates able to compete with the physiological substrate impairing the membrane recruitment, is extremely interesting.

For these reasons, in order to find specific inhibitors for PLCγ1, I tested the inositol pentakisphosphate InsP(1,3,4,5,6)P5 and its derivative compound 2-O-Bn-InsP5 on PLCγ1 activity. My data showed that 2-O-Bn-InsP5 and less potently InsP(1,3,4,5,6)P5 inhibit PLCγ1 activity upon EGF stimulation and that in MDA-MB-231, PLCγ1 is the only PLC isoform involved in EGF signalling. The effect observed in cancer cell migration and invasion, together with the potent PLCγ1 inhibition upon treatment with 2-O-Bn-InsP5, indicated that this compound might inhibit PLCγ1 in vivo and might have anti-metastatic activity. We recently reported that 2-O-Bn-InsP5 is a specific and potent inhibitor for PDK1 with antitumor effect (Falasca et al., 2010). Therefore considering the role of PDK1 in cell migration and invasion and the effect observed upon 2-O-Bn-InsP5 treatment in cancer cell migration and invasion and on PLCγ1 activation, I investigated a potential role of PDK1 in PLCγ1 activation. Strikingly, my data demonstrated a novel PDK1-dependent mechanism of PLCγ1 activation. Indeed transient or stable downregulation of PDK1 inhibited calcium mobilisation, inositol phosphates accumulation and PLCγ1 phosphorylation in Y783 upon EGF stimulation. Similarly, 2-O-Bn-InsP5 treatment inhibited PLCγ1 tyrosine phosphorylation and PLCγ1 activity. Therefore these data demonstrated that PDK1 is essential for PLCγ1
phosphorylation, which is an essential step for PLCγ1 activation. However my data did not explain the mechanism by which PDK1 is involved in PLCγ1 phosphorylation. Indeed PDK1 is a threonine/serine kinase and therefore it is unlikely that the enzyme direct phosphorylates of PLCγ1. To further gain insight into the novel identified PDK1-dependent mechanism, I decided to investigate the existence of a protein-protein complex between PLCγ1 and PDK1 which might be important for PLCγ1 activation independently of PDK1 kinase activity. Indeed a report showed that PDK1 association to ROCK1 regulates ROCK1 activity independently from PDK1 kinase activity (Pinner and Sahai, 2008). My data demonstrated not only the existence of a complex between PLCγ1 and PDK1 but also that this interaction is modulated upon EGF stimulation in breast cancer cells with an increased association in cellular protrusion. My work therefore identified a novel PDK1/PLCγ1 pathway, linking two major proteins involved in the regulation of cell motility and reported to play a major role in metastases. Moreover it improves the understanding of the molecular mechanism involved in the regulation of PLCγ1 in cancer. These data shows that the PDK1/PLCγ1 is pharmacologically targetable and its inhibition may have antimetastatic effect in vivo. In particular these data indicate that 2-O-Bn-InsP₃ inhibits the PDK1/PLCγ1 pathway and is a promising anticancer and potential antimetastatic drug. My data strengthened the idea of PDK1 as a promising therapeutic target and suggest a major role of PDK1 in controlling metastasis development and progression by promoting PLCγ1 activation. Indeed PDK1 is overexpressed in breast cancer and increased copy number correlates with upstream lesion such as PTEN loss, PK3CA mutation and EGFR amplification which result in increased tumour growth, increased cell motility and poor prognosis (Maurer et al., 2009). In this scenario the novel PDK1/PLCγ1 might play an important role and could be an important therapeutic target for metastasis.

Data showed in this thesis highlighted the potential therapeutic properties of inositol phosphates compounds such as Ins(1,3,4,5,6)P₅ and 2-O-Bn-InsP₃. However it is currently unknown how inositol phosphates are transported through the membrane. Recent evidence identified the role of ABCC family
members in inositol phosphates export, but no data are available in mammalian cells. My data showed for the first time that ABC transporters are involved in Ins(1,3,4,5,6)P_5 uptake in mammalian cells. In particular ABCC1 inhibition reduced Ins(1,3,4,5,6)P_5 uptake in breast cancer cells. The ABC transporters have a main role in chemoresistance and multidrug resistance. It was reported by my group that ABCC1 transporter promotes an autocrine loop by which cancer cells can stimulate their proliferation (Pineiro et al., 2010). Therefore this report suggests ABCC1 as a potential target to block cancer cell proliferation. However, according to the data showed in this thesis, the overexpression of ABCC1 might increase the intracellular uptake of exogenous inositol phosphates such as Ins(1,3,4,5,6)P_5 or potential synthetic derivative and could correlate with increased sensitivity showed by different cancer cell lines to inositol phosphates treatment. Therefore enhanced expression of ABCC1 might be used as potentially marker to identify tumour responsiveness to specific anti-cancer treatment, such as inositol phosphates.
8.2 Future work

Several questions, arisen form the experiments showed in this thesis, remain pending.

Further work will focus on:

**PDK1/PLCγ1**

Investigation of the mechanism by which PDK1 regulates PLCγ1 activity. Further experiments should investigate whether kinase activity of PDK1 is required for PLCγ1 activation or it is dispensable.

**2-O-Bn-InsP₅ in metastases**

*In vitro* data showed that 2-O-Bn-InsP₅ inhibits PLCγ1 activity and cancer cell invasion. Further *in vivo* work is required to investigate the role in metastases development and progression and to investigate the pharmacokinetic of this compound.

**ABC transporter and Inositol phosphates active transport**

Further work is required to investigate the role of ABC transporter family members. In particular, modulation of expression of different ABC transporters, especially ABCC and ABCG family members by overexpression or siRNAs could the contribution of ABC transporter in inositol phosphate intake. Furthermore, screening of ABCC and ABCG transporter expression in cancer cell could correlate their expression with increased sensitivity to Inositol phosphates treatment.
Bibliography


Poulin, B., F. Sekiya, et al. (2000). "Differential roles of the Src homology 2 domains of phospholipase C-gamma1 (PLC-gamma1) in platelet-


Appendices
1.1 5X denaturing sample buffer (per 16 ml)
- 6.8 ml of ddH₂O
- 2 ml of 0.5M tris-HCl pH 6.8
- 4 ml of Glycerol 87%
- 1.6 ml of SDS 20%
- 1.6 ml of bromphenol blue

1.2 10% separating gel solution (per 5 ml)
- 1.7 ml of Acrylamide mix [Protogel 30% (w/v) acrylamide: 0.8% (w/v) stock solution (37.5:1)]
- 1.9 ml of ddH₂O
- 1.3 ml of 1.5M Tris, pH 8.8
- 0.05 ml of 10% SDS
- 0.05 ml of 10% APS
- 0.02 ml of TEMED

1.3 5% stacking gel solution (per 1 ml)
- 0.17 ml of Acrylamide mix [Protogel 30% (w/v) acrylamide: 0.8% (w/v) stock solution (37.5:1)]
- 0.68 ml of ddH₂O
- 0.13 ml of 1.0M Tris, pH 6.8
- 0.01 ml of 10% SDS
- 0.01 ml of 10% APS
- 0.01 ml of TEMED

1.4 1X running buffer
- 25 mM tris, pH 8.9
- 192 mM glycine
- 0.2% SDS

1.5 1X Transfer buffer
- 25 mM Tris, pH 8.3
- 192 mM Glycine

1.6 1X TAE buffer
- 96.8 g Tris
- 22.84 mL Acetic Acid
- 14.88 g EDTA
2. Map of pSUPERIOR.retro.puro used for generation of PDK1 targeting shRNA

2.2

Key Sites
- BglII: 2424
- HindIII: 1441
- EcoRI: 2046
- SalI: 1428
- XhoI: 1420

Vector Features
- PGK promoter: 2767-3165
- Puro ORF: 3180-3779
- H1 promoter: 2651-2444
- Stuffer: 1447-2423
- Ampicillin resistance ORF: 6368-5502
- 3' delta LTR: 3835-4202
- 5' delta LTR: 7294-513

Sequencing primer 5’-GGAAGCCCTTGGCTTTTG-3’ binding site: 1241-1257
Sequencing primer 5’-GATGACGTACCGTTCG-3’ binding site: 2646-2830
2.1 Plasmids:

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Selection</th>
<th>Provided by</th>
</tr>
</thead>
<tbody>
<tr>
<td>pEGFP</td>
<td>Kanamycin</td>
<td>Clontech, US</td>
</tr>
<tr>
<td>PRK5-PLCγ1</td>
<td>Ampicillin</td>
<td>Prof. M. Falasca (BD, UK)</td>
</tr>
<tr>
<td>PALM-PLCγ1</td>
<td>Kanamycin</td>
<td>Dr. E. Bonvini (Macrogenics Inc., US)</td>
</tr>
<tr>
<td>pEBG2t-GST-PDK1</td>
<td>Ampicillin</td>
<td>Dr. D. Alessi</td>
</tr>
<tr>
<td>pOZ-PDK1</td>
<td>Kanamycin</td>
<td>Prof. R. Parsons</td>
</tr>
<tr>
<td>pCDNA</td>
<td>Ampicillin</td>
<td>Invitrogen, UK</td>
</tr>
</tbody>
</table>

2.2 siRNA

2.2.1 siRNA SMARTpool siRNA D-003017-02-0010, PDK1

target sequence 1: CAAGAGACCUCUGUGGAGAA
target sequence 2: GACCAGAGGCCAAGAAUUU
target sequence 3: GGAAACGAGUAUCUUAUAU
target sequence 4: UGGCCAAAUUGCACCGGAAU

2.2.3 siRNA SMARTpool siRNA D-003559-01-0010, PLCγ1

target sequence 1: CCAACCAGCUUAAGAGGA

target sequence 2: GAGAUGAACAUGUGGUA

target sequence 3: GCAGACCUUUUGAGA

target sequence 4: CCAAGAAGGACUCGGUCA

2.3 Primers

ABCC1 forward: 5'-AGTGGAAACCCTCTCTGTGTT-3'
ABCC1 reverse: 5'-CCTGATACGCTTTGGGTTTT-3'
ABCC5 forward: 5'-GGAGCTCTCAATGGGAAGACG-3'
ABCC5 reverse: 5'-GTTTCAACCATGAAGGGCTGGT-3'
β-actin forward: 5'-CTGGCAACCACACCTTCTACTATG-3'
β-actin reverse: 5'-TCCAAAGGACAGGGCTGGATG-3'